

Curriculum Vitae
Prabir Roy-Chaudhury

I. PERSONAL INFORMATION

Name: Prabir Roy-Chaudhury
Address: 50123 Manly, Chapel Hill, NC 27517
Phone: +1 513 312-5045
E-mail: prabir_roy-chaudhury@med.unc.edu

II. EDUCATION

2000	FRCP (Edin) Medicine	Royal College of Physicians of Edinburgh, Edinburgh, Scotland
1998-96	Fellowship in Nephrology	Beth Israel Hospital, Harvard Medical School, Boston MA
1995-98	Resident in Medicine	University of Cincinnati, Cincinnati, OH
1990-93	PhD, Medicine/Nephrology	University of Aberdeen, Scotland (awarded 1997)
1989-90	Renal Registrar	(Nephrology Fellow equivalent). Department of Medicine, University of Aberdeen, Scotland
1987-89	Medical Registrar	(Internal Medicine Resident equivalent)/Senior House Officer. Department of Medicine, University of Aberdeen, Scotland
1985-86	MSc, Clinical Pharmacology	University of Aberdeen, Scotland
1984	Medicine Intern	General Hospital, Chandigarh, India
1979-83	MBBS, Medicine	Armed Forces Medical College, University of Poona, India

III. PROFESSIONAL EXPERIENCE/EMPLOYMENT HISTORY

12/2022 onwards	Drs. Ronald and Katherine Falk Eminent Professor, University of North Carolina at Chapel Hill
03/2019 – present	Professor of Medicine and Co-Director, UNC Kidney Center, University of North Carolina, Chapel Hill, North Carolina, from March 2019
09/2019 – present	Staff Physician and Nephrologist: Salisbury (Bill Hefner) VA Medical Center, Salisbury, North Carolina, from September 2019
07/2015 – 03/2019	Professor of Medicine and Division Director, Nephrology: University of Arizona and Banner University Medical Centers Tucson and South, Tucson, AZ
07/2015 – 03/2019	Director, Arizona Kidney and Vascular Center: University of Arizona, Tucson, AZ
10/2015 – 03/2019	Staff Physician and Nephrologist: Southern Arizona Veterans Administration Healthcare System
01/2013 – 12/2018	American Society of Nephrology Co-Chair: Kidney Health Initiative
09/2008 – 06/2015	Professor of Medicine: University of Cincinnati, Cincinnati, OH
09/2008 – 06/2015	Professor of Biomedical Engineering: University of Cincinnati, Cincinnati, OH
06/2003 – 06/2015	Staff Physician: Veterans Administration Medical Center, Cincinnati
08/2010 – 06/2015	Medical Director: UC Health Vascular Access Center, University of Cincinnati
08/2013 – 06/2015	Section Head, Dialysis Vascular Access: Division of Nephrology, University of Cincinnati
2010 – 2015	Director, Dialysis Vascular Access Research Group: Division of Nephrology, University of Cincinnati

09/2002 – 09/2008 Associate Professor of Medicine: University of Cincinnati, Cincinnati, OH
 10/1998 – 09/2002 Assistant Professor of Medicine: University of Cincinnati, Cincinnati, OH

IV. HONORS/AWARDS

2023 Plenary Oration on “Innovating for Global Kidney Care” at the 75th Jubilee Celebrations of AFMC
 2023 Lifetime Achievement Award, American Society of Diagnostic and Interventional Nephrology
 2023 ASN Council (Executive track); Secretary 2023, President Elect 2024 and Preseident 2025
 2022 Drs. Ronald and Katherine Falk Eminent Professor, University of North Carolina at Chapel Hill
 2021 JVIR Editor’s Award for Outstanding Clinical Study
 2020 JVIR Editor’s Award for Outstanding Clinical Study
 2019 Rogosin Professorship, Weil Medical School, Cornell University
 2019-22 Councilor, American Society of Nephrology
 2018 Plenary Lecture at the American Society of Artificial and Internal Organs
 2018 Henry Lecture, Vascular Access Society of the Americas
 2016 Academic Excellence Award, American Nephrologists of Indian Origin
 2015 Opening Plenary at the Australian and New Zealand Society of Nephrology Annual meeting
 2015 KS Chugh Oration at the Indian Society of Nephrology Meeting, Bangalore
 2013 – 15 Department of Medicine Distinguished Research Award, University of Cincinnati, “Mouse models for dialysis vascular access”
 2014 Cincinnati Business Courier, Health Care Heroes Finalist (Innovator Category)
 2013 Department of Internal Medicine, Distinguished Research Award, University of Cincinnati
 2013 CCTST Community Practice Research Award
 2012 Program Committee for the American Society of Nephrology Annual Meeting
 2012 Gerald Beathard Award, American Society of Diagnostic and Interventional Nephrology, New Orleans
 2011 Gerald Beathard State of the Art Address, American Society of Diagnostic and Interventional Nephrology, Las Vegas
 2006 7th John Cunio Memorial Lecture, University of Miami Medical Grand Rounds
 1991 Best Presentation, Scottish Renal Association Meeting, Aberdeen, Scotland
 1986 Glaxo Chem Prize, MSc (Clinical Pharmacology), University of Aberdeen, Scotland

V. BIBLIOGRAPHY AND PRODUCTS OF SCHOLARSHIP

a. Books and Book Chapters

1. Roy-Chaudhury P, Verma A. Improving patient safety in vascular access: a role for individualization and patient preferences. *Contributions to Nephrology* 2015;184:136-4
2. Roy-Chaudhury P, Emerging Therapies in Chronic Kidney Disease, In Kimmel and Rosenberg (editors), Elsevier 2014.
3. Kher A, Roy-Chaudhury P, Govil A. BK Virus Nephropathy and other Viral Infections. In Kher V (editor), Transplantation, Elsevier India, 2013.

4. Roy-Chaudhury P, Woodle ES. Novel Therapeutic Pathways for Antibody mediated Rejection and Desensitization. In Abraham, G (editor), Antibody Mediated Rejection, Elsevier, India, 2012.
5. Roy-Chaudhury P, Hentschel D, Agarwal A, Asif A. Research Opportunities in Interventional Nephrology. In Asif A, Agarwal A, Yevzlin A, Wu S, Beathard G (eds.) Interventional Nephrology, McGraw Hill 2012.
6. Roy-Chaudhury P, Lee T, Ramani K, Wadehra D. Pharmacological Approaches to Vascular Access Dysfunction. In Asif A, Agarwal A, Yevzlin A, Wu S, Beathard G (eds.) Interventional Nephrology, McGraw Hill 2012.
7. Roy-Chaudhury P, Banerjee R. Flow Dynamics, Maturity and Access Failure. In Asif A, Agarwal A, Yevzlin A, Wu S, Beathard G (eds.) Interventional Nephrology, McGraw Hill 2012
8. Roy-Chaudhury P, Anastomotic geometry of arteriovenous fistulae. In Tordoir J (editor), Techniques of Vascular Access Creation and Maintenance, Maastricht University Press 2011
9. Roy-Chaudhury P, Kelly B, Narayana A, Desai P, Melhem M, Duncan H, Heffelfinger S. Hemodialysis Vascular Access Dysfunction: from bedside to bench to bedside. In Henry M (eds), Vascular Access for Hemodialysis VIII, Precept Press, 2002.
10. Roy-Chaudhury P, Whiting JF, Miller MA, Reaves A, Denman D, Munda R, First MR, Heffelfinger SC. Venous Neointimal Hyperplasia in PTFE Dialysis Grafts: A role for specific cell types, cytokines and native proteins. In Ferguson R and Henry M (eds), Vascular Access for Hemodialysis VI., Precept Press 1998, 45-56.
11. Nickerson PW, Steiger J, Steurer W, Zheng XX, Steele AW, Roy-Chaudhury P, Strom TB. Cytokine networks in transplantation. In Tilney N, Strom TB, Paul L eds. Transplantation Biology; Cellular and Molecular Aspects. Lippincott-Raven, Philadelphia 1997, 391-402.
12. Macleod AM, Roy-Chaudhury P, Catto GRD. The immunosuppressive effects of blood. In Madhok R, Forbes CD, Evatt BL (eds). Blood, Blood Products and AIDS. 2nd Edition. Chapman Hall Medical, London, 1994, 117-153.

b. Refereed Papers/Articles (Original Research)

1. Liu, Z...**Roy-Chaudhury, P**, Singapogu, R. Relating process and outcome metrics for meaningful and interpretable cannulation skill assessment: A machine learning paradigm. *Comput Methods Programs Biomed* **236**, 107429, doi:10.1016/j.cmpb.2023.107429 (2023).
2. He, Y. Shiu YT ... **Roy-Chaudhury P**, ...Cheung AK. Association of Shear Stress with Subsequent Lumen Remodeling in Hemodialysis Arteriovenous Fistulas. *Clin J Am Soc Nephrol* **18**, 72-83, doi:10.2215/CJN.04630422 (2023).
3. Soomro, Q. H. Bansal N, ... **Roy-Chaudhury P**, ... Charytan DM. Association of Bradycardia and Asystole Episodes with Dialytic Parameters: An Analysis of the Monitoring in Dialysis (MiD) Study. *Kidney360* **3**, 1871-1880, doi:10.34067/KID.0003142022 (2022).
4. Vinson, A. J.; Singh, S.; Chadban, S.; Cherney, D.; Gaber, O.; Gill, J. S.; Helgeson, E.; Herzog, C. A.; Jardine, M.; Jha, V.; Kasiske, B. L.; Mannon, R. B.; Michos, E. D.; Mottl, A. K.; Newby, K.; **Roy-Chaudhury, P.**; Sawinski, D.; Sharif, A.; Sridhar, V. S.; Tuttle, K. R.; Vock, D. M.; Matas, A., Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. *J Am Soc Nephrol* 2022, **33** (4), 665-673.
5. Rosado-Toro, J. A.; Philip, R. C.; Dunn, S. T.; Celdran-Bonafonte, D.; He, Y.; Berceli, S. A.; **Roy-Chaudhury, P.**; Tubaldi, E., Functional analysis of arteriovenous fistulae in non-contrast magnetic resonance images. *Comput Methods Programs Biomed* 2022, **222**, 106938.
6. Pochopien, M.; Cherney, D. Z. I.; Drzewiecka, A.; Folkerts, K.; Levy, P.; Millier, A.; Morris, S.; Palarczyk, M.; **Roy-Chaudhury, P.**; Sullivan, S. D.; Mernagh, P., Validation of the FINE-CKD model for future health technology assessments for finerenone in patients with chronic kidney disease and type 2 diabetes. *Am J Manag Care* 2022, **28** (6 Suppl), S104-S111.

7. McGill, J. B.; Haller, H.; **Roy-Chaudhury, P.**; Cherrington, A.; Wada, T.; Wanner, C.; Ji, L.; Rossing, P., Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria. *BMJ Open Diabetes Res Care* 2022, 10 (4).
8. Li, Y.; He, Y.; Falzon, I.; Fairbourn, B.; Tingey, S.; Imrey, P. B.; Radeva, M. K.; Beck, G. J.; Gassman, J. J.; **Roy-Chaudhury, P.**; Berceli, S. A.; Cheung, A. K.; Shiu, Y. T.; Hemodialysis Fistula Maturation, S., Dynamic Remodeling of Human Arteriovenous Fistula Wall Obtained From Magnetic Resonance Imaging During the First 6 Months After Creation. *Kidney Int Rep* 2022, 7 (8), 1905-1909.
9. Koury, M. J.; Agarwal, R.; Chertow, G. M.; Eckardt, K. U.; Fishbane, S.; Ganz, T.; Haase, V. H.; Hanudel, M. R.; Parfrey, P. S.; Pergola, P. E.; **Roy-Chaudhury, P.**; Tumlin, J. A.; Anders, R.; Farag, Y. M. K.; Luo, W.; Minga, T.; Solinsky, C.; Vargo, D. L.; Winkelmayer, W. C., Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. *Am J Hematol* 2022, 97 (9), 1178-1188.
10. Koplan, B. A.; Winkelmayer, W. C.; Costea, A. I.; **Roy-Chaudhury, P.**; Tumlin, J. A.; Kher, V.; Williamson, D. E.; Pokhariyal, S.; Charytan, D. M.; Monitoring in Dialysis, I.; Committees, Implantable Loop Recorder Monitoring and the Incidence of Previously Unrecognized Atrial Fibrillation in Patients on Hemodialysis. *Kidney Int Rep* 2022, 7 (2), 189-199.
11. He, Y.; Shiu, Y. T.; Imrey, P.; Radeva, M.; Beck, G.; Gassman, J.; Northrup, H.; **Roy-Chaudhury, P.**; Berceli, S.; Cheung, A., Association of Shear Stress with Subsequent Lumen Remodeling in Hemodialysis Arteriovenous Fistulas. *Clin J Am Soc Nephrol* 2022.
12. Bakris, G. L.; Ruilope, L. M.; Anker, S. D.; Filippatos, G.; Pitt, B.; Rossing, P.; Fried, L.; **Roy-Chaudhury, P.**; Sarafidis, P.; Ahlers, C.; Brinker, M.; Joseph, A.; Lawatscheck, R.; Agarwal, R.; Fidelio, D. K. D.; Investigators, F.-D., A prespecified exploratory analysis from FIDELITY examined finerenone use and kidney outcomes in patients with chronic kidney disease and type 2 diabetes. *Kidney Int* 2022.
13. Liu Z, Bible J, Petersen L, ... **Roy-Chaudhury P** ... et al. Measuring Cannulation Skills for Hemodialysis: Objective Versus Subjective Assessment. *Front Med (Lausanne)* 2021;8:777186. DOI: 10.3389/fmed.2021.777186.
14. Chan JS, Wang Y, Cornea V, **Roy-Chaudhury P**, Campos B. Early Adventitial Activation and Proliferation in a Mouse Model of Arteriovenous Stenosis: Opportunities for Intervention. *Int J Mol Sci* 2021;22(22). DOI: 10.3390/ijms222212285.
15. Correa S, Scovner KM, Tumlin JA, **Roy-Chaudhury P** et al. Electrolyte Changes in Contemporary Hemodialysis: A Secondary Analysis of the Monitoring in Dialysis (MiD) Study. *Kidney360* 2021;2(4):695-707. DOI: 10.34067/kid.0007452020.
16. Huber TS, Berceli SA, Scali ST, ... **Roy-Chaudhury P** ... et al. Arteriovenous Fistula Maturation, Functional Patency, and Intervention Rates. *JAMA Surg* 2021. DOI: 10.1001/jamasurg.2021.4527.
17. Pochopien MT, Cherney DZI, Folkerts K, ... **Roy-Chaudhury P** ... et al. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes. *Am J Manag Care* 2021;27(20 Suppl):S375-S382. DOI: 10.37765/ajmc.2021.88808.
18. Celdran-Bonafonte D, Wang LH, Jarrouj A, Campos-Naciff B, Janda J, **Roy-Chaudhury P**. A pig model of tunneled dialysis catheter (TDC) infection and dysfunction: Opportunities for therapeutic innovation. *J Vasc Access* 2021;11297298211046751.
19. **Roy-Chaudhury P**, Saad TF, Trerotola S. Drug Coated Balloons and Dialysis Vascular Access-Is there Light at the End of the Tunnel. *Kidney Int.* 2021 Aug;100(2):278-280

20. Skinner SC, Derebail VK, Poulton CJ, Bunch DC, **Roy-Chaudhury P**, Key NS. Hemodialysis-Related Complement and Contact Pathway Activation and Cardiovascular Risk: A Narrative Review. *Kidney Med.* 2021 Jun 9;3(4):607-618.
21. Woo K, Fuld R, Grandinetti A, **Roy-Chaudhury P**, et al. Patient-reported outcomes in hemodialysis vascular access: A call to action. *J Vasc Access* 2021.
22. Trerotola SO, **Roy-Chaudhury P**, Saad TF. Drug-Coated Balloon Angioplasty in Failing Arteriovenous Fistulas: More Data, Less Clarity. *Am J Kidney Dis* 2021.
23. Chertow GM, Pergola PE, Farag YMK ... **Roy-Chaudhury P** ... et al. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. *N Engl J Med* 2021;384:1589-1600.
24. Chan JS, Hsiao PJ, Chiang WF, **Roy-Chaudhury P**. The Role of Oxidative Stress Markers in Predicting Acute Thrombotic Occlusion of Haemodialysis Vascular Access and Progressive Stenotic Dysfunction Demanding Angioplasty. *Antioxidants (Basel)* 2021;10.
25. He Y, Northrup H, **Roy-Chaudhury P**, Cheung AK, Berceli SA, Shiu YT. Analyses of hemodialysis arteriovenous fistula geometric configuration and its associations with maturation and reintervention. *J Vasc Surg* 2021;73(5):1778-1786 e1. DOI: 10.1016/j.jvs.2020.09.033.
26. Liu Z, Zhang Z, Kunkel D, **Roy-Chaudhury P**, Singapogu R. Is Experience in Hemodialysis Cannulation Related to Expertise? A Metrics-based Investigation for Skills Assessment. *Ann Biomed Eng* 2021.
27. Ravikiran Singapogu, Anika Chowdhury, **Prabir Roy-Chaudhury** and Deborah Brouwer-Maier. Simulator-based hemodialysis cannulation skills training: a new horizon? *Kidney Care Journal* 2021
28. Simon Correa, Katherine Mikovna Scovner, James A. Tumlin, **Prabir Roy-Chaudhury**, Bruce A. Koplan, Alexandru I. Costea, Vijay Kher, Don Williamson, Saurabh Pokhariyal, Candace K. McClure, Finnian R. McCausland, David M. Charytan, on behalf of the MiD Investigators, *Kidney* 360, February 2021
29. McCausland FR, Tumlin JA, **Roy-Chaudhury P**, et al. Intradialytic Hypotension and Cardiac Arrhythmias in Patients Undergoing Maintenance Hemodialysis: Results from the Monitoring in Dialysis Study. *Clin J Am Soc Nephrol* 2020;15:805-12.
30. Trerotola SO, **Roy-Chaudhury P**, Saad TF. Drug-Coated Balloons in Dysfunctional Arteriovenous Fistulas: Is it Time? *Am J Kidney Dis* 2020.
31. Lawson JH, Niklason LE, **Roy-Chaudhury P**. Challenges and novel therapies for vascular access in haemodialysis. *Nat Rev Nephrol* 2020;16:586-602.
32. Hegde AS, Kshirsagar AV, **Roy-Chaudhury P**. Dialysis Access: At the Intersection of Policy, Innovation, and Clinical Care. *Adv Chronic Kidney Dis* 2020;27:263-7.
33. Flythe JE, Hilliard TS, Ikeler K, et al. Toward Patient-Centered Innovation: A Conceptual Framework for Patient-Reported Outcome Measures for Transformative Kidney Replacement Devices. *Clin J Am Soc Nephrol* 2020;15:1522-30.
34. Trerotola SO, Saad TF, **Roy-Chaudhury P**, Lutonix AVCTI. The Lutonix AV Randomized Trial of Paclitaxel-Coated Balloons in Arteriovenous Fistula Stenosis: 2-Year Results and Subgroup Analysis. *J Vasc Interv Radiol* 2020;31:1-14 e5.
35. Bonventre JV, Hurst FP, West M, Wu I, **Roy-Chaudhury P**, Sheldon M. A Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies: A Catalyst for Change. *Clin J Am Soc Nephrol* 2019;14:1539-47.

36. Nordyke, R. J., Reichert, H., Bylsma, L. C., Jackson, J. J., Gage, S. M., Fryzek, J., **Roy-Chaudhury, P.** and Lithgow, T. Costs Attributable to Arteriovenous Fistula and Arteriovenous Graft Placements in Hemodialysis Patients with Medicare coverage. *Am J Nephrol* 2019 e pub; DOI: 10.1159/000502507
37. Bijol V, Farag YMK, Harris DCH, Levin A, **Roy-Chaudhury P**, Singh AK, Jhaveri KD. Renal pathology practice globally: identifyin needs and meeting the challenge. *Kidney Int.* 2019 Aug;96(2):258-261. doi: 10.1016/j.kint.2018.10.040. PubMed PMID: 31331460.
38. Celdran Bonafonte D, **Roy-Chaudhury P**. A coming of age for vascular access research: the good, the bad, and the ugly! *Kidney Int.* 2019 Jun;95(6):1294-1295. doi: 10.1016/j.kint.2019.02.035. PubMed PMID: 31122705.
39. Kubiak RW, Zelnick LR, Hoofnagle AN, Alpers CE, Terry CM, Shiu YT, Cheung AK, de Boer IH, Robinson-Cohen C, Allon M, Dember LM, Feldman HI, Himmelfarb J, Huber TS, **Roy-Chaudhury P**, Vazquez MA, Kusek JW, Beck GJ, Imrey PB, Kestenbaum B; Hemodialysis Fistula Maturation Study Group. Mineral Metabolism Disturbances and Arteriovenous Fistula Maturation. *Eur J Vasc Endovasc Surg.* 2019 May;57(5):719-728. doi: 10.1016/j.ejvs.2019.01.022. Epub 2019 Apr 15. PubMed PMID: 31000459.
40. Tumlin JA, **Roy-Chaudhury P**, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and Committees. Relationship between dialytic parameters and reviewer confirmed arrhythmias in hemodialysis patients in the monitoring in dialysis study. *BMC Nephrol.* 2019 Mar 5;20(1):80. doi: 10.1186/s12882-019-1212-6. PubMed PMID: 30836948; PubMed Central PMCID: PMC6402171.
41. Mohr BA, Sheen AL, **Roy-Chaudhury P**, Schultz SR, Aruny JE; REVISE Investigators. Clinical and Economic Benefits of Stent Grafts in Dysfunctional and Thrombosed Hemodialysis Access Graft Circuits in the REVISE Randomized Trial. *J Vasc Interv Radiol.* 2019 Feb;30(2):203-211.e4. doi: 10.1016/j.jvir.2018.12.006. PubMed PMID: 30717951.
42. Bylsma LC, Reichert H, Gage SM, **Roy-Chaudhury P**, Nordyke RJ, Fryzek J, Dahl SLM, Lithgow T, Lawson JH. Clinical Outcomes of Arteriovenous Access in Incident Hemodialysis Patients with Medicare Coverage, 2012-2014. *Am J Nephrol.* 2019;49(2):156-164. doi: 10.1159/000495355. Epub 2019 Jan 24. PubMed PMID: 30677763.
43. Howlader A, Thajudeen B, Kodali L, Martin D, Harland R, **Roy-Chaudhury P**. Page Kidney Following Nephroureteral Stent Placement in a Renal Transplant Allograft. *Prog Transplant.* 2018 Dec 4;1526924818817014. doi: 10.1177/1526924818817014. [Epub ahead of print] PubMed PMID: 30514167.
44. Tong A, Manns B, Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, Crowe S, Harris T, Van Biesen W, Winkelmayr WC, Levin A, Thompson A, Perkovic V, Ju A, Gutman T, Bernier-Jean A, Viecelli AK, O'Lone E, Shen J, Josephson MA, Cho Y, Johnson DW, Sautenet B, Tonelli M, Craig JC; SONG Implementation Workshop Investigators. Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop. *Kidney Int.* 2018 Dec;94(6):1053-1068. doi: 10.1016/j.kint.2018.08.018. Epub 2018 Oct 22. PubMed PMID: 30360959; PubMed Central PMCID: PMC6620755.
45. Robbin ML, Greene T, Allon M, Dember LM, Imrey PB, Cheung AK, Himmelfarb J, Huber TS, Kaufman JS, Radeva MK, **Roy-Chaudhury P**, Shiu YT, Vazquez MA, Umphrey HR, Alexander L, Abts C, Beck GJ, Kusek JW, Feldman HI; Hemodialysis Fistula Maturation Study Group. Prediction of Arteriovenous Fistula Clinical Maturation from Postoperative Ultrasound Measurements: Findings from the Hemodialysis Fistula Maturation Study. *J Am Soc Nephrol.* 2018 Nov;29(11):2735-2744. doi: 10.1681/ASN.2017111225. Epub 2018 Oct 11. PubMed PMID: 30309898; PubMed Central PMCID: PMC6218859.
46. Wang K, Zelnick LR, Imrey PB, deBoer IH, Himmelfarb J, Allon MD, Cheung AK, Dember LM, **Roy-Chaudhury P**, Vazquez MA, Kusek JW, Feldman HI, Beck GJ, Kestenbaum B; the Hemodialysis Fistula Maturation Study Group. Effect of Anti-Hypertensive Medication History on Arteriovenous Fistula Maturation Outcomes. *Am J Nephrol.* 2018;48(1):56-64. doi: 10.1159/000491828. Epub 2018 Aug 2. PubMed PMID: 30071516; PubMed Central PMCID: PMC6421073.

47. Trerotola SO, Lawson J, **Roy-Chaudhury P**, Saad TF; Lutonix AV Clinical Trial Investigators. Drug Coated Balloon Angioplasty in Failing AV Fistulas: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1215-1224. doi: 10.2215/CJN.14231217. Epub 2018 Jul 24. Erratum in: Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1073. PubMed PMID: 30042225; PubMed Central PMCID: PMC6086699.
48. He Y, Shiu YT, Pike DB, **Roy-Chaudhury P**, Cheung AK, Berceli SA. Comparison of hemodialysis arteriovenous fistula blood flow rates measured by Doppler ultrasound and phase-contrast magnetic resonance imaging. J Vasc Surg. 2018 Dec;68(6):1848-1857.e2. doi: 10.1016/j.jvs.2018.02.043. Epub 2018 May 18. PubMed PMID: 29779960; PubMed Central PMCID: PMC6240398.
49. Shenoy S, Allon M, Beathard G, Brouwer-Maier D, Dember LM, Glickman M, Lee C, Litchfield T, Lok C, Huber T, **Roy-Chaudhury P**, Work J, West M, Wasse H. Clinical Trial End Points for Hemodialysis Vascular Access: Background, Rationale, and Definitions. Clin J Am Soc Nephrol. 2018 Mar 7;13(3):490-494. doi: 10.2215/CJN.13321216. Epub 2018 Feb 27. PubMed PMID: 29487092; PubMed Central PMCID: PMC5967685.
50. Vieceilli AK, Tong A, O'Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, Manns B, Howell M, Chemla E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Hawley CM; SONG-HD Vascular Access Workshop Investigators. Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. Am J Kidney Dis. 2018 May;71(5):690-700. doi: 10.1053/j.ajkd.2017.12.003. Epub 2018 Feb 23. PubMed PMID: 29478866.
51. Allon M, Imrey PB, Cheung AK, Radeva M, Alpers CE, Beck GJ, Dember LM, Farber A, Greene T, Himmelfarb J, Huber TS, Kaufman JS, Kusek JW, **Roy-Chaudhury P**, Robbin ML, Vazquez MA, Feldman HI; Hemodialysis Fistula Maturation (HFM) Study Group. Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study. Am J Kidney Dis. 2018 May;71(5):677-689. doi: 10.1053/j.ajkd.2017.10.027. Epub 2018 Feb 2. PubMed PMID: 29398178; PubMed Central PMCID: PMC5916528.
52. **Roy-Chaudhury P**, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, Pokhariyal S, Charytan DM; MiD investigators and committees. Primary outcomes of the Monitoring in Dialysis Study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018 Apr;93(4):941-951. doi: 10.1016/j.kint.2017.11.019. Epub 2018 Feb 12. PubMed PMID: 29395340.
53. **Roy-Chaudhury P**. Exploring Novel Endpoints for Clinical Trials in Kidney Disease: Challenges and Opportunities. Kidney Int Rep. 2017 Apr 7;2(3):295-296. doi: 10.1016/j.ekir.2017.04.001. eCollection 2017 May. PubMed PMID: 29318213; PubMed Central PMCID: PMC5720537.
54. Saum K, Campos B, Celdran-Bonafonte D, Nayak L, Sangwung P, Thakar C, **Roy-Chaudhury P**, Owens AP Iii PhD. Uremic Advanced Glycation End Products and Protein-Bound Solutes Induce Endothelial Dysfunction Through Suppression of Krüppel-Like Factor 2. J Am Heart Assoc. 2018 Jan 4;7(1). pii: e007566. doi: 10.1161/JAHA.117.007566. PubMed PMID: 29301761; PubMed Central PMCID: PMC5778969.
55. Beathard GA, Lok CE, Glickman MH, Al-Jaishi AA, Bednarski D, Cull DL, Lawson JH, Lee TC, Niyyar VD, Syracuse D, Trerotola SO, **Roy-Chaudhury P**, Shenoy S, Underwood M, Wasse H, Woo K, Yuo TH, Huber TS. Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. Clin J Am Soc Nephrol. 2018 Mar 7;13(3):501-512. doi: 10.2215/CJN.11531116. Epub 2017 Jul 20. PubMed PMID: 28729383; PubMed Central PMCID: PMC5967683.
56. Allon M, Brouwer-Maier DJ, Abreo K, Baskin KM, Bregel K, Chand DH, Easom AM, Mermel L, Mokrzycki MH, Patel PR, **Roy-Chaudhury P**, Shenoy S, Valentini RP, Wasse H. Recommended Clinical Trial End Points for Dialysis Catheters. Clin J Am Soc Nephrol. 2018 Mar 7;13(3):495-500. doi: 10.2215/CJN.12011116. Epub 2017 Jul 20. PubMed PMID: 28729382; PubMed Central PMCID: PMC5967684.

57. Alpers CE, Imrey PB, Hudkins KL, Wietecha TA, Radeva M, Allon M, Cheung AK, Dember LM, **Roy-Chaudhury P**, Shiu YT, Terry CM, Farber A, Beck GJ, Feldman HI, Kusek JW, Himmelfarb J; Hemodialysis Fistula Maturation Study Group. Histopathology of Veins Obtained at Hemodialysis Arteriovenous Fistula Creation Surgery. *J Am Soc Nephrol*. 2017 Oct;28(10):3076-3088. doi: 10.1681/ASN.2016050598. Epub 2017 Jul 19. PubMed PMID: 28724774; PubMed Central PMCID: PMC5619951.
58. Cheung AK, Imrey PB, Alpers CE, Robbin ML, Radeva M, Larive B, Shiu YT, Allon M, Dember LM, Greene T, Himmelfarb J, **Roy-Chaudhury P**, Terry CM, Vazquez MA, Kusek JW, Feldman HI; Hemodialysis Fistula Maturation Study Group. Intimal Hyperplasia, Stenosis, and Arteriovenous Fistula Maturation Failure in the Hemodialysis Fistula Maturation Study. *J Am Soc Nephrol*. 2017 Oct;28(10):3005-3013. doi: 10.1681/ASN.2016121355. Epub 2017 Jul 14. PubMed PMID: 28710091; PubMed Central PMCID: PMC5619966.
59. van Ballegooijen AJ, Zelnick L, Hoofnagle AN, Hamburg NM, Robinson-Cohen C, **Roy-Chaudhury P**, Cheung AK, Shiu YT, de Boer IH, Himmelfarb J, Beck G, Imrey PB, Kusek JW, Kestenbaum B; Hemodialysis Fistula Maturation (HFM) Study Group. Association of Vitamin D Metabolites with Arterial Function in the Hemodialysis Fistula Maturation Study. *Am J Kidney Dis*. 2017 Jun;69(6):805-814. doi: 10.1053/j.ajkd.2017.01.049. Epub 2017 Mar 27. PubMed PMID: 28359657; PubMed Central PMCID: PMC5441944.
60. Buszek SM, **Roy-Chaudhury P**, Yadlapalli G. Olanzapine-Induced Hypertriglyceridemia Resulting in Necrotizing Pancreatitis. *ACG Case Rep J*. 2016 Aug 17;3(4):e104. eCollection 2016 Aug. PubMed PMID: 27807566; PubMed Central PMCID: PMC5062670.
61. **Roy-Chaudhury P**. Pragmatic, Precision Medicine Approaches for Dialysis Vascular Access Dysfunction: Challenges and Opportunities. *Clin J Am Soc Nephrol*. 2016 Sep 7;11(9):1525-6. doi: 10.2215/CJN.08160816. Epub 2016 Aug 30. PubMed PMID: 27577242; PubMed Central PMCID: PMC5012483.
62. **Roy-Chaudhury P**. Dialysis: Bioengineered vessels for dialysis access: soon to be a reality? *Nat Rev Nephrol*. 2016 Sep;12(9):516-7. doi: 10.1038/nrneph.2016.119. Epub 2016 Aug 1. PubMed PMID: 27477493.
63. Dember LM, Imrey PB, Duess MA, Hamburg NM, Larive B, Radeva M, Himmelfarb J, Kraiss LW, Kusek JW, **Roy-Chaudhury P**, Terry CM, Vazquez MA, Vongpatanasin W, Beck GJ, Vita JA; Hemodialysis Fistula Maturation Study Group. Feldman H, Farber A, Kaufman J, Stern L, LeSage P, Kivork Cm Soares D, Malikova M, Allon M, Young C, Taylor M, Woodard L, Mangadi K, Munda R, Lee T, AllowayR, El-Khatib M, Canaan T, Pflum A, Thieken L, Campos-Naciff B, Huber T, Berceli S, Jansen M, McCaslin G, Trahan Y, Davidson I, Hwang C, Lightfoot T, Livingston C, Valencia A, Dolmatch B, Fenves A, Hawkins N, Cheung A, Kinikini D, Treiman G, Ihnat D, Sarfati M, Lavasanil MM, Schlotfeldt L, Buchanan C, Clark C, Crawford C, Hamlett J, Kundzins J, Manahan L, Wise J, Gassman J, Greene T. Vascular Function at Baseline in the Hemodialysis Fistula Maturation Study. *J Am Heart Assoc*. 2016 Jul 22;5(7). pii: e003227. doi: 10.1161/JAHA.116.003227. PubMed PMID: 27451463; PubMed Central PMCID: PMC5015367.
64. Epstein M, **Roy-Chaudhury P**. Arrhythmias and sudden cardiac death in hemodialysis patients. Temporal profile, electrolyte abnormalities, and potential targeted therapies. *Nephrol News Issues*. 2016 Apr;30(4):suppl 23-6. PubMed PMID: 27254902.
65. Linde PG, Archdeacon P, Breyer MD, Ibrahim T, Inrig JK, Kewalramani R, Lee CC, Neuland CY, **Roy-Chaudhury P**, Sloand JA, Meyer R, Smith KA, Snook J, West M, Falk RJ. Overcoming Barriers in Kidney Health-Forging a Platform for Innovation. *J Am Soc Nephrol*. 2016 Jul;27(7):1902-10. doi: 10.1681/ASN.2015090976. Epub 2016 Apr 28. PubMed PMID: 27127187; PubMed Central PMCID: PMC4926987.
66. Wong CY, de Vries MR, Wang Y, van der Vorst JR, Vahrmeijer AL, van Zonneveld AJ, Hamming JF, **Roy-Chaudhury P**, Rabelink TJ, Quax PH, Rotmans JI. A Novel Murine Model of Arteriovenous Fistula Failure: The Surgical Procedure in Detail. *J Vis Exp*. 2016 Feb 3;(108):e53294. doi: 10.3791/53294. PubMed PMID: 26863177; PubMed Central PMCID: PMC4781715.

67. Farber A, Imrey PB, Huber TS, Kaufman JM, Kraiss LW, Larive B, Li L, Feldman HI; HFM Study Group. Multiple preoperative and intraoperative factors predict early fistula thrombosis in the Hemodialysis Fistula Maturation Study. *J Vasc Surg.* 2016 Jan;63(1):163-70.e6. doi: 10.1016/j.jvs.2015.07.086. PubMed PMID: 26718822; PubMed Central PMCID: PMC4698902.
68. Robbin ML, Greene T, Cheung AK, Allon M, Berceli SA, Kaufman JS, Allen M, Imrey PB, Radeva MK, Shiu YT, Umphrey HR, Young CJ; Hemodialysis Fistula Maturation Study Group. Arteriovenous Fistula Development in the First 6 Weeks after Creation. *Radiology.* 2016 May;279(2):620-9. doi: 10.1148/radiol.2015150385. Epub 2015 Dec 22. PubMed PMID: 26694050; PubMed Central PMCID: PMC4851120.
69. Mittal T, Dedhia P, **Roy-Chaudhury P**, Abu Jawdeh BG, Mogilishetty G, Cuffy MC, Alloway RR, Woodle ES, Govil A. Complete Remission of Post-transplantation Recurrence of Focal Segmental Glomerulosclerosis with the Use of Adrenocorticotrophic Hormone Gel: Case Report. *Transplant Proc.* 2015 Sep;47(7):2219-22. doi: 10.1016/j.transproceed.2015.07.013. PubMed PMID: 26361683.
70. Glickman MH, Burgess J, Cull D, **Roy-Chaudhury P**, Schanzer H. Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis. *J Vasc Surg.* 2015 Aug;62(2):434-41. doi: 10.1016/j.jvs.2015.03.020. Epub 2015 May 4. PubMed PMID: 25953016.
71. Liang M, Wang Y, Liang A, Mitch WE, **Roy-Chaudhury P**, Han G, Cheng J. Migration of smooth muscle cells from the arterial anastomosis of arteriovenous fistulas requires Notch activation to form neointima. *Kidney Int.* 2015 Sep;88(3):490-502. doi: 10.1038/ki.2015.73. Epub 2015 Mar 18. PubMed PMID: 25786100; PubMed Central PMCID: PMC4677993.
72. **Roy-Chaudhury P**, Verma A. Improving patient safety in vascular access: a role for individualization and patient preferences. *Contrib Nephrol.* 2015;184:136-42. doi: 10.1159/000367680. Epub 2015 Feb 9. PubMed PMID: 25676298.
73. Nikam M, Chemla ES, Evans J, Summers A, Brenchley P, Tavakoli A, **Roy-Chaudhury P**, Mitra S. Prospective controlled pilot study of arteriovenous fistula placement using the novel Optiflow device. *J Vasc Surg.* 2015 Apr;61(4):1020-5. doi: 10.1016/j.jvs.2014.11.082. Epub 2015 Jan 13. PubMed PMID: 25595404.
74. Woodle ES, Shields AR, Ejaz NS, Sadaka B, Girnita A, Walsh RC, Alloway RR, Brailey P, Cardi MA, Abu Jawdeh BG, **Roy-Chaudhury P**, Govil A, Mogilishetty G. Prospective iterative trial of proteasome inhibitor-based desensitization. *Am J Transplant.* 2015 Jan;15(1):101-18. doi: 10.1111/ajt.13050. PubMed PMID: 25534446.
75. Chitalia N, Ross L, Krishnamoorthy M, Kapustin A, Shanahan CM, Kaski JC, **Roy-Chaudhury P**, Chemla E, Banerjee D. Neointimal hyperplasia and calcification in medium sized arteries in adult patients with chronic kidney disease. *Semin Dial.* 2015 May-Jun;28(3):E35-40. doi: 10.1111/sdi.12335. Epub 2014 Dec 9. PubMed PMID: 25488635.
76. Zahedi K, Barone S, Wang Y, Murray-Stewart T, **Roy-Chaudhury P**, Smith RD, Casero RA Jr, Soleimani M. Proximal tubule epithelial cell specific ablation of the spermidine/spermine N1-acetyltransferase gene reduces the severity of renal ischemia/reperfusion injury. *PLoS One.* 2014 Nov 12;9(11):e110161. doi: 10.1371/journal.pone.0110161. eCollection 2014. PubMed PMID: 25390069; PubMed Central PMCID: PMC4229091.
77. Nolin TD, Aronoff GR, Fissell WH, Jain L, Madabushi R, Reynolds K, Zhang L, Huang SM, Mehrotra R, Flessner MF, Leyppoldt JK, Witcher JW, Zineh I, Archdeacon P, **Roy-Chaudhury P**, Goldstein SL; Kidney Health Initiative. Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative. *Clin J Am Soc Nephrol.* 2015 Jan 7;10(1):159-64. doi: 10.2215/CJN.05630614. Epub 2014 Sep 4. PubMed PMID: 25189923; PubMed Central PMCID: PMC4284416.
78. Brahmbhatt A, NievesTorres E, Yang B, Edwards WD, Roy Chaudhury P, Lee MK, Kong H, Mukhopadhyay D, Kumar R, Misra S. The role of Irf-1 in the pathogenesis of venous neointimal hyperplasia associated with

hemodialysis arteriovenous fistula. PLoS One. 2014 Jul 18;9(7):e102542. doi: 10.1371/journal.pone.0102542. eCollection 2014. PubMed PMID: 25036043; PubMed Central PMCID: PMC4103828.

79. Chan JS, Campos B, Wang Y, Mistry M, Lee T, Munda R, Arend L, **Roy-Chaudhury P**. Proliferation patterns in a pig model of AV fistula stenosis: can we translate biology into novel therapies? Semin Dial. 2014 Nov-Dec;27(6):626-32. doi: 10.1111/sdi.12240. Epub 2014 May 28. PubMed PMID: 24865128.
80. Dwivedi AJ, **Roy-Chaudhury P**, Peden EK, Browne BJ, Ladenheim ED, Scavo VA, Gustafson PN, Wong MD, Magill M, Lindow F, Blair AT, Jaff MR, Franano FN, Burke SK. Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease. J Vasc Access. 2014 Sep-Oct;15(5):376-84. doi: 10.5301/jva.5000235. Epub 2014 May 3. PubMed PMID: 24811601; PubMed Central PMCID: PMC6159820.
81. Reddy YN, Abraham G, Pavanathan A, **Roy-Chaudhury P**. Current state of renal transplantation in India. J Indian Med Assoc. 2013 Aug;111(8):518-20, 522-3. PubMed PMID: 24783389.
82. Lee T, Somarathna M, Hura A, Wang Y, Campos B, Arend L, Munda R, **Roy-Chaudhury P**. Natural history of venous morphologic changes in dialysis access stenosis. J Vasc Access. 2014 Jul-Aug;15(4):298-305. doi: 10.5301/jva.5000212. Epub 2014 Feb 4. PubMed PMID: 24500849.
83. Lee T, Wang Y, Arend L, Cornea V, Campos B, Munda R, **Roy-Chaudhury P**. Comparative analysis of cellular phenotypes within the neointima from vein segments collected prior to vascular access surgery and stenotic arteriovenous dialysis accesses. Semin Dial. 2014 May-Jun;27(3):303-9. doi: 10.1111/sdi.12172. Epub 2013 Dec 17. PubMed PMID: 24341903; PubMed Central PMCID: PMC3999181.
84. **Roy-Chaudhury P**, Lee TC, Munda R. Predicting dialysis vascular access blood flow and diameter: too much, too little, or just right. Kidney Int. 2013 Dec;84(6):1076-8. doi: 10.1038/ki.2013.307. PubMed PMID: 24280751.
85. Rajabi-Jagahrgh E, **Roy-Chaudhury P**, Wang Y, Al-Rjoub M, Campos-Naciff B, Choe A, Dumoulin C, Banerjee RK. New techniques for determining the longitudinal effects of local hemodynamics on the intima-media thickness in arteriovenous fistulae in an animal model. Semin Dial. 2014 Jul-Aug;27(4):424-35. doi: 10.1111/sdi.12162. Epub 2013 Nov 22. PubMed PMID: 24261988.
86. Chemla E, Tavakoli A, Nikam M, Mitra S, Malette T, Evans J, **Roy-Chaudhury P**. Arteriovenous fistula creation using the Optiflow™ vascular anastomotic connector: the OPEN (Optiflow PatEncy and MaturationN) study. J Vasc Access. 2014 Jan-Feb;15(1):38-44. doi: 10.5301/jva.5000169. Epub 2013 Sep 11. PubMed PMID: 24043330.
87. **Roy-Chaudhury P**, Khan R, Campos B, Wang Y, Kurian M, Lee T, Arend L, Munda R. Pathogenetic role for early focal macrophage infiltration in a pig model of arteriovenous fistula (AVF) stenosis. J Vasc Access. 2014 Jan-Feb;15(1):25-8. doi: 10.5301/jva.5000151. Epub 2013 Sep 3. PubMed PMID: 24043320.
88. Dember LM, Imrey PB, Beck GJ, Cheung AK, Himmelfarb J, Huber TS, Kusek JW, **Roy-Chaudhury P**, Vazquez MA, Alpers CE, Robbin ML, Vita JA, Greene T, Gassman JJ, Feldman HI; Hemodialysis Fistula Maturation Study Group. Objectives and design of the hemodialysis fistula maturation study. Am J Kidney Dis. 2014 Jan;63(1):104-12. doi: 10.1053/j.ajkd.2013.06.024. Epub 2013 Aug 28. PubMed PMID: 23992885; PubMed Central PMCID: PMC4134933.
89. Archdeacon P, Shaffer RN, Winkelmayer WC, Falk RJ, **Roy-Chaudhury P**. Fostering innovation, advancing patient safety: the kidney health initiative. Clin J Am Soc Nephrol. 2013 Sep;8(9):1609-17. doi: 10.2215/CJN.01140113. Epub 2013 Jun 6. PubMed PMID: 23744001; PubMed Central PMCID: PMC3805066.
90. Wong CY, de Vries MR, Wang Y, van der Vorst JR, Vahrmeijer AL, van Zonneveld AJ, **Roy-Chaudhury P**, Rabelink TJ, Quax PH, Rotmans JJ. Vascular remodeling and intimal hyperplasia in a novel murine model of arteriovenous fistula failure. J Vasc Surg. 2014 Jan;59(1):192-201.e1. doi: 10.1016/j.jvs.2013.02.242. Epub 2013 May 15. PubMed PMID: 23684425.

91. Rajabi-Jagahrgh E, Krishnamoorthy MK, Wang Y, Choe A, **Roy-Chaudhury P**, Banerjee RK. Influence of temporal variation in wall shear stress on intima-media thickening in arteriovenous fistulae. *Semin Dial.* 2013 Jul-Aug;26(4):511-9. doi: 10.1111/sdi.12045. Epub 2012 Dec 23. PubMed PMID: 23278290.
92. Peden EK, Leaser DB, Dixon BS, El-Khatib MT, **Roy-Chaudhury P**, Lawson JH, Menard MT, Dember LM, Glickman MH, Gustafson PN, Blair AT, Magill M, Franano FN, Burke SK. A multi-center, dose-escalation study of human type I pancreatic elastase (PRT-201) administered after arteriovenous fistula creation. *J Vasc Access.* 2013 Apr-Jun;14(2):143-51. doi: 10.5301/jva.5000125. Epub 2012 Nov 20. PubMed PMID: 23172172; PubMed Central PMCID: PMC6159815.
93. **Roy-Chaudhury P**, Chan JS, Lee T, Mistry M, Campos B, Wang Y, Munda R. Of veins, valves, and vascular access! *Kidney Int.* 2012 Dec;82(11):1236-7. doi: 10.1038/ki.2012.316. PubMed PMID: 23151987.
94. **Roy-Chaudhury P**, Arnold P, Seigel J, Misra S. From basic biology to randomized clinical trial: The Beta Radiation for Arteriovenous Graft Outflow Stenosis (BRAVO II). *Semin Dial.* 2013 Mar-Apr;26(2):227-32. doi: 10.1111/sdi.12000. Epub 2012 Oct 16. PubMed PMID: 23067015; PubMed Central PMCID: PMC3837299.
95. Rajabi-Jagahrgh E, Krishnamoorthy MK, **Roy-Chaudhury P**, Succop P, Wang Y, Choe A, Banerjee RK. Longitudinal assessment of hemodynamic endpoints in predicting arteriovenous fistula maturation. *Semin Dial.* 2013 Mar-Apr;26(2):208-15. doi: 10.1111/j.1525-139X.2012.01112.x. Epub 2012 Aug 14. PubMed PMID: 22892020.
96. Manson RJ, Ebner A, Gallo S, Chemla E, Mantell M, Deaton D, **Roy-Chaudhury P**. Arteriovenous fistula creation using the Optiflow vascular anastomosis device: a first in man pilot study. *Semin Dial.* 2013 Jan-Feb;26(1):97-9. doi: 10.1111/j.1525-139X.2012.01062.x. Epub 2012 Apr 4. PubMed PMID: 22486998.
97. Lee T, Safdar N, Mistry MJ, Wang Y, Chauhan V, Campos B, Munda R, Cornea V, **Roy-Chaudhury P**. Preexisting venous calcification prior to dialysis vascular access surgery. *Semin Dial.* 2012 Sep-Oct;25(5):592-5. doi: 10.1111/j.1525-139X.2012.01063.x. Epub 2012 Mar 27. PubMed PMID: 22452638; PubMed Central PMCID: PMC3961753.
98. Lee T, Tindni A, **Roy-Chaudhury P**. Improved cumulative survival in fistulas requiring surgical interventions to promote fistula maturation compared with endovascular interventions. *Semin Dial.* 2013 Jan-Feb;26(1):85-9. doi: 10.1111/j.1525-139X.2012.01060.x. Epub 2012 Mar 9. PubMed PMID: 22404567; PubMed Central PMCID: PMC3965258.
99. Krishnamoorthy MK, Banerjee RK, Wang Y, Choe AK, Rigger D, **Roy-Chaudhury P**. Anatomic configuration affects the flow rate and diameter of porcine arteriovenous fistulae. *Kidney Int.* 2012 Apr;81(8):745-50. doi: 10.1038/ki.2011.468. Epub 2012 Feb 22. PubMed PMID: 22358147.
100. **Roy-Chaudhury P**, Duncan HJ, Zuckerman D, Faiyaz R, Munda R, Kant S, Kelly B, Narayana A. External beam radiation therapy for PTFE dialysis grafts: a pilot study. *J Vasc Access.* 2012 Jul-Sep;13(3):329-31. doi: 10.5301/jva.5000052. PubMed PMID: 22287221.
101. Ahmed S, **Roy-Chaudhury P**. Radiation therapy for dialysis access stenosis: unfulfilled promise or false expectations. *Semin Dial.* 2012 Jul;25(4):464-9. doi: 10.1111/j.1525-139X.2011.01006.x. Epub 2012 Jan 25. PubMed PMID: 22276964.
102. Abraham G, Reddy YN, Amalorpavanathan J, Daniel D, **Roy-Chaudhury P**, Shroff S, Reddy Y. How deceased donor transplantation is impacting a decline in commercial transplantation-the Tamil Nadu experience. *Transplantation.* 2012 Apr 27;93(8):757-60. doi: 10.1097/TP.0b013e3182469b91. PubMed PMID: 22245870.
103. Calderon KN, Sachdeva MB, **Roy-Chaudhury PT**, Jhaveri KD. Nephrology Crossword: Interventional nephrology--dialysis access and beyond! *Kidney Int.* 2012 Feb;81(3):327-8. doi: 10.1038/ki.2011.373. PubMed PMID: 22241567.

104. Conte MS, Nugent HM, Gaccione P, **Roy-Chaudhury P**, Lawson JH. Influence of diabetes and perivascular allogeneic endothelial cell implants on arteriovenous fistula remodeling. *J Vasc Surg.* 2011 Nov;54(5):1383-9. doi: 10.1016/j.jvs.2011.05.005. Epub 2011 Aug 15. PubMed PMID: 21840154.
105. Walsh RC, Brailey P, Girnita A, Alloway RR, Shields AR, Wall GE, Sadaka BH, Cardi M, Tevar A, Govil A, Mogilishetty G, **Roy-Chaudhury P**, Woodle ES. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. *Transplantation.* 2011 Jun 15;91(11):1218-26. doi: 10.1097/TP.0b013e318218e901. PubMed PMID: 21617586.
106. Lee T, **Roy-Chaudhury P**, Thakar CV. Improving incident fistula rates: a process of care issue. *Am J Kidney Dis.* 2011 Jun;57(6):814-7. doi: 10.1053/j.ajkd.2011.04.007. PubMed PMID: 21601127; PubMed Central PMCID: PMC3966103.
107. Lee T, Chauhan V, Krishnamoorthy M, Wang Y, Arend L, Mistry MJ, El-Khatib M, Banerjee R, Munda R, **Roy-Chaudhury P**. Severe venous neointimal hyperplasia prior to dialysis access surgery. *Nephrol Dial Transplant.* 2011 Jul;26(7):2264-70. doi: 10.1093/ndt/gfq733. Epub 2011 Jan 10. PubMed PMID: 21220751; PubMed Central PMCID: PMC3145379.
108. Lee T, Ullah A, Allon M, Succop P, El-Khatib M, Munda R, **Roy-Chaudhury P**. Decreased cumulative access survival in arteriovenous fistulas requiring interventions to promote maturation. *Clin J Am Soc Nephrol.* 2011 Mar;6(3):575-81. doi: 10.2215/CJN.06630810. Epub 2010 Nov 18. PubMed PMID: 21088288; PubMed Central PMCID: PMC3082416.
109. Guasch A, **Roy-Chaudhury P**, Woodle ES, Fitzsimmons W, Holman J, First MR; FK778 BK Nephropathy Study Group. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. *Transplantation.* 2010 Oct 27;90(8):891-7. doi: 10.1097/TP.0b013e3181f2c94b. PubMed PMID: 20811320.
110. Walsh RC, Everly JJ, Brailey P, Rike AH, Arend LJ, Mogilishetty G, Govil A, **Roy-Chaudhury P**, Alloway RR, Woodle ES. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. *Transplantation.* 2010 Feb 15;89(3):277-84. doi: 10.1097/TP.0b013e3181c6ff8d. PubMed PMID: 20145517.
111. Conte MS, Nugent HM, Gaccione P, Guleria I, **Roy-Chaudhury P**, Lawson JH. Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: The V-HEALTH study. *J Vasc Surg.* 2009 Dec;50(6):1359-68.e1. doi: 10.1016/j.jvs.2009.07.108. PubMed PMID: 19958986.
112. **Roy-Chaudhury P**, Wang Y, Krishnamoorthy M, Zhang J, Banerjee R, Munda R, Heffelfinger S, Arend L. Cellular phenotypes in human stenotic lesions from haemodialysis vascular access. *Nephrol Dial Transplant.* 2009 Sep;24(9):2786-91. doi: 10.1093/ndt/gfn708. Epub 2009 Apr 17. PubMed PMID: 19377054; PubMed Central PMCID: PMC2734173.
113. Everly MJ, Everly JJ, Arend LJ, Brailey P, Susskind B, Govil A, Rike A, **Roy-Chaudhury P**, Mogilishetty G, Alloway RR, Tevar A, Woodle ES. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. *Am J Transplant.* 2009 May;9(5):1063-71. doi: 10.1111/j.1600-6143.2009.02577.x. Epub 2009 Mar 16. PubMed PMID: 19344434.
114. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, **Roy-Chaudhury P**, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Brown E, Tevar A, Woodle ES. Proteasome inhibition reduces donor-specific antibody levels. *Transplant Proc.* 2009 Jan-Feb;41(1):105-7. doi: 10.1016/j.transproceed.2008.10.073. PubMed PMID: 19249489.
115. Walker JK, Alloway RR, **Roy-Chaudhury P**, Mogilishetty G, Cardi MA, Weimert NA, Rike AH, First MR, Woodle ES. A prospective trial of a steroid-free/calcineurin inhibitor minimization regimen in human leukocyte antigen (HLA)-identical live donor renal transplantation. *Transplantation.* 2009 Feb 15;87(3):408-14. doi: 10.1097/TP.0b013e318194515c. PubMed PMID: 19202447.

116. Govil A, Walsh RC, Tevar A, Alloway R, **Roy-Chaudhury P**, Mogilishetty G, Wall GE, Brailey P, Girnita A, Woodle ES. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients. Clin Transpl. 2009;443-53. PubMed PMID: 20524313.
117. Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR, **Roy-Chaudhury P**, Govil A, Mogilishetty G, Rike AH, Cardi M, Wadih G, Tevar A, Woodle ES. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation. 2008 Dec 27;86(12):1754-61. doi: 10.1097/TP.0b013e318190af83. PubMed PMID: 19104417.
118. Krishnamoorthy MK, Banerjee RK, Wang Y, Zhang J, Sinha Roy A, Khoury SF, Arend LJ, Rudich S, **Roy-Chaudhury P**. Hemodynamic wall shear stress profiles influence the magnitude and pattern of stenosis in a pig AV fistula. Kidney Int. 2008 Dec;74(11):1410-9. doi: 10.1038/ki.2008.379. Epub 2008 Sep 24. PubMed PMID: 18818686.
119. Wu Y, Zhang F, Wang Y, Krishnamoorthy M, **Roy-Chaudhury P**, Bleske BE, Meyerhoff ME. Photoinstability of S-nitrosothiols during sampling of whole blood: a likely source of error and variability in S-nitrosothiol measurements. Clin Chem. 2008 May;54(5):916-8. doi: 10.1373/clinchem.2007.102103. PubMed PMID: 18443178.
120. Krishnamoorthy M, **Roy-Chaudhury P**, Wang Y, Sinha Roy A, Zhang J, Khoury S, Munda R, Banerjee R. Measurement of hemodynamic and anatomic parameters in a swine arteriovenous fistula model. J Vasc Access. 2008 Jan-Mar;9(1):28-34. PubMed PMID: 18379977.
121. Rike AH, Mogilishetty G, Alloway RR, Succop P, **Roy-Chaudhury P**, Cardi M, Kaiser TE, Thomas M, Woodle ES. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant. 2008 Mar-Apr;22(2):229-35. doi: 10.1111/j.1399-0012.2007.00779.x. PubMed PMID: 18339144.
122. Besarab A, Ravani P, Spergel LM, **Roy-Chaudhury P**, Asif A. The native arteriovenous fistula in 2007. Research needs. J Nephrol. 2007 Nov-Dec;20(6):668-73. PubMed PMID: 18046668.
123. Wang Y, Krishnamoorthy M, Banerjee R, Zhang J, Rudich S, Holland C, Arend L, **Roy-Chaudhury P**. Venous stenosis in a pig arteriovenous fistula model--anatomy, mechanisms and cellular phenotypes. Nephrol Dial Transplant. 2008 Feb;23(2):525-33. Epub 2007 Nov 23. PubMed PMID: 18037619.
124. **Roy-Chaudhury P**. Utility of formaldehyde-fixed arterial allografts for hemodialysis access. Nat Clin Pract Nephrol. 2008 Feb;4(2):74-5. Epub 2007 Nov 20. PubMed PMID: 18030292.
125. **Roy-Chaudhury P**, Arend L, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Samaha A, Munda R. Neointimal hyperplasia in early arteriovenous fistula failure. Am J Kidney Dis. 2007 Nov;50(5):782-90. PubMed PMID: 17954291.
126. Asif A, Besarab A, **Roy-Chaudhury P**, Spergel LM, Ravani P. Interventional nephrology: from episodic to coordinated vascular access care. J Nephrol. 2007 Jul-Aug;20(4):399-405. PubMed PMID: 17879204.
127. Asif A, **Roy-Chaudhury P**, Beathard GA. Early arteriovenous fistula failure: a logical proposal for when and how to intervene. Clin J Am Soc Nephrol. 2006 Mar;1(2):332-9. Epub 2005 Nov 30. Review. PubMed PMID: 17699225.
128. Zhang J, Melhem M, Kassing W, Kelly B, Wang Y, Krishnamoorthy M, Heffelfinger S, Desai P, **Roy-Chaudhury P**. In vitro paclitaxel and radiation effects on the cell types responsible for vascular stenosis: a preliminary analysis. Blood Purif. 2007;25(2):155-60. Epub 2006 Dec 18. PubMed PMID: 17179736.
129. Duncan HJ, Pittman S, Govil A, Sorn L, Bissler G, Schultz T, Faith J, Kant S, **Roy-Chaudhury P**. Alternative medicine use in dialysis patients: potential for good and bad! Nephron Clin Pract. 2007;105(3):c108-13. Epub 2006 Dec 15. PubMed PMID: 17179733.

130. Misra S, Bonan R, Pflederer T, **Roy-Chaudhury P**; BRAVO I Investigators. BRAVO I: A pilot study of vascular brachytherapy in polytetrafluoroethylene dialysis access grafts. *Kidney Int.* 2006 Dec;70(11):2006-13. Epub 2006 Oct 11. PubMed PMID: 17035947.
131. **Roy-Chaudhury P**. Spontaneous self-alkalinization in spontaneous tumor lysis syndrome. *Kidney Int.* 2006 Sep;70(5):824. PubMed PMID: 16929328.
132. Kelly B, Melhem M, Zhang J, Kasting G, Li J, Krishnamoorthy M, Heffelfinger S, Rudich S, Desai P, **Roy-Chaudhury P**. Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. *Nephrol Dial Transplant.* 2006 Sep;21(9):2425-31. Epub 2006 Jul 5. PubMed PMID: 16822794.
133. Alexander JW, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, Huang S, Munda R, Fidler JP, Buell JF, Hanaway M, Susskind B, **Roy-Chaudhury P**, Trofe J, Alloway R, Woodle ES. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. *Transpl Int.* 2006 Apr;19(4):295-302. PubMed PMID: 16573545.
134. **Roy-Chaudhury P**, Melhem M, Husted T, Kelly BS. Solutions for hemodialysis vascular access dysfunction: thinking out of the box!! *J Vasc Access.* 2005 Jan-Mar;6(1):3-8. PubMed PMID: 16552674.
135. Chen Y, Trofe J, Gordon J, Du Pasquier RA, **Roy-Chaudhury P**, Kuroda MJ, Woodle ES, Khalili K, Koralknik IJ. Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. *J Virol.* 2006 Apr;80(7):3495-505. PubMed PMID: 16537617; PubMed Central PMCID: PMC1440396.
136. Melhem M, Kelly B, Zhang J, Kasting G, Li J, Davis H, Heffelfinger S, Desai P, **Roy-Chaudhury P**. Development of a local perivascular paclitaxel delivery system for hemodialysis vascular access dysfunction: polymer preparation and in vitro activity. *Blood Purif.* 2006;24(3):289-98. Epub 2006 Feb 7. PubMed PMID: 16465049.
137. Woodle ES, Alloway RR, Buell JF, Alexander JW, Munda R, **Roy-Chaudhury P**, First MR, Cardi M, Trofe J. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. *Am J Transplant.* 2005 Nov;5(11):2740-4. PubMed PMID: 16212635.
138. Rogers CC, Alloway RR, Buell JF, Boardman R, Alexander JW, Cardi M, **Roy-Chaudhury P**, First MR, Succop P, Munda R, Woodle ES. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. *Transplantation.* 2005 Jul 15;80(1):26-33. PubMed PMID: 16003229.
139. **Roy-Chaudhury P**. Endothelial progenitor cells, neointimal hyperplasia, and hemodialysis vascular access dysfunction: novel therapies for a recalcitrant clinical problem. *Circulation.* 2005 Jul 5;112(1):3-5. PubMed PMID: 15998692.
140. Hanaway MJ, **Roy-Chaudhury P**, Buell JF, Thomas M, Munda R, Alloway RR, Ellison V, Rudich SM, Fisher L, Woodle ES. Pilot study of early corticosteroid elimination after pancreas transplantation. *Transplant Proc.* 2005 Mar;37(2):1287-8. PubMed PMID: 15848698.
141. Buell JF, Gross TG, Hanaway MJ, Trofe J, **Roy-Chaudhury P**, First MR, Woodle ES. Posttransplant lymphoproliferative disorder: significance of central nervous system involvement. *Transplant Proc.* 2005 Mar;37(2):954-5. PubMed PMID: 15848587.
142. Trofe J, **Roy-Chaudhury P**, Gordon J, Wadih G, Maru D, Cardi MA, Succop P, Alloway RR, Khalili K, Woodle ES. Outcomes of patients with rejection post-polyomavirus nephropathy. *Transplant Proc.* 2005 Mar;37(2):942-4. PubMed PMID: 15848582.
143. Boardman R, Trofe J, Alloway R, Rogers C, **Roy-Chaudhury P**, Cardi M, Safdar S, Groene B, Buell J, Hanaway M, Thomas M, Alexander W, Munda R, Woodle ES. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. *Transplant Proc.* 2005 Mar;37(2):817-8. PubMed PMID: 15848542.

144. Boardman RE, Alloway RR, Alexander JW, Buell JF, Cardi M, First MR, Hanaway MT, Munda R, Rogers CC, **Roy-Chaudhury P**, Susskind B, Trofe J, Woodle ES. African American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. *Transplant Proc.* 2005 Mar;37(2):814-6. PubMed PMID: 15848541.
145. Rogers CC, Alloway RR, Boardman R, Trofe J, Hanaway MJ, Alexander JW, **Roy-Chaudhury P**, Buell JF, Thomas M, Susskind B, Woodle ES. Global cardiovascular risk under early corticosteroid cessation decreases progressively in the first year following renal transplantation. *Transplant Proc.* 2005 Mar;37(2):812-3. PubMed PMID: 15848540.
146. Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas M, Buell J, Alexander JW, **Roy-Chaudhury P**, Succop P, Cardi M, Boardman R, Rogers C. Histocompatibility testing predicts acute rejection risk in early corticosteroid withdrawal regimens. *Transplant Proc.* 2005 Mar;37(2):809-11. PubMed PMID: 15848539.
147. Alloway RR, Hanaway MJ, Trofe J, Boardman R, Rogers CC, Hanaway MJ, Buell JF, Munda R, Alexander JW, Thomas MJ, **Roy-Chaudhury P**, Cardi M, Woodle ES. A prospective, pilot study of early corticosteroid cessation in high-immunologic-risk patients: the Cincinnati experience. *Transplant Proc.* 2005 Mar;37(2):802-3. PubMed PMID: 15848537.
148. Rogers CC, Alloway RR, Hanaway M, Buell JF, **Roy-Chaudhury P**, Succop P, Woodle ES. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. *Transplant Proc.* 2005 Mar;37(2):800-1. PubMed PMID: 15848536.
149. Woodle ES, Alloway RR, Hanaway MJ, Buell JF, Thomas M, **Roy-Chaudhury P**, Trofe J. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation: multivariate analysis of risk factors for acute rejection. *Transplant Proc.* 2005 Mar;37(2):798-9. PubMed PMID: 15848535.
150. Rogers CC, Hanaway M, Alloway RR, Alexander JW, Boardman RE, Trofe J, Gupta M, Merchen T, Buell JF, Cardi M, **Roy-Chaudhury P**, Succop P, Woodle ES. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy. *Transplant Proc.* 2005 Mar;37(2):795-7. PubMed PMID: 15848534.
151. Davis HW, VandenBerg E, Reid MD, **Roy-Chaudhury P**, Edwards JD. Paclitaxel impairs endothelial cell adhesion but not cytokine-induced cellular adhesion molecule expression. *Ann Vasc Surg.* 2005 May;19(3):398-406. PubMed PMID: 15834684.
152. Boardman RE, Alloway RR, Alexander JW, Buell JF, Cardi M, First MR, Hanaway MJ, Munda R, Rogers CC, **Roy-Chaudhury P**, Susskind B, Trofe J, Woodle ES. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. *Am J Transplant.* 2005 Feb;5(2):356-65. PubMed PMID: 15643996.
153. DeSalvo D, **Roy-Chaudhury P**, Peddi R, Merchen T, Konijetti K, Gupta M, Boardman R, Rogers C, Buell J, Hanaway M, Broderick J, Smith R, Woodle ES. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death. *Transplantation.* 2004 Feb 15;77(3):466-9. PubMed PMID: 14966429.
154. **Roy-Chaudhury P**, Munda R, Edwards J, Kelly BS. Hemodialysis vascular access dysfunction: from clinical stenosis to specific cell types. *J Nephrol.* 2003 Mar-Apr;16(2):277. PubMed PMID: 12768077.
155. Aull MJ, Buell JF, Peddi VR, Trofe J, Beebe TM, Hanaway MJ, **Roy-Chaudhury P**, Alloway RR, First MR, Woodle ES; Israel Penn International Transplant Tumor Registry. MALToma: A *Helicobacter pylori*-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. *Transplantation.* 2003 Jan 27;75(2):225-8. PubMed PMID: 12548128.
156. Kelly BS, Heffelfinger SC, Whiting JF, Miller MA, Reaves A, Armstrong J, Narayana A, **Roy-Chaudhury P**. Aggressive venous neointimal hyperplasia in a pig model of arteriovenous graft stenosis. *Kidney Int.* 2002 Dec;62(6):2272-80. PubMed PMID: 12427156.

157. Kelly BS, Narayana A, Heffelfinger SC, Denman D, Miller MA, Elson H, Armstrong J, Karle W, Nanayakkara N, **Roy-Chaudhury P**. External beam radiation attenuates venous neointimal hyperplasia in a pig model of arteriovenous polytetrafluoroethylene (PTFE) graft stenosis. *Int J Radiat Oncol Biol Phys*. 2002 Sep 1;54(1):263-9. PubMed PMID: 12183000.
158. Trofe J, Cavallo T, First MR, Weiskittel P, Peddi VR, **Roy-Chaudhury P**, Alloway RR, Safdar S, Buell JF, Hanaway MJ, Woodle ES. Polyomavirus in kidney and kidney-pancreas transplantation: a defined protocol for immunosuppression reduction and histologic monitoring. *Transplant Proc*. 2002 Aug;34(5):1788-9. PubMed PMID: 12176577.
159. Peddi VR, Bryant M, **Roy-Chaudhury P**, Woodle ES, First MR. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. *Transplantation*. 2002 May 15;73(9):1514-8. PubMed PMID: 12023634.
160. **Roy-Chaudhury P**, Kelly BS, Miller MA, Reaves A, Armstrong J, Nanayakkara N, Heffelfinger SC. Venous neointimal hyperplasia in polytetrafluoroethylene dialysis grafts. *Kidney Int*. 2001 Jun;59(6):2325-34. PubMed PMID: 11380837.
161. Kelly BS, Heffelfinger SC, Narayana A, **Roy-Chaudhury P**. External beam radiation reduces venous neointimal hyperplasia in PTFE dialysis grafts. *Curr Surg*. 2000 Nov;57(6):640. PubMed PMID: 11120327.
162. Zand MS, Li Y, Hancock W, Li XC, **Roy-Chaudhury P**, Zheng XX, Strom TB. Interleukin-2 and interferon-gamma double knockout mice reject heterotopic cardiac allografts. *Transplantation*. 2000 Nov 15;70(9):1378-81. PubMed PMID: 11087156.
163. Zheng XX, Li Y, Li XC, **Roy-Chaudhury P**, Nickerson P, Tian Y, Sayegh MH, Strom TB. Blockade of CD40L/CD40 costimulatory pathway in a DST presensitization model of islet allograft leads to a state of Allo-Ag specific tolerance and permits subsequent engraftment of donor strain islet or heart allografts. *Transplant Proc*. 1999 Feb-Mar;31(1-2):627-8. PubMed PMID: 10083268.
164. Li XC, **Roy-Chaudhury P**, Hancock WW, Manfro R, Zand MS, Li Y, Zheng XX, Nickerson PW, Steiger J, Malek TR, Strom TB. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. *J Immunol*. 1998 Jul 15;161(2):890-6. PubMed PMID: 9670967.
165. **Roy-Chaudhury P**, Nickerson PW, Manfro RC, Zheng XX, Steiger J, Li YS, Strom TB. CTLA4Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model. *Transplantation*. 1997 Jul 15;64(1):172-5. PubMed PMID: 9233722.
166. **Roy-Chaudhury P**, Meisels IS, Freedman S, Steinman TI, Steer M. Combined gastric and ileocecal toxicity (serpiginous ulcers) after oral kayexalate in sorbitol therapy. *Am J Kidney Dis*. 1997 Jul;30(1):120-2. PubMed PMID: 9214411.
167. **Roy-Chaudhury P**, Hillis G, McDonald S, Simpson JG, Power DA. Importance of the tubulointerstitium in human glomerulonephritis. II. Distribution of integrin chains beta 1, alpha 1 to 6 and alpha V. *Kidney Int*. 1997 Jul;52(1):103-10. PubMed PMID: 9211352.
168. Hillis GS, **Roy-Chaudhury P**, Duthie LA, Stewart KN, Brown PA, Simpson JG, MacLeod AM. Expression of beta 1 integrins in IgA nephropathy. *Nephrol Dial Transplant*. 1997 Jun;12(6):1137-42. PubMed PMID: 9198041.
169. **Roy-Chaudhury P**, Manfro RC. Renal replacement therapy for hemophiliacs. *Int J Artif Organs*. 1997 May;20(5):241-3. PubMed PMID: 9209922.
170. Zheng XX, Steele AW, Hancock WW, Stevens AC, Nickerson PW, **Roy-Chaudhury P**, Tian Y, Strom TB. A noncytolytic IL-10/Fc fusion protein prevents diabetes, blocks autoimmunity, and promotes suppressor phenomena in NOD mice. *J Immunol*. 1997 May 1;158(9):4507-13. PubMed PMID: 9127018.

171. **Roy-Chaudhury P**, Manfro RC, Steiger J, Nickerson PW, Tian Y, Zheng XX, Li YS, Strom TB. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors? Transplant Proc. 1997 Feb-Mar;29(1-2):1083-4. PubMed PMID: 9123210.
172. Manfro RC, **Roy-Chaudhury P**, Zheng XX, Steiger J, Nickerson PW, Li Y, Maslinski W, Strom TB. Interleukin-15 gene transcripts are present in rejecting islet allografts. Transplant Proc. 1997 Feb-Mar;29(1-2):1077-8. PubMed PMID: 9123207.
173. **Roy-Chaudhury P**, Simpson JG, Power DA. Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Exp Nephrol. 1997 Jan-Feb;5(1):55-60. PubMed PMID: 9052849.
174. Nickerson P, Zheng XX, Steiger J, Steele AW, Steurer W, **Roy-Chaudhury P**, Müller W, Strom TB. Prolonged islet allograft acceptance in the absence of expression of interleukin-4. Adv Nephrol Necker Hosp. 1997; 26:171-80. PubMed PMID: 8922133.
175. **Roy-Chaudhury P**, Khong TF, Williams JH, Haites NE, Wu B, Simpson JG, Power DA. CD44 in glomerulonephritis: expression in human renal biopsies, the Thy 1.1 model, and by cultured mesangial cells. Kidney Int. 1996 Jul;50(1):272-81. PubMed PMID: 8807598.
176. Nickerson P, Zheng XX, Steiger J, Steele AW, Steurer W, **Roy-Chaudhury P**, Müller W, Strom TB. Prolonged islet allograft acceptance in the absence of interleukin 4 expression. Transpl Immunol. 1996 Mar;4(1):81-5. PubMed PMID: 8762019.
177. Meisels IS, **Roy-Chaudhury P**. Serum ferritin level in hemodialysis patients. Nephron. 1996;72(3):496. PubMed PMID: 8852510.
178. **Roy-Chaudhury P**, Wu B, King G, Campbell M, Macleod AM, Haites NE, Simpson JG, Power DA. Adhesion molecule interactions in human glomerulonephritis: importance of the tubulointerstitium. Kidney Int. 1996 Jan;49(1):127-34. PubMed PMID: 8770958.
179. **Roy-Chaudhury P**. ACE genotype and progression of IgA nephropathy. Lancet. 1995 Aug 26;346(8974):571-2. PubMed PMID: 7658791.
180. **Roy-Chaudhury P**, Wu B, McDonald S, Haites NE, Simpson JG, Power DA. Phenotypic analysis of the glomerular and periglomerular mononuclear cell infiltrates in the Thy 1.1 model of glomerulonephritis. Lab Invest. 1995 May;72(5):524-31. PubMed PMID: 7745948.
181. Meisels IS, Strom TB, **Roy-Chaudhury P**, Abrams J, Shapiro ME. Renal allograft rejection in a patient with the Wiskott-Aldrich syndrome. Transplantation. 1995 Apr 27;59(8):1214-5. PubMed PMID: 7732568.
182. Stewart KN, Hillis G, **Roy-Chaudhury P**, Brown PA, Simpson JG, MacLeod AM. Integrin distribution in normal kidney and cultured human glomerular cells. Exp Nephrol. 1995 Mar-Apr;3(2):140-1. PubMed PMID: 7773634.
183. **Roy-Chaudhury P**, Khan IH. Angiotensin-converting enzyme (ACE) polymorphisms, angiotensin II, ACE inhibitors and glomerulosclerosis--a hypothesis. Nephron. 1995;71(3):359. PubMed PMID: 8569988.
184. **Roy-Chaudhury P**, Edward N. ACE inhibitors in the management of haemodialysis ascites. Nephrol Dial Transplant. 1994;9(11):1695-6. PubMed PMID: 7870368.
185. **Roy-Chaudhury P**, Jones MC, MacLeod AM, Haites NE, Simpson JG, Power DA. An immunohistological study of epidermal growth factor receptor and neu receptor and neu receptor expression in proliferative glomerulonephritis. Pathology. 1993 Oct;25(4):327-32. PubMed PMID: 7909365.
186. **Roy-Chaudhury P**, Khan IH, Catto GR. ACE inhibitors for myocardial infarction and unstable angina. Lancet. 1992 Dec 19-26;340(8834-8835):1549. PubMed PMID: 1361636.

187. Ballmer PE, Weber BK, **Roy-Chaudhury P**, McNurlan MA, Watson H, Power DA, Garlick PJ. Elevation of albumin synthesis rates in nephrotic patients measured with [1-13C]leucine. *Kidney Int.* 1992 Jan;41(1):132-8. PubMed PMID: 1593848.
188. **Roy-Chaudhury P**, Jones MC, MacLeod AM, Haites NE, Simpson JG, Power DA. Establishing a normal baseline for immunohistochemical studies of the kidney. *Nephron.* 1992;62(4):479. PubMed PMID: 1338644.
189. **Roy-Chaudhury P**, Simpson JG, Edward N. Profuse haematuria and clot colic in thin basement membrane nephropathy. *Nephrol Dial Transplant.* 1992;7(11):1139-41. PubMed PMID: 1336143.
190. Webster J, Petrie JC, Jeffers TA, **Roy-Chaudhury P**, Crichton W, Witte K, Jamieson M, MacDonald FC, Beard M, Dow RJ, et al. Nicardipine sustained release in hypertension. *Br J Clin Pharmacol.* 1991 Oct;32(4):433-9. PubMed PMID: 1958436; PubMed Central PMCID: PMC1368602.
191. Stewart KN, **Roy-Chaudhury P**, Lumsden L, Jones MC, Brown PA, Macleod AM, Haites NE, Simpson JG, Power DA. Monoclonal antibodies to cultured human glomerular mesangial cells. I. Reactivity with haematopoietic cells and normal kidney sections. *J Pathol.* 1991 Mar;163(3):265-72. PubMed PMID: 1707453.
192. Marshall FI, Hagen S, Mahaffy RG, Petrie JC, **Roy-Chaudhury P**, Russell IT, Webster J. Percutaneous transluminal angioplasty for atheromatous renal artery stenosis--blood pressure response and discriminant analysis of outcome predictors. *Q J Med.* 1990 May;75(277):483-9. PubMed PMID: 2143839.
193. Scott AK, **Roy-Chaudhury P**, Webster J, Petrie JC. Does a selective 5-hydroxytryptamine antagonist (ICI 169, 369) lower blood pressure in hypertensive patients? *Br J Clin Pharmacol.* 1989 Apr;27(4):417-21. PubMed PMID: 2655688; PubMed Central PMCID: PMC1379719.

c. Other Peer-Reviewed Articles (Reviews)

1. Viecelli AK, Mori TA, **Roy-Chaudhury P**, Polkinghorne KR, Hawley CM, Johnson DW, Pascoe EM, Irish AB. The pathogenesis of hemodialysis vascular access failure and systemic therapies for its prevention: Optimism unfulfilled. *Semin Dial.* 2018 May;31(3):244-257. doi: 10.1111/sdi.12658. Epub 2017 Nov 26. Review. PubMed PMID: 29178510.
2. Tong A, Manns B, Hemmelgarn B, Wheeler DC, Evangelidis N, Tugwell P, Crowe S, Van Biesen W, Winkelmayr WC, O'Donoghue D, Tam-Tham H, Shen JJ, Pinter J, Larkins N, Youssouf S, Mandayam S, Ju A, Craig JC; SONG-HD Investigators. Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop. *Am J Kidney Dis.* 2017 Jan;69(1):97-107. doi: 10.1053/j.ajkd.2016.05.022. Epub 2016 Aug 3. PubMed PMID: 27497527; PubMed Central PMCID: PMC5369351.
3. Dember LM, Archdeacon P, Krishnan M, Lacson E Jr, Ling SM, **Roy-Chaudhury P**, Smith KA, Flessner MF. Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative. *J Am Soc Nephrol.* 2016 Oct;27(10):2955-2963. Epub 2016 Jul 11. Review. PubMed PMID: 27401689; PubMed Central PMCID: PMC5042681.
4. **Roy-Chaudhury P**, Kruska L. Future directions for vascular access for hemodialysis. *Semin Dial.* 2015 Mar-Apr;28(2):107-13. doi: 10.1111/sdi.12329. Epub 2014 Dec 7. Review. PubMed PMID: 25482103.
5. Campos B, Lee T, **Roy-Chaudhury P**. Arteriovenous fistula failure: is there a role for epigenetic regulation? *Semin Nephrol.* 2013 Jul;33(4):400-6. doi: 10.1016/j.semnephrol.2013.05.012. Review. PubMed PMID: 24011582.
6. Riella MC, **Roy-Chaudhury P**. Vascular access in haemodialysis: strengthening the Achilles' heel. *Nat Rev Nephrol.* 2013 Jun;9(6):348-57. doi: 10.1038/nrneph.2013.76. Epub 2013 Apr 16. Review. PubMed PMID: 23591442.
7. **Roy-Chaudhury P**, Lee T, Woodle B, Wadehra D, Campos-Naciff B, Munda R. Balloon-assisted maturation (BAM) of the arteriovenous fistula: the good, the bad, and the ugly. *Semin Nephrol.* 2012 Nov;32(6):558-63.

doi: 10.1016/j.semnephrol.2012.10.007. Review. PubMed PMID: 23217336; PubMed Central PMCID: PMC4309013.

8. **Roy-Chaudhury P**, El-Khatib M, Campos-Naciff B, Wadehra D, Ramani K, Leesar M, Mistry M, Wang Y, Chan JS, Lee T, Munda R. Back to the future: how biology and technology could change the role of PTFE grafts in vascular access management. *Semin Dial.* 2012 Sep-Oct;25(5):495-504. doi: 10.1111/j.1525-139X.2012.01091.x. Epub 2012 Aug 22. Review. PubMed PMID: 22908978.
9. **Roy-Chaudhury P**, Yevzlin A, Bonventre JV, Agarwal A, Almehmi A, Besarab A, Dwyer A, Hentschel DM, Kraus M, Maya I, Pflederer T, Schon D, Wu S, Work J. Academic interventional nephrology: a model for training, research, and patient care. *Clin J Am Soc Nephrol.* 2012 Mar;7(3):521-4. doi: 10.2215/CJN.08360811. Epub 2012 Feb 16. Review. PubMed PMID: 22344507.
10. Yevzlin AS, Chan MR, Becker YT, **Roy-Chaudhury P**, Lee T, Becker BN. "Venopathy" at work: recasting neointimal hyperplasia in a new light. *Transl Res.* 2010 Oct;156(4):216-25. doi: 10.1016/j.trsl.2010.07.004. Epub 2010 Aug 13. Review. PubMed PMID: 20875897; PubMed Central PMCID: PMC4310704.
11. Lee T, **Roy-Chaudhury P**. Advances and new frontiers in the pathophysiology of venous neointimal hyperplasia and dialysis access stenosis. *Adv Chronic Kidney Dis.* 2009 Sep;16(5):329-38. doi: 10.1053/j.ackd.2009.06.009. Review. PubMed PMID: 19695501; PubMed Central PMCID: PMC2764321.
12. **Roy-Chaudhury P**, Lee T, Duncan H, El-Khatib M. Combining novel technologies with improved logistics to reduce hemodialysis vascular access dysfunction. *J Vasc Access.* 2009 Jan-Mar;10(1):1-4. Review. PubMed PMID: 19340792.
13. Woodle ES, Alloway R, Rike A, **Roy-Chaudhury P**, Tevar A, Susskind B, Everly J, Mogilishetty G, Brailey P, Govil A, Rudich S, First MR, Alexander JW, Munda R, Cardi M, Arend L. Corticosteroid elimination: the Cincinnati experience. *Clin Transpl.* 2007;51-60. Review. PubMed PMID: 18637458.
14. **Roy-Chaudhury P**, Lee TC. Vascular stenosis: biology and interventions. *Curr Opin Nephrol Hypertens.* 2007 Nov;16(6):516-22. Review. PubMed PMID: 18089964.
15. Besarab A, Asif A, **Roy-Chaudhury P**, Spergel LM, Ravani P. The native arteriovenous fistula in 2007. Surveillance and monitoring. *J Nephrol.* 2007 Nov-Dec;20(6):656-67. Review. PubMed PMID: 18046667.
16. Spergel LM, Ravani P, **Roy-Chaudhury P**, Asif A, Besarab A. Surgical salvage of the autogenous arteriovenous fistula (AVF). *J Nephrol.* 2007 Jul-Aug;20(4):388-98. Review. PubMed PMID: 17879203.
17. Asif A, Ravani P, **Roy-Chaudhury P**, Spergel LM, Besarab A. Vascular mapping techniques: advantages and disadvantages. *J Nephrol.* 2007 May-Jun;20(3):299-303. Review. PubMed PMID: 17557262.
18. Spergel LM, Ravani P, Asif A, **Roy-Chaudhury P**, Besarab A. Autogenous arteriovenous fistula options. *J Nephrol.* 2007 May-Jun;20(3):288-98. Review. PubMed PMID: 17557261.
19. **Roy-Chaudhury P**, Spergel LM, Besarab A, Asif A, Ravani P. Biology of arteriovenous fistula failure. *J Nephrol.* 2007 Mar-Apr;20(2):150-63. Review. PubMed PMID: 17514619.
20. Ravani P, Spergel LM, Asif A, **Roy-Chaudhury P**, Besarab A. Clinical epidemiology of arteriovenous fistula in 2007. *J Nephrol.* 2007 Mar-Apr;20(2):141-9. Review. PubMed PMID: 17514618.
21. Asif A, **Roy-Chaudhury P**, Beathard GA. Early arteriovenous fistula failure: a logical proposal for when and how to intervene. *Clin J Am Soc Nephrol.* 2006 Mar; 1(2):332-9. Epub 2005 Nov 30. Review. PubMed PMID: 17699225.
22. **Roy-Chaudhury P**, Sukhatme VP, Cheung AK. Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. *J Am Soc Nephrol.* 2006 Apr;17(4):1112-27. Review. PubMed PMID: 16565259.
23. **Roy-Chaudhury P**, Kelly BS, Melhem M, Zhang J, Li J, Desai P, Munda R, Heffelfinger SC. Vascular access in hemodialysis: issues, management, and emerging concepts. *Cardiol Clin.* 2005 Aug;23(3):249-73. Review. PubMed PMID: 16084276.

24. **Roy-Chaudhury P**, Kelly BS, Melhem M, Zhang J, Li J, Desai P, Munda R, Heffelfinger SC. Novel therapies for hemodialysis vascular access dysfunction: fact or fiction! *Blood Purif.* 2005;23(1):29-35. Review. PubMed PMID: 15627734.
25. Trofe J, Gordon J, **Roy-Chaudhury P**, Koralnik I, Atwood W, Eash S, Alloway RR, Khalili K, Alexander JW, Woodle ES. Basic and clinical research in polyomavirus nephropathy. *Exp Clin Transplant.* 2004 Jun;2(1):162-73. Review. PubMed PMID: 15859923.
26. Trofe J, Gordon J, **Roy-Chaudhury P**, Koralnik IJ, Atwood WJ, Alloway RR, Khalili K, Woodle ES. Polyomavirus nephropathy in kidney transplantation. *Prog Transplant.* 2004 Jun;14(2):130-40; quiz 141-2. Review. PubMed PMID: 15264457.
27. **Roy-Chaudhury P**, Duncan H, Barrett W, Elson H, Narayana A, Foley J, Misra S, Lynch PM, Zuckerman D. Vascular brachytherapy for hemodialysis vascular access dysfunction: exploring an unmet clinical need. *J Invasive Cardiol.* 2003 Jan;15 Suppl A:25A-30A. Review. PubMed PMID: 12668839.
28. **Roy-Chaudhury P**, Kelly BS, Zhang J, Narayana A, Desai P, Melham M, Duncan H, Heffelfinger SC. Hemodialysis vascular access dysfunction: from pathophysiology to novel therapies. *Blood Purif.* 2003;21(1):99-110. Review. PubMed PMID: 12596755.
29. **Roy-Chaudhury P**, Kelly BS, Narayana A, Desai P, Melhem M, Munda R, Duncan H, Heffelfinger SC. Hemodialysis vascular access dysfunction from basic biology to clinical intervention. *Adv Ren Replace Ther.* 2002 Apr;9(2):74-84. Review. PubMed PMID: 12085383.
30. Nickerson P, Steiger J, Zheng XX, Steele AW, Steurer W, **Roy-Chaudhury P**, Strom TB. Manipulation of cytokine networks in transplantation: false hope or realistic opportunity for tolerance? *Transplantation.* 1997 Feb 27;63(4):489-94. Review. PubMed PMID: 9047139.
31. Strom TB, **Roy-Chaudhury P**, Manfro R, Zheng XX, Nickerson PW, Wood K, Bushell A. The Th1/Th2 paradigm and the allograft response. *Curr Opin Immunol.* 1996 Oct;8(5):688-93. Review. PubMed PMID: 8902395.

d. Editorials or Letters

1. Charytan DM, Roy-Chaudhury P. The Authors Reply. *Kidney Int.* 2018 Aug;94(2):430-431. doi: 10.1016/j.kint.2018.05.012. PubMed PMID: 30031449.
2. Roy-Chaudhury P, Munda R. Infections associated with surgical implants. *N Engl J Med.* 2004 Jul 8;351(2):193-5; author reply 193-5. PubMed PMID: 15250067.

e. Published Abstracts

1. Prakash Parthiban Selvakumar; Unimunkh Uriyanghai; Richard D. Johnson; Christine Wai, **Prabir Roy-Chaudhury**, Wei Tan. Biofunctionalized Vascular Access Graft Enhanced Patency and Endothelialization in a Pig Arteriovenous (AV) Model. American Society of Nephrology Oral Presentation, Orlando 2022.
2. Akhil Hegde, Jennifer E. Flythe, Cynthia J. Denu-Ciocca, Kawan A. Swain, Raven A. Voora, Heather J. Ansedee, Gerald A. Hladik, Peter Kotanko, **Prabir Roy-Chaudhury**, Abhijit V. Kshirsagar. Non-Hospitalized Maintenance Hemodialysis Patients with COVID-19 Have Elevated Inflammatory Markers. American Society of Nephrology Poster Presentation, 2020.
3. Simon Correa, Katherine M. Scovner, James A. Tumlin, **Prabir Roy-Chaudhury**, Finnian R. McCausland, David M. Charytan. Electrolyte Changes in Contemporary Hemodialysis: An Analysis of the Monitoring in Dialysis (MiD) Study. American Society of Nephrology Poster Presentation, 2020.
4. Global Phase 3 Clinical Trials of Vadadustat vs Darbepoetin Alfa for Treatment of Anemia in Patients with Non-Dialysis-Dependent Chronic Kidney Disease; Late Breaking Abstract at ASN 2020
5. Taylor G. Lewis, Aous Jarrouj, Li H. Wang, Begoña Campos, Keith L. Saum, Jaroslav Janda, Albert P. Owens, **Prabir Roy-Chaudhury**, Diego Celdran-Bonafonte. Uremia Induces Functional and Histological Changes in a

Mouse Model of Arteriovenous Fistula (AVF) Stenosis. American Society of Nephrology Poster Presentation, 2019.

6. **Prabir Roy-Chaudhury**, Theodore F. Saad, Scott O. Trerotola on behalf of the Lutonix AV IDE investigators and the Medical Advisory Board. No Increase in All-Cause Mortality from Paclitaxel Coated Balloons (DCB) Used in an Arteriovenous Circuit in Dialysis Patients. American Society of Nephrology Poster Presentation, 2019.
7. Jenq-shyong Chan, **Prabir Roy-Chaudhury**, Tao-cheng Wu. The Effect of the Sodium-Glucose Co-Transporter-2 Inhibitor in Angiogenesis of Diabetic Cardiovascular Disease. American Society of Nephrology Poster Presentation, 2019.
8. Saum KL, Campos B, Jarrouj A, Celdran-Bonafonte D, **Roy-Chaudhury P**, Owens AP. Endothelial-specific Kruppel-like Factor 2 inactivation promotes endothelial dysfunction in the setting of uremia. J Am Soc Nephrol 2018 Oct, 29:993. SA-PO983 (poster presentation)
9. Celdran-Bonafonte D, Wang LH, Lautner-Csorba O, Brisbois E, Jarrouj A, Kim M, Janda J, Kohler LN, Lewis TG, Brosius FC, Meyerhoff M, **Roy-Chaudhury P**. Nitric oxide (NO) releasing tunneled dialysis catheters (TDC) reduce catheter-related blood stream infection (CRBSI) and dysfunction. J Am Soc Nephrol 2018 Oct, 29:990. SA-PO972 (poster presentation)
10. McCausland FR, **Roy-Chaudhury P**, Tumlin JA, Charytan DM. Intra-dialytic hypotension risk of intra-dialytic cardiac arrhythmia. J Am Soc Nephrol 2018 Oct, 29:967. SA-PI884 (poster presentation)
11. Iyer S, Kopyt NP, Gandhi N, Atray NK, Wooldridge TD, Lee JJ, Hendon KS, Paulson WD, Khawar OS, Lynn RI, **Roy-Chaudhury P**, Deite MV. On behalf of the ACCESS Trial Investigators. J Am Soc Nephrol 2018 Oct, 29:604. FR-PO715 (poster presentation)
12. Iyer S, DeVita MV, Kopyt NP, Gandhi N, Atray NK, Wooldridge TD, Lee JJ, Hendon KS, Paulson WD, Khawar OS, Lynn RI, **Roy-Chaudhury P**. On behalf of ACCESS Study Investigators. J Am Soc Nephrol 2018 Oct, 29:63. FR-OR094 (oral presentation)
13. Saum K, Campos B, Celdran-Bonafonte D, Phillips Owens A, **Roy-Chaudhury P**. Uremic regulation of endothelial Kruppel-Like Factor 2 in arteriovenous fistula (AVF) maturation failure. J Vasc Access 2017 Apr 5, 18(Suppl2).
14. Celdran-Bonafonte D, Stowell CE, Campos B, Janda J, Raksasuk S, Jarrouj A, Wang Y, **Roy-Chaudhury P**. Cellular integration and early cannulation potential in a bioengineered arteriovenous vascular access (PHOENIX). J Vasc Access 2017 Apr 5, 18(Suppl2).
15. Celdran-Bonafonte D, Campos B, Jarrouj A, Wang Y, Raksasuk S, Janda J, Misra S, Kurian M, **Roy-Chaudhury P**. Creation of a pig model of renal insufficiency. J Vasc Access 2017 Apr 5, 18(Suppl2).
16. Janda J, Campos B, Brosius FC, Jarrouj A, Saun KL, Kohler LN, **Roy-Chaudhury P**, Celdran-Bonafonte C. Uremia alters vascular gene expression in pig carotid artery and jugular vein. J Am Soc Nephrol 2017, 28:1102. PUB544
17. Celdran-Bonafonte D, Campos B, Jarrouj A, Wang LH, Kohler LN, Janda J, Saum KL, Brosius FC, **Roy-Chaudhury P**. A swine model of tunneled dialysis catheter (TDC) infection and dysfunction: opportunities for therapeutic innovation. J Am Soc Nephrol 2017, 28:599. FR-PO757
18. Saum K, Campos B, Celdran-Bonafonte D, Owens III AP, **Roy-Chaudhury P**. Endothelial dysfunction in end stage renal disease results from advanced glycation end-products mediated suppression of Kruppel-Like Factor 2. J Am Soc Nephrol 2017, 28:448. FR-PO186

19. J Janda, B. Campos, A. Jarrouj, F Brosius, L Kohler, **Roy-Chaudhury P**, Bonafonte DC. Altered molecular profiles in hemodynamically vulnerable segments of arteriovenous fistulae (AVF) in a uremic pig model. J Am Soc Nephrol 2017, 28:292-3. TH-PO749
20. Bonafonte DC, B. Campos, A. Jarrouj, L.Wang, J Janda, L Kohler, K Saum, F Brosius, **Roy-Chaudhury P**. MRI modeling of arteriovenous fistula (AVF) stenosis in a pig model: creating a test bed for mechanistic and therapeutic innovation. J Am Soc Nephrol 2017, 28:293. TH-PO750
21. Altriki, M., Roy-Chaudhury, P., Thajudeen, B. Calcific Atrial Mass in End-Stage Renal Disease. J Am Soc Nephrol 2016, 27: 1010A.
22. Sarsah, B., **Roy-Chaudhury P**, Sussman, A., Thajudeen, B., Kodali, L. Traumatic AKI: Trivial fall. Am J Kidney Dis 2016, 67(5): A94.
23. Sarsah, B., **Roy-Chaudhury P**, Sussman, A., Thajudeen, B., Kodali, P., Kadambi, P.,Sardar, A., Koppula, S. Carboplatin Induced Severe and Persistent Hypokalemia. Am J Kidney Dis 2016, 67(5): A94.
24. Altriki, M., Bechtold, L., Thajudeen, B., **Roy-Chaudhury P**. Cinacalcet treatment for primary hyperparathyroidism following bone marrow transplant. Am J Kidney Dis 2016, 67(5): A24.
25. Khan, H., Bechtold, L., Thajudeen, B., **Roy-Chaudhury P**. A symptomatic sporadic bilateral giant angiomyolipoma: a case report. Am J Kidney Dis 2016, 67(5): A62.
26. Daheshpour, S., Bechtold, L., Sarsah, B., Thajudeen, B., **Roy-Chaudhury P**. Immune complexes in pauci-immune glomerulonephritis-a clinicopathologic outcome study. Am J Kidney Dis 2016, 67(5): A38.
27. Saleem, K., Bechtold, L., Thajudeen, B., **Roy-Chaudhury P**. A case of yellow filter. Am J Kidney Dis 2016, 67(5):A92.
28. Howlader, A., Bechtold, L., Thajudeen, B., **Roy-Chaudhury P**] Hypercalcemia induced metabolic acidosis secondary to primary hyperparathyroidism. Am J Kidney Dis 2016, 67(5):A55.
29. Kodali L, Bloss VR, Bracamonte ER, Spier CM, **Roy-Chaudhury P**. Histological and electron microscopy (EM) predictors for progressive transplant glomerulopathy. J Am Soc Nephrol 2016 Nov, 27:1084A. PUB783
30. Altriki M, **Roy-Chaudhury P**, Thajudeen B. Calcific atrial mass in end-stage renal disease. J Am Soc Nephrol 2016 Nov, 27:1010A. PUB460
31. Celdran-Bonafonte D, Stowell CE, Campos B, Jarrouj A, Raksasuk S, Jernigan PL, Wang Y, **Roy-Chaudhury P**. Cellular integration and early cannulation potential in a bioengineered arteriovenous vascular access (Phoenix). J Am Soc Nephrol 2016 Nov, 27:878A. SA-PO1049
32. Celdran-Bonafonte D, Campos B, Jarrouj A, Misra S, Kurian M, Raksasuk S. Creation of a pig model of chronic renal insufficiency. J Am Soc Nephrol 2016 Nov, 27:877A. SA-PO1048 (poster presentation)
33. Saum KL, Campos B, Celdran-Bonafonte D, Owens AP, **Roy-Chaudhury P**. Uremic regulation of endothelial Kruppel-like Factor 2 in arteriovenous fistula (AVF) maturation failure. J Am Soc Nephrol 2016 Nov, 27:350A. TH-PO1092 (poster presentation)
34. Williamson D, **Roy-Chaudhury P**, Tumlin J, Charytan D. Relationship of Heart Rate Variability and Heart Rate to Fluid Load in Hemodialysis Patients. Preliminary Results of the Monitoring in Dialysis (MiD) Study. J Am Soc Nephrol 2014, 25:603A. FR-PO1009 (poster presentation)
35. Charytan D, Williamson D, **Roy-Chaudhury P**, Tumlin J. Greater Frequency of Clinically Significant Bradycardia than Ventricular Tachycardia in Hemodialysis Patients, Preliminary Results of the Monitoring in Dialysis (MiD) Study. J Am Soc Nephrol 2014, 25:35A. TH-OR145 (oral presentation)

36. Tumlin J, **Roy-Chaudhury P**, Charytan D, Williamson D. Frequency and Distribution of Dialysis Associated Atrial Fibrillation: Results of the MiD Study. J Am Soc Nephrol 2014, 25:35A. TH-OR144 (oral presentation)
37. **Roy-Chaudhury P**, Tumlin J, Charytan D, Williamson D. Timing of Arrhythmias with Dialysis Schedule: Preliminary Results of the Monitoring in Dialysis (MiD) Study. J Am Soc Nephrol 2014, 25:19A-20A. TH-OR078 (oral presentation)
38. Zahedi KA, Barone SL, Murray-Stewart T, Wang Y, **Roy-Chaudhury P**, Casero RA, Soleimani M. Polyamine catabolism in renal ischemia/reperfusion (I/R) injury. J Am Soc Nephrol 2013, 23:95A-6A. SA-OR107 (oral presentation)
39. Lee TC, Chen J, **Roy-Chaudhury P**, Campos B, Medvedovic M. Genomics of arteriovenous fistula maturation. J Am Soc Nephrol 2013, 24:57A. FR-O090 (oral presentation).
40. Lee TC, Somarathna MS, Campos B, Wang Y, Arend LJ, **Roy-Chaudhury P**. Natural History of Venous morphologic changes in dialysis access stenosis. J Am Soc Nephrol 2013, 24:213A. TH-PO487 (poster presentation)
41. Nikam M, Tavakoli A, Evans J, Summers AM, Brenchley PE, Chemla ES, **Roy-Chaudhury P**, Mistra S. Optiflow anastomotic connector: safety and efficacy: results from the OPEN study. J Am Soc Nephrol 2012, 23:274A. TH-PO759 (oral presentation).
42. Terry CM, He Y, Shiu YTE, Banerjee R, **Roy-Chaudhury P**, Berceli SA, Cheung AK. Development of sequential techniques to correlate hemodynamics with subsequent lumen geometry changes in arteriovenous fistula. J Am Soc Nephrol 2012, 23:5A. TH-OR021 (oral presentation).
43. **Roy-Chaudhury P**, Wang Y, Zahedi KA, Mistry MJ, Cornea V, Soleimani M. Thymoglobulin attenuates renal ischemia reperfusion injury. J Am Soc Nephrol 2011, 22:832A. SA-PO3091 (poster presentation).
44. **Roy-Chaudhury P**, Wang Y, Mistry MJ, Campos B, Lee TC, Choe KA. "Hybrid" graft reduces venous stenosis in a pig arteriovenous graft model. J Am Soc Nephrol 2011, 22:572A. FR-PO1978 (poster presentation).
45. Lee TC, Tindi A, Roy-Chaudhury. Prolonged cumulative survival in fistulas with surgical intervention to promote maturation compared to endovascular intervention. J Am Soc Nephrol 2011, 22:567A. FR-PO1956 (poster presentation).
46. Matyas L, Mogan I, Ebner A, Mantell M, Manson R, Chemia E, Mitra S, Nikam M, Tavakoli A, **Roy-Chaudhury P**. Arteriovenous anastomosis creation using the Optiflow anastomotic connector. J Am Soc Nephrol 2011, 22:564A. FR-PO1946 (poster presentation).
47. Rajabi-Jaghargh E, **Roy-Chaudhury P**, Wang Y, Choe KA, Succop P, Banerjee R. The effect of temporal variation in wall shear stress on the remodeling of arteriovenous fistulae. J Am Soc Nephrol 2011, 22:561A. FR-PO1931 (post presentation).
48. Dixon BS, Peden EK, Leeser DB, El-Khatib MT, **Roy-Chaudhury P**, Lawson J, Menard M, Glickman MH, Dember LM, Burke SK. Effect of recombinant human type 1 pancreatic elastase (PRT-201) treatment on fistula patency. J Am Soc Nephrol 2011, 22:110A. SA-OR457 (oral presentation).
49. Lee TC, Safdar N, Mistry MJ, Wang Y, Campos B, **Roy-Chaudhury P**. Pre-existing venous calcification prior to dialysis vascular access surgery. J Am Soc Nephrol 2011, 22:109A. SA-OR454 (oral presentation).
50. Beck GJ, Cheung AK, Dember LM, Feldman HI, Himmelfarb J, Huber TS, Kusek JW, **Roy-Chaudhury P**, Vazquez MA, Alpers CE, Robbin ML, Vita J. Progress of the hemodialysis fistula maturation (HFM) study. J Am Soc Nephrol 2011, 22:108A. SA-OR452 (oral presentation).

51. **Roy-Chaudhury P**, Safdar N, Mistry MJ, Wang Y, Hura AS, Lee TC, Cornea V, Campos B. Venous segment calcification in a mouse model of arteriovenous stenosis. J Am Soc Nephrol 2011, 22:79A. FR-OR329 (oral presentation).
52. Campos B, Wang Y, Mistry MJ, Woodle BK, Cornea V, Lee TC, **Roy-Chaudhury P**. Early adventitial activation and proliferation in a mouse model of arteriovenous stenosis. J Am Soc Nephrol 2011, 22:78A. FR-OR324 (oral presentation).
53. Lee TC, **Roy-Chaudhury P**. Comparative analysis of cellular phenotypes between pre-existing venous neointimal hyperplasia prior to access surgery and venous neointimal hyperplasia from stenotic arteriovenous dialysis accesses. J Am Soc Nephrol 2011, 22:77A. FR-OR321 (oral presentation).
54. E. S. Woodle, P. Brailey, R. R. Alloway, P. Roy Chaudhury, A. Rike-Shields, A. Govil, G. Wall, A. Girnita. Immunodominant HLA Antibody IgG Subtypes Demonstrate Differential Sensitivities and Class Switching in Response to Proteasome Inhibitor-Based Desensitization. Am J Transplant 2011 Apr, 11(s2):482-3.
55. Walsh RC, Shields AR, Safdar S, Huang S, Cardi M, Govil A, Mogilshetty G, **Roy-Chaudhury P**, Young S, Alloway RR, Woodle ES. Toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Am J Transplant 2010 Apr, 19(s4):171. (oral presentation)
56. Govil A, Arend LJ, Brailey P, Alloway RR, Mogilshetty G, Tevar AD, **Roy-Chaudhury P**, Woodle ES. DSA and C4d deposition: paradoxical dissociation in acute pancreas allograft rejection. Am J Transplant 2010 Apr, 19(s4):89. (oral presentation).
57. Walsh RC, Shields AR, Safdar S, Huang S, Cardi M, Govil A, Mogilshetty G, **Roy-Chaudhury P**. Toxicity profile of proteasome inhibitor-based antihumoral therapy in renal transplant candidates and recipients. Am J Transplant 2010 Apr, 10(s4):171. (oral presentation)
58. Walsh RC, Shields R, Safdar S, Huang S, Cardi M, Govil A, Mogilshetty G, **Roy-Chaudhury P**, Cole L, Alloway RR, Woodle ES. Prospective analysis of peripheral neuropathy with bortezomib-based therapy for antibody-mediated rejection and desensitization. Am J Transplant 2010 Apr, 10(s4):45. (oral presentation)
59. Lee TC, Allon M, **Roy-Chaudhury P**. Decreased Cumulative Access Survival in Arteriovenous Fistulas Requiring Interventions to Promote Maturation. J Am Soc Nephrol 2010, 21:87A. (SA-FC378)
60. Conte MS, Nugent H, **Roy-Chaudhury P**. Arteriovenous Fistula Remodeling from a Multi-Center Phase I/II Trial Investigating the Use of Allogeneic Endothelial Cell Implants: V-HEALTH Study. J Am Soc Nephrol 2010, 21:365A. (F-PO1110)
61. Beck GJ, Cheung AK, Dember LM, Feldman HI, Himmelfarb J, Huber TS, Kusek JW, **Roy-Chaudhury P**, Vazquez MA, Alpers CE, Robbin M, Vita J. Design of the Hemodialysis Fistula Maturation (HFM) Study, J Am Soc Nephrol 2010, 21:247A. (TH-PO585)
62. Lee TC, Lancaster EI, **Roy-Chaudhury P**, Thakar CV. Low Rate of Incident Fistulas in a Veterans Administration Healthcare System Are Due to Poor Processes of Care. J Am Soc Nephrol 2010, 21:243A. (TH-PO568)
63. Chitalia N, Morsey M, Krishnamoorthy M, Wang Y, Chemla E, Kaska JC, **Roy-Chaudhury P**, Banerjee D. Histopathological features of muscular arteries in predialysis CKD patients. J Am Soc Nephrol 2009; 20:850A. (PUB098)
64. M. R. Bennett, I. Meyer, R. Alloway, E. S. Woodle, A. Jain, P. Devarajan, P. Roy-Chaudhury, C. V. Thakar. Early Proteomic Changes in Post-Transplant Urine as Predictors of Allograft Function. J Am Soc Nephrol 2009, 20:804A. (SA-PO3042)
65. Lee TC, Ullah A, Duncan H, El-Khatib M, **Roy-Chaudhury P**. Aggressive Interventions for Fistula Maturation: A Double-Edged Sword? J Am Soc Nephrol 2009, 20:476A. (F-PO1579)

66. **Roy-Chaudhury P**, Lawson J, Conte M, Glickman M, Earl S, Schild F, Ross J, Berman S. Perivascular Endothelial Cell Matrices (Vascugel) Enhance Dialysis Vascular Access Survival in Diabetic Patients. J Am Soc Nephrol 2009, 20:475A. (F-PO1576)
67. **Roy-Chaudhury P**, Manson R, Mantell M, Ebner A. Arteriovenous Fistula (AVF) Creation Using the Optiflow Vascular Anastomosis Device. J Am Soc Nephrol 2009, 20:475A. (F-PO1575)
68. Khan R, Krishnamoorthy M, Wang Y, Kurian M, Lee T, Banerjee R, El-Khatib M, Munda R, Arend L, **Roy-Chaudhury P**. Pathogenetic Role for Early Focal Macrophage Infiltration in a Pig Model of Arteriovenous Fistula (AVF) Stenosis. J Am Soc Nephrol 2009, 20:472A. (F-PO1563)
69. Lee TC, Chauhan V, Wang Y, Krishnamoorthy M, Arend L, Munda R, El-Khatib M, **Roy-Chaudhury P**. Aggressive Pre-Existing Venous Stenosis at the Time of AV Access Surgery: A Morphometric and Cellular Phenotyping Analysis. J Am Soc Nephrol 2009, 29:69A. (F-FC297)
70. Krishnamoorthy M, **Roy-Chaudhury P**, Wang Y, Arend L, Banerjee R. Changes in Wall Shear Stress Influence Changes in Intima-Media Thickening in a Pig Model of Arteriovenous Fistula Stenosis. J Am Soc Nephrol 2009, 20:472A. (F-PO1565)
71. Krishnamoorthy M, Kurian M, Wang Y, Rao Khan TL, El-Khatib M, Banerjee R, Munda R, Arend L, **Roy-Chaudhury P**. Cellular Infiltration and Proliferation in Arteriovenous Fistula Failure. J Am Soc Nephrol 2009, 20:474A. (F-PO1574)
72. Krishnamoorthy M, Banerjee R, Wang Y, Choe A, Arend L, **Roy-Chaudhury P**. Differences in Anatomical Configuration Influence Flow and Diameter in Arteriovenous Fistulae in a Pig Model. J Am Soc Nephrol 2009, 20:472A-3A. (F-PO1566)
73. Rike A, Alloway RR, Lee R, Mogilishetty G, **Roy-Chaudhury P**, Cardi M, Munda R, Everly J, Tevar A, Woodle ES. African-American kidney transplant recipients undergoing early corticosteroid withdrawal long term (5-year) results similar to non-African-Americans. XXII International Congress of Transplantation Society, Sydney, Australia. Transplantation 2008 July, 86(2S). (oral presentation).
74. Mogilishetty G, Hair D, Alloway RR, Everly MJ, Cole L, Meyer M, Govil A, **Roy-Chaudhury P**, Holland EJ, Woodle ES. Comparison of immunosuppression related toxicities and complications in ocular surface transplant and renal transplant recipients: implications for composite tissue transplantation. XXII International Congress of Transplantation Society, Sydney, Australia. Transplantation 2008 July, 86(2S). (oral presentation)
75. Prabir Roy-Chaudhury, Yang Wang, Mahesh Krishnamoorthy, Adam Dakin. OptiFlow: A Novel Anastomotic Conduit for Reducing AV Fistula Dysfunction. J Am Soc Nephrol 2008, 19:253A. (TH-PO648)
76. Jeffrey H. Lawson, Michael S. Conte, Marc Glickman, Earl Schuman, A. Frederick Schild, John Ross, Scott Berman, Prabir Roy-Chaudhury. Safety of Vascugel Treatment after the Creation of Arteriovenous Access. J Am Soc Nephrol 2008, 19:251A. (TH-PO642)
77. Krishnamoorthy M, Arend L, Wang Y, Banerjee R, **Roy-Chaudhury P**. Adventitial Proliferation Precedes Endothelial Proliferation in Arteriovenous Fistula Stenosis. J Am Soc Nephrol 2007, 18:34A. (F-FC157)
78. Wang Y, Frost M, Krishnamoorthy M, Hwang SY, Zhang J, Banerjee R, Rudich S, Meyerhoff M, **Roy-Chaudhury P**. PTFE Grafts Coated with Cu(II)-Complex Polymer Coatings Generate Nitric Oxide: Potential for Reducing Arteriovenous Graft Stenosis and Thrombosis. J Am Soc Nephrol 2007, 18:34A. (F-FC158)
79. Krishnamoorthy M, Banerjee R, Wang Y, Zhang J, Rudich S, Arend L, **Roy-Chaudhury P**. Anatomical Configuration of an AV Fistula Influences the Pattern of Intima-Media Thickening. J Am Soc Nephrol 2007, 18:33A. (F-FC-156)

80. **Roy-Chaudhury P**, Kohler T, Avelar R. Rationale, Design, Methods and Statistical Aspects of a Randomized, Multicenter, Clinical Study to Assess the Effectiveness of Maintaining Patency and the Safety of the Vascular Wrap Paclitaxel-Eluting Mesh Implanted with a Lifespan ePTFE Vascular Graft for Hemodialysis Vascular Access. J Am Soc Nephrol 2007, 18:469A. (SA-PO580)
81. **Roy-Chaudhury P** and the Mercator Study Investigators. Perivascular Dexamethasone for PTFE Graft Stenosis: The HAPPI (Hemodialysis Access Patency Extension with Percutaneous Transluminal Infusion of Dexamethasone) Study. J Am Soc Nephrol 2007, 18:468A-9A. (SA-PO579)
82. Krishnamoorthy M, **Roy-Chaudhury P**, Holland C, Paik E, Wang Y, Kwon O, Kurtzman M, Kemper D, Choe A, Banerjee R. Generation of a Complete Wall Shear Stress Profile in AV Fistulae using 64 slice CT Angiography. J Am Soc Nephrol 2007, 18:265A. (F-PO745)
83. Alloway RR, Mogilishetty G, Cole L, Vasilic D, Barker JH, Skeens H, Holland EJ, **Roy-Chaudhury P**, Woodle ES. Ocular Surface Transplant Recipients Experience Fewer Immunosuppression Complications Than Renal Transplant Recipients: Implications for Facial and Composite Tissue Transplantation. Am J Transplant 2007 May, 7(s2).
84. **Roy-Chaudhury P**, Arend L, Samaha T, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Munda R, Heffelfinger S. Aggressive Early Neointimal Hyperplasia Contributes to AV Fistula Maturation Failure. J Am Soc Nephrol 2006, 17:558A. (F-PO1056)
85. Krishnamoorthy M, Wang Y, Zhang J, Sinha Roy A, Khoury S, Desai P, Banerjee R and **Roy-Chaudhury P**. Hemodynamic Shear Stress Modeling and AV Fistula Stenosis in a Pig AV Fistula Model. J Am Soc Nephrol, 2006; 17:158A. (F-PO1055)
86. Krishnamoorthy M, Wang Y, Zhang J, Sinha Roy A, Khoury S, Rudich S, Desai P, Banerjee R, Arend L and **Roy-Chaudhury P**. Cellular Dynamics and Phenotypes in a Pig AV Fistula Model. J Am Soc Nephrol, 2006; 17:557A-8A. (F-PO1054)
87. **Roy-Chaudhury P**, Misra S and for the BRAVO II Study Investigators. Efficacy and Safety of Brachytherapy in PTFE Graft Stenosis. J Am Soc Nephrol, 2006; 17:495A. (F-PO747)
88. **Roy-Chaudhury P**, Aronoff G, Silver M, Brier M and the Medical Review Board. High Incidence of Central Venous Catheters in Patients returning to Hemodialysis following a Failed Renal Transplant. J Am Soc Nephrol, 2006; 17:494A. (F-PO746)
89. **Roy-Chaudhury P**, Arend L, Zhang J, Krishnamoorthy M, Wang Y, Banerjee R, Tevar A, Heffelfinger S, Munda R. Cellular Phenotypes in Dialysis Access Stenosis: Myofibroblasts, Fibroblasts and Contractile Smooth Muscle Cells. J Am Soc Nephrol, 2006; 17:75A. (SA-FC024)
90. Krishnamoorthy M, Wang Y, Zhang J, Sinha Roy A, Khoury S, Desai P, Banerjee R and **Roy-Chaudhury P**. Hemodynamic Shear Stress Modeling and AV Fistula Stenosis in a Pig AV Fistula Model. J Am Soc Nephrol, 2006; 17:74A. (SA-FC020)
91. Krishnamoorthy M, Wang Y, Zhang J, Sinha Roy A, Khoury S, Desai P, Banerjee R, **Roy-Chaudhury P**. Altering Hemodynamics through Computer Modeling of AV Fistula Configuration: Opportunities for Reducing AV Fistula Failure? J Am Soc Nephrol, 2006; 17:74A. (SA-FC018)
92. Gordon J, Rossi F, Tremolada S, Shollar D, Otte J, **Roy-Chaudhury P**, Woodle ES, Ferrante P, Khalili K, Trofe J. Prevalence of Rare BK Virus Subtypes and Donor vs. Recipient Mismatch in Polyomavirus Nephropathy. Am J Transplant 2006, 6(2):687.
93. Weimert N, Alloway RR, Cardi M, Buell J, Thomas M, Tevar A, Mogilishetty G, **Roy-Chaudhury P**, Munda R, Woodle ES. Long-Term Outcomes with Early Corticosteroid Withdrawal: A Single Center Experience. Am J Transplant 2006, 6(s2):655.

94. Weimert N, Kaiser T, Arend L, Jain A, Mogilishetty G, Revello P, Alloway RR, Cardi M, Susskind B, Woodle ES, **Roy-Chaudhury P**. Pattern of C4d Deposition in Patients with or Without Donor Specific Antibodies. Am J Transplant 2006, 6(s2):470.
95. Chen Y, Trofe J, Gordon J, Du Pasquier R, **Roy-Chaudhury P**, Kuroda M, Woodle ES, Khalili K, Koralnik I. Immune Control of BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy. Am J Transplant 2006, 6(s2):93.
96. Weimert N, Walker J, Mogilishetty G, **Roy-Chaudhury P**, Alloway R, Young S, Buell J, Munda R, Woodle ES. Early Corticosteroid Withdrawal for Renal Diseases with High Recurrence Risks. Am J Transplant 2006, 6(s2):943.
97. Walker JK, Trofe J, Alloway RR, Weimert N, Succop P, Buell J, Tevar A, **Roy-Chaudhury P**, Cardi M, Woodle ES. Polyomavirus Nephropathy: Multivariate Analysis of Risk Factors with Early Corticosteroid Cessation. Am J Transplant 2006, 6(s2):92.
98. Walker J, Boardman R, Alloway R, Arend L, Mogilishetty G, **Roy-Chaudhury P**, Cole E, Thomas M, Cardi M, Woodle ES. Early Corticosteroid Withdrawal in Patients with Focal Segmental Glomerulosclerosis: 3-Year Results. Am J Transplant 2006, 6(s2):240.
99. Walker JK, Alloway RR, Weimert NA, Cardi M, Balducci A, Rike A, **Roy-Chaudhury P**, Mogilishetty G, Buell J, Munda R, First MR, Thomas MJ, Woodle ES. A Steroid-Free, Short-Term Calcineurin Inhibitor, Long Term MMF Monotherapy Regimen for HLA Identical Live Donor Kidney Transplantation: A Prospective Trial. Am J Transplant 2006, 6(s2):432.
100. Rike AH, Mogilishetty G, Alloway RR, Cardi M, **Roy-Chaudhury P**, Succop P, Buell J, Woodle ES. Metabolic Syndrome in Renal Transplantation: Comparison of Early Corticosteroid Withdrawal vs. Chronic Corticosteroid Therapy. Am J Transplant 2006, 6(s2):522.
101. Rike AH, Alexander JW, Alloway RR, Cardi M, **Roy-Chaudhury P**, Safdar S, Goodman H, Thomas M, Woodle ES. Corticosteroid Avoidance and Calcineurin Inhibitor Minimization in Renal Transplantation: Two to Five Year Results. Am J Transplant 2006, 6(s2): 290.
102. Kaiser TE, Mogilishetty G, **Roy-Chaudhury P**, Weimert N, Zacharias V, Kemmer N, Alloway R, Tevar A, Buell J, Neff G. Liver Failure Etiology: Can it be Used to Predict Progression of Renal Dysfunction? Am J Transplant 2006, 6(s2): 847.
103. Kaiser TE, Susskind B, Alloway RR, **Roy-Chaudhury P**, Mogilishetty G, Tevar A, Rike A, Jain A, Munda R, Woodle ES. Early Corticosteroid Cessation in Living Donor Renal Transplant Recipients with Positive Flow Cytometric Crossmatches: 2-Year Experience. Am J Transplant 2006, 6(s2):772.
104. Woodle ES, Alloway RR, **Roy-Chaudhury P**, Alexander W, Hanaway M, Munda R, Tevar A, Rike A. Multivariate analysis of early and late acute rejection risk in 318 renal transplants following early corticosteroid withdrawal. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11). (poster).
105. Woodle ES, Alloway RR, **Roy-Chaudhury P**, Boardman R, Cardi M, Munda R, Thomas M, Mogilishetty G. Early corticosteroid withdrawal in African American renal transplant recipients: a 2-year follow-up. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11). (oral presentation).
106. Ueda KR, Jain A, **Roy-Chaudhury P**, Alloway RR, Succop P, Kaiser T, Mogilishetty G, Cardi M, Safdar S, Woodle ES. Anemia in kidney transplant recipients: a multivariate analysis. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11). (poster).
107. Rike AH, Alloway RR, **Roy-Chaudhury P**, El-Khatib M, Mogilishetty G, Hanaway M, Munda R, Buell J, Woodle ES. Long-term effects of acute rejection episodes following early corticosteroid cessation in renal

- transplantation. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11) (oral presentation).
108. Rike AH, Mogilishetty G, Alloway RR, Succop P, **Roy-Chaudhury P**, Ueda KR, Cardi M, Thomas M, Woodle ES. Global cardiovascular risk and cardiovascular events in renal transplant patients receiving early corticosteroid withdrawal versus chronic corticosteroids. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11). (oral presentation).
 109. Rike, AH, Mogilishetty G, Alloway RR, Succop P, Kaiser TE, **Roy-Chaudhury P**, Hanaway M, Woodle ES, Munda R. Early corticosteroid cessation minimizes new onset metabolic syndrome following renal transplantation. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11). (poster).
 110. Mogilishetty G, Rike AH, Alloway RR, Woodle ES, Succop P, Kaiser TE, Cardi M, Thomas M, Buell J, **Roy-Chaudhury P**. Predictors of cardiovascular risk in renal transplant patients. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005; 5(11). (poster).
 111. Kaiser TE, Alloway RR, Mogilishetty G, **Roy-Chaudhury P**, Rike AH, Young S, Woodle ES, Hanaway MJ. Early corticosteroid elimination with extended thymoglobulin therapy provides lower acute rejection compared to steroid treated controls in simultaneous kidney pancreas transplantation. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005, 5(11). (poster).
 112. Kaiser TE, **Roy-Chaudhury P**, Susskind BM, Alloway RR, Trofe J, Brailey PA, Rike AH, Arend L, Cardi M, Austin J, Woodle ES. Donor specific antibody detection by solid phase assay is a strong predictor of C4d positivity in renal allograft biopsies performed to evaluate renal dysfunction. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005; 5(11). (poster).
 113. Kaiser TE, Susskind BM, Alloway RR, **Roy-Chaudhury P**, Trofe J, Brailey PA, Ueda K, Cardi M, Thomas M, Goel S, Woodle ES. Early corticosteroid cessation in living donor renal transplant recipients with positive flow cytometric cross matches: one-year results. American Transplant Congress, Seattle WA, May 2005. Am J Transplant 2005; 5(11). (oral presentation).
 114. Chen Y, Trofe J, Gordon J, **Roy-Chaudhury P**, Woodle ES, Alloway RR, Khalili K, Koralnik IJ. Cytotoxic lymphocytes control BK virus replication in renal transplant recipients with polyomavirus nephropathy. Am J Transplant 2005; 5(11).
 115. Woodle ES, Alloway RR, **Roy-Chaudhury P**, Alexander W, Hanaway M, Munda R, Tevar A, Rike A. Multivariate analysis of early and late acute rejection risk in 318 renal transplants following early corticosteroid withdrawal. Am J Transplant, 2005; 5(11):161.
 116. Woodle ES, Alloway RR, **Roy-Chaudhury P**, Boardman R, Cardi M, Munda R, Thomas M, Mogilishetty G. Early corticosteroid withdrawal in African American renal transplant recipients: Two year follow up. Am J Transplant, 2005; 5(11):287.
 117. Ueda KR, Jain A, **Roy-Chaudhury P**, Alloway RR, Succop P, Kaiser T, Mogilishetty G, Cardi M, Safdar S, Woodle ES. Anemia in kidney transplant recipients: A multivariate analysis. Am J Transplant, 2005; 5(11):201.
 118. Rike AH, Alloway RR, **Roy-Chaudhury P**, El-Khatib M, Mogilishetty G, Hanaway M, Munda R, Buell J, Woodle ES. Long-term effects of acute rejection episodes following early corticosteroid cessation in renal transplantation. Am J Transplant, 2005; 5(11):517.
 119. Rike AH, Mogilishetty G, Alloway RR, Succop P, **Roy-Chaudhury P**, Ueda KR, Cardi M, Thomas M, Woodle ES. Global cardiovascular risk and cardiovascular events in renal transplant patients receiving early corticosteroid withdrawal versus chronic corticosteroids. Am J Transplant 2005; 5(11):288.

120. Rike AH, Mogilishetty G, Alloway RR, Succop P, Kaiser TE, **Roy-Chaudhury P**, Hanaway M, Woodle ES, Munda R. Early corticosteroid cessation minimizes new onset metabolic syndrome following renal transplantation. *Am J Transplant*, 2005; 5(11):194.
121. Mogilishetty G, Rike AH, Alloway RR, Woodle ES, Succop P, Kaiser TE, Cardi M, Thomas M, Buell J, **Roy-Chaudhury P**. Predictors of cardiovascular risk in renal transplant patients. *Am J Transplant*, 2005; 5(11):193.
122. Kaiser TE, Alloway RR, Mogilishetty G, **Roy-Chaudhury P**, Rike AH, Young S, Woodle ES, Hanaway MJ. Early corticosteroid elimination with extended thymoglobulin therapy provides lower acute rejection compared to steroid treated controls in simultaneous kidney pancreas transplantation. *Am J Transplant*, 2005; 5(11):357-358.
123. Kaiser TE, **Roy-Chaudhury P**, Susskind BM, Alloway RR, Trofe J, Braily PA, Rike AH, Arend L, Cardi M, Austin J, Woodle ES. Donor specific antibody detection by solid phase assay is a strong predictor of C4d positivity in renal allograft biopsies performed to evaluate renal dysfunction. *Am J Transplant*, 2005; 5(11):160.
124. Kaiser TE, Susskind BM, Alloway RR, **Roy-Chaudhury P**, Trofe J, Braily PA, Ueda K, Cardi M, Thomas M, Goel S, Woodle ES. Early corticosteroid cessation in living donor renal transplant recipients with positive flow cytometric crossmatches: One-year results. *Am J Transplant*, 2005; 5(11):246.
125. Jain A, Maru D, Revelo P, Smith R, Mogilishetty G, Arend L, Foster K, El-Khatib M, Mediwalla R, Susskind B, Woodle E, **Roy-Chaudhury P**. Characterization of the glomerular infiltrate and pattern of C4d deposition in patients with transplant glomerulitis. *Am J Transplant*, 2005; 5(11):454.
126. Chen Y, Trofe J, Gordon J, **Roy-Chaudhury P**, Woodle ES, Alloway RR, Khalili K, Koralnik IJ. Cytotoxic lymphocytes control BK Virus replication in renal transplant recipients with polyomavirus nephropathy. *Am J Transplant*, 2005; 5(11):227.
127. Woodle ES, Susskind B, Alloway RR, Hanaway MJ, Thomas M, Alexander JW, Merchen T, Gupta M, Succop P, **Roy-Chaudhury P**, Cardi M, Boardman R, Rogers C. Histocompatibility Testing Predicts Acute Renal Allograft Rejection Risk in Early Corticosteroid Cessation (ECS) Regimens. American Transplant Congress, Boston, 2004. *Am J Transplant* 2004, 4 Suppl 8.
128. **Roy-Chaudhury P**, Frost M, Zhang H, Batchelor M, Chang E, Meyerhoff M, Rudich S. Local Nitric Oxide Delivery Systems: Implications for Transplant Preservation. American Transplant Congress, Boston, 2004. *Am J Transplant* 2004, 4 Suppl 8.
129. Boardman RE, Trofe J, Alloway RR, Rogers C, **Roy-Chaudhury P**, Cardi MR, Safdar S, Groene B, Buell JF, Hanaway MJ, Thomas M, Alexander JW, Munda R, Woodle ES. Early Steroid Withdrawal Does Not Increase Risk for Recurrent Focal Segmental Glomerulosclerosis. American Transplant Congress, Boston, 2004. *Am J Transplant* 2004, 4 Suppl 8.
130. Trofe J, Woodle ES, Gordon J, Wadih G, Succop P, Alloway RR, Mutema G, Cavallo T, Heffelfinger S, Cardi MA, Austin J, Goel S, Safdar S, Huang S, Raabe S, Munda R, Buell J, Hanaway M, Alexander JW, Boardman R, Rogers C, Kidd M, Jain A, Berilla E, Demmey A, Khalili K, **Roy-Chaudhury P**. Histologic Grading of PVN Biopsies: Correlation with Viral Load Monitoring And Renal Function. American Transplant Congress, Boston, 2004 (oral presentation). *Am J Transplant* 2004, 4 Suppl 8.
131. **Roy-Chaudhury P**, Jain A, Trofe J, Alloway RR, Clippard M, McKee L, Heffelfinger S, Petrovic S, Ma L, Zahedi K, Rudich, S. Woodle ES, Soleimani M. Expression of Stathmin (A Novel Marker for Tubular Proliferation/Injury) in Renal Transplant Patients with Delayed Graft Function. American Transplant Congress, Boston, 2004 (oral presentation). *Am J Transplant* 2004, 4 Suppl 8.

132. Boardman RE, Trofe J, Alloway RR, Rogers C, **Roy-Chaudhury P**, Cardi M, Safdar S, Woodle ES. Bone Pain in Renal Transplantation: Does Sirolimus Play A Role? American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
133. Rogers CC, Alloway RR, Hanaway MJ, Buell JF, Alexander JW, Gupta M, Merchen TD, Thomas MJ, **Roy-Chaudhury P**, Trofe J, Cardi M, Munda R, Woodle ES. Impact of Early Corticosteroid Cessation on Body Weight Alterations in Renal Transplant Recipients. American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
134. Rogers CC, Alloway RR, Boardman RE, Trofe J, Hanaway MJ, Alexander JW, **Roy-Chaudhury P**, Buell JF, Thomas JF, Cardi M, Susskind B, Woodle ES. Global Cardiovascular Risk Under Early Steroid Cessation Decreases Progressively in the First Year Post Transplant. American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
135. Susskind B, Brailey P, **Roy-Chaudhury P**, Cardi M, Buell J, Munda R, Goel S, Austin J, Hanaway M, Woodle ES. Assessment of Immunologic Risk by Accurate, Sensitive and Quantitative Measurement of Anti-HLA Antibody in a Single-Tube Assay. American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
136. Susskind B, Karim R, Brailey P, **Roy-Chaudhury P**, Hanaway M, Cardi M, Woodle ES. Donor Specific Anti-Hla Class I Antibody Detection by an Elisa-Based Transplant Monitoring System (TMS®). American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
137. Alloway RR, Trofe J, Boardman RE, Rogers CC, Kidd M, Buell JF, Hanaway MJ, Munda R, Alexander JW, Thomas MJ, **Roy-Chaudhury P**, Cardi MA, Austin J, Goel S, Safdar S, Huang S, Woodle ES. A Prospective Pilot Study of Early Corticosteroid Elimination Under Modern Immunosuppression in Patients at High Immunologic Risk: One-Year Results. American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
138. Rogers CC, Alexander JW, Alloway RR, Metze TJ, Boardman RE, Trofe J, Gupta M, Merchen T, Hanaway MJ, Buell JF, Cardi M, **Roy-Chaudhury P**, Woodle ES. Corticosteroid Avoidance Ameliorates Lymphocele Formation and Wound Healing Complications Associated with Sirolimus Therapy: 2 Year Follow-Up In 109 Patients. American Transplant Congress, Boston, 2004. Am J Transplant 2004, 4 Suppl 8.
139. **Roy-Chaudhury P**, Mishra S, Mikkelsen Lynch P (for the BRAVO Study Investigators). Endovascular radiation therapy for venous stenosis. Poster presentation at the World Congress of Nephrology, Berlin, Germany 2003. Nephrol Dial Transplant 2003 Jun; 18 Suppl 4.
140. Trofe J, Gordon J, **Roy-Chaudhury P**, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalili K, Woodle ES. Polyomavirus nephropathy in kidney and kidney pancreas transplantation. J Neurovirol, 2003; 9(2):48.
141. Woodle ES, **Roy-Chaudhury P**, Cavallo T, Mutema G, Peddi VR, Alloway RR, Khalil K, Gordon J, Trofe J. Pathology of polyomavirus nephropathy in renal transplant recipients. J Neurovirol, 2003; 9(2):16.
142. **Roy-Chaudhury P**, Mishra S, Mikkelsen Lynch P (for the BRAVO Study Investigators). Endovascular radiation therapy for venous stenosis in dialysis access grafts (the bravo study): study design and initial recruitment. 3rd Vascular Access Society Meeting, Lisbon, May 21, 2003. Blood Purif 2003, 21.
143. **Roy-Chaudhury P**, Kelly B, Armstrong J, McKee L, Miller M, Heffelfinger S. Cellular phenotypes in venous neointimal hyperplasia (VNH) in dialysis access grafts. 3rd Vascular Access Society Meeting, Lisbon, May 21, 2003. Blood Purif 2003, 21.
144. **Roy-Chaudhury P**, Zhang J, Melhem M, Kassing W, Desai P, Kelly B, Narayana A, Heffelfinger S. Effect of radiation therapy and paclitaxel on endothelial cell proliferation. 3rd Vascular Access Society Meeting, Lisbon, May 21, 2003. Blood Purif 2003, 21.
145. **Roy-Chaudhury P**. Alternatives to avoid hyperplasia. 3rd Vascular Access Society meeting, Lisbon, May 21, 2003. Blood Purif 2003, 21:418.

146. Susskind B, McNeal N, Blanton M, Ram Peddi V, **Roy-Chaudhury P**, Buell J, Hanaway M, Woodle ES. Sensitivity and specificity of pronase treated cells in flow cytometry T- and B-Lymphocyte crossmatches (FCXM). American Transplant Congress, Washington D.C., 2003. Am J Transplant 2003, 3 Suppl 5.
147. **Roy-Chaudhury P**, Trofe J, Mutema G, Gordon J, Khalili K, McKee L, Heffelfinger S, Buell J, Hanaway M, Alloway R, Cavallo T, Peddi R, Woodle ES. Is tubular proliferation a prognostic marker In Polyomavirus nephropathy? American Transplant Congress, Washington D.C., 2003. Am J Transplant 2003, 3 Suppl 5. (oral presentation).
148. **Roy-Chaudhury P**, Rogers C, McKee L, Armstrong J, Alloway R, Heffelfinger S, Smith R, Peddi R, Kelly B, Cavallo T, Woodle ES, Mutema G. Is glomerular deposition of C4d a prognostic marker in chronic allograft dysfunction? American Transplant Congress, Washington D.C., 2003. Am J Transplant 2003, 3 Suppl 5 (poster).
149. **Roy-Chaudhury P**, Mutema G, Trofe J, Gordon J, Khalili K, McKee L, Armstrong J, Heffelfinger S, Buell J, Hanaway M, Susskind B, Alloway R, Peddi R, Cavallo T, Woodle ES. interstitial infiltrates (INF) in Polyomavirus nephropathy (PVN): cellular phenotyping and correlation with clinical parameters. American Transplant Congress, Washington D.C., 2003. Am J Transplant 2003, 3 Suppl 5. (oral presentation).
150. Rogers C, Alexander JW, Metze T, Boardman R, Trofe J, Gupta M, Merchen T, Hanaway MJ, Buell JF, Cardi M, **Roy-Chaudhury P**, Peddi VR, Goodman H, Sethuraman G, Woodle ES. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with Sirolimus therapy. American Transplant Congress, Washington D.C., May 2003. Am J Transplant 2003, 3 Suppl 5. (poster).
151. DeSalvo D, **Roy-Chaudhury P**, Merchen T, Konijetti K, Gupta M, Boardman R, Rogers C, Hanaway M, Buell J, Konoplev K, Smith R, Woodle ES, Peddi R. West Nile virus encephalitis in organ transplant recipients: another high-risk group for meningoencephalitis and death? American Transplant Congress, Washington D.C., 2003. Am J Transplant 2003, 3 Suppl 5.
152. Trofe J, **Roy-Chaudhury P**, Gordon J, Mutema G, Cavallo T, Cardi M, Austin J, Goel S, Rogers C, Boardman R, Clippard M, Alloway RR, Alexander JW, Metze T, Goodman H, Hanaway MJ, Munda R, Buell JF, Peddi VR, Safdar S, Huang S, Fidler J, Khalili K, Woodle ES. Early steroid cessation/avoidance regimens are associated with a lower incidence of Polyoma virus nephropathy compared to steroid based immunosuppression in kidney transplant recipients. American Transplant Congress, Washington D.C., May 2003. Am J Transplant 2003, 3 Suppl 5 (poster).
153. Trofe J, Gordon J, **Roy-Chaudhury P**, Mutema G, Cavallo T, Buell JF, Alloway RR, Safdar S, Cardi M, Hanaway MJ, Austin J, Goel S, Huang S, Peddi VR, C Rogers, Boardman R, Munda R, Alexander JW, Khalili K, Woodle ES. Correlation of BK viral load monitoring and host immune responses in post-transplant polyomavirus nephropathy. American Transplant Congress, Washington D.C., May 2003. Am J Transplant 2003, 3 Suppl 5 (poster).
154. Woodle ES, Alloway RR, Alexander JW, Sethuraman G, Hanaway KJ, Buell JF, Peddi VR, **Roy-Chaudhury P**, Cardi M, First MR, Trofe J. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation: Multivariate analysis of factors that determine rejection risk. American Transplant Congress, Washington D.C., May 2003. Am J Transplant 2003, 3 Suppl 5 (oral presentation).
155. Rogers C, Alloway R, Boardman R, Trofe J, Hanaway M, Alexander J, Peddi R, **Roy-Chaudhury P**, Cardi M, Susskind B, Woodle ES. Cardiovascular risk alterations with early corticosteroid cessation under modern immunosuppression: Objective assessment by Framingham risk analysis. American Transplant Congress, Washington D.C., 2003. Am J Transplant 2003, 3 Suppl 5 (poster).
156. Metze T, Alexander JW, Alloway RR, Clippard M, Rogers C, Susskind B, Alonzo M, Peddi VR, **Roy-Chaudhury P**, Woodle ES. Early steroid withdrawal in renal transplantation: Elderly patients and recipients of HLA

matched kidneys have lower rejection rates compared to “normal risk” patients. American Transplant Congress, Washington D.C., May 2003. Am J Transplant 2003, 3 Suppl 5 (oral presentation).

157. Clippard M, Alloway RR, Boardman R, Hanaway M, Buell JF, Trofe J, Alexander JW, Metze T, Cardi M, **Roy-Chaudhury P**, Gupta M, Munda R, Woodle ES. Delayed graft function: Implications for steroid elimination in kidney transplantation. American Transplant Congress, Washington D.C., May 2003. Am J Transplant 2003, 3 Suppl 5.
158. Peddi VR, Govil A, Weiskittel P, Alloway R, **Roy-Chaudhury P**, Goel S, Woodle ES, First MR. Long term follow up of Sirolimus substitution for calcineurin inhibitors in kidney and kidney-pancreas allograft recipients with nephrotoxicity. J Am Soc Nephrol, 2002; 13:184A.
159. **Roy-Chaudhury P**, Rogers C, First MR, Peddi VR, Woodle ES, Smith R, Mutema G, Cavallo T, Govil A, Armstrong J, McKee L, Heffelfinger S. C4d deposition in chronic allograft dysfunction. J Am Soc Nephrol, 2002; 13:558A.
160. Duncan H, Kant S, **Roy-Chaudhury P**. HMG coenzyme reductase inhibitors for hemodialysis vascular access dysfunction. J Am Soc Nephrol 2002; 13:231A.
161. Zhang J, Melhem M, Kelly B, Desai P, Kassing W, Narayana A, Heffelfinger S, **Roy-Chaudhury P**. Paclitaxel inhibits venous endothelial cells: A role for therapeutic intervention in dialysis access stenosis. J Am Soc Nephrol, 2002; 13:228A.
162. Zhang J, Melhem M, Kelly B, Desai P, Kassing W, Narayana A, Heffelfinger S, **Roy-Chaudhury P**. Radiation inhibits venous endothelial cells: A role for intervention in hemodialysis vascular access stenosis. J Am Soc Nephrol, 2002; 13:228A.
163. Trofe J, Cavallo T, First MR, **Roy-Chaudhury P**, Peddi VR, Weiskittel P, Rilo H, Bryant M, Brown S, Khalili K, Gordon J, Alloway R, Hanaway MJ, Buell JF, Woodle ES. Polyomavirus in kidney and kidney pancreas transplantation: Minimizing renal allograft injury/loss by defined immunosuppression reduction and histologic monitoring. Am J Transplant, 2002.
164. Buell JF, Potter SR, Hanaway MJ, Alexander JW, Munda R, Fidler J, Peddi VR, **Roy-Chaudhury P**, Cardi M, First MR, Woodle ES. Implications of obesity in laparoscopic nephrectomy donors. Am J Transplant, 2002.
165. Govil A, Peddi V, Goel S, **Roy-Chaudhury P**, Weiskittel P, Woodle ES, First MR. Sirolimus substitution for calcineurin inhibitors in renal allograft recipients with nephrotoxicity. J Am Soc Nephrol, 2001; 12:891A.
166. **Roy-Chaudhury P**, Miller MA, Reaves A, Peddi R, Woodle S, First MR, Smith R. Cytokine expression and cellular phenotyping in transplant glomerulopathy. J Am Soc Nephrol, 2001; 12:866A.
167. Pittman, S., Govil, A., Sorn, L., Bissler, G., Schultz, T, Faith, J., Kant, S., Roy-Chaudhury, P., Duncan, H. Alternative medicine use in dialysis patients: potential for good and bad! J Am Soc Nephrol, 2001; 12:343A.
168. Duncan, H., Faiyaz, R., Kelly, B., Kant, S., Roy-Chaudhury, P. Prognostic Determinants for hemodialysis vascular graft survival. J Am Soc Nephrol, 2001; 12:287A.
169. Faiyaz, R., Duncan, H., Zuckerman, D., Alspaugh, J., Munda, R., Kelly, B., Kant, S., Roy-Chaudhury, P. Increase in vascular access blood flow following venous angioplasty determines PTFE Graft Survival. J Am Soc Nephrol, 2001; 12:288A.
170. Duncan, H., Narayana, A., Zuckerman, D., Alspaugh, H., Vu, D., Kant, S., Faiyaz, R., Kelly, B., Roy Chaudhury, P. External radiation therapy for hemodialysis vascular access dysfunction. J Am Soc Nephrol, 2001; 12:287A.
171. **Roy-Chaudhury P**, Kelly B, Miller MA, Reaves A, Armstrong J, Heffelfinger S. Adventitial Fibroblasts Contribute to Venous Neointimal Hyperplasia (VNH) in PTFE Dialysis Grafts. J Am Soc Nephrol, 2001; 12:301A.
172. Kelly B, Heffelfinger S, Miller MA, Reaves A, Armstrong J, **Roy-Chaudhury P**. Cytokine Expression in a Pig Model of Venous Stenosis in Arteriovenous PTFE Grafts. J Am Soc Nephrol, 2001; 12:291A.

173. Peddi VR, Bryant M, **Roy-Chaudhury P**, Woodle ES, First MR: Cost-Analysis of Thymoglobulin Induction with Intermittent Dosing Based on CD3+ Lymphocyte Counts in High-Risk Cadaver Renal Transplant Recipients. American Society of Transplantation annual meeting, Chicago, Illinois. Am J Transplant, 2001.
174. Peddi VR, Bryant M, **Roy-Chaudhury P**, Woodle ES, First MR. Safety and Efficacy of Thymoglobulin Induction with Intermittent Dosing Based on CD3+ Lymphocyte Counts in High-Risk Cadaver Renal Transplant Recipients. American Society of Transplantation annual meeting, Chicago, Illinois. Am J Transplant, 2001.
175. Kelly B, Narayana A, Heffelfinger S, Miller MA, Reaves A, Armstrong J, Manzoor K, Whiting J, **Roy-Chaudhury P**. External beam irradiation for venous neointimal hyperplasia in PTFE dialysis grafts. J Am Soc Nephrol, 2000.
176. Peddi VR, Bryant M, **Roy-Chaudhury P**, Woodle ES, First MR. Thymoglobulin induction therapy in cadaveric renal allograft recipients: Intermittent dosing with CD3+ lymphocyte count monitoring. American Society of Transplantation, 19th annual meeting, Chicago, Illinois. Am J Transplant, 2000.
177. Kelly BS, Heffelfinger SC, Narayana A, **Roy-Chaudhury P**. External beam radiation reduces venous neointimal hyperplasia in PTFE dialysis grafts. Curr Surg, 2000; 57(6):640.
178. Peddi VR, Bryant M, **Roy-Chaudhury P**, Woodle ES, First MR - Thymoglobulin induction therapy in high-risk renal allograft recipients. American Society of Nephrology, 33rd annual meeting, Toronto, Canada. J Am Soc Nephrol, 2000.
179. Kelly B, Heffelfinger S, Miller MA, Reaves A, Armstrong J, Manzoor K, Narayana A, Whiting J, **Roy-Chaudhury P**. Differences between venous and arterial neointimal hyperplasia in PTFE dialysis grafts. J Am Soc Nephrol, 1999; 10:208-209.
180. **Roy-Chaudhury P**, SC Heffelfinger, M Miller, A Reaves, D Denman, MR First, J Whiting. Venous Stenosis in PTFE dialysis grafts: Development of a pig model of AV graft stenosis. J Am Soc Nephrol, 1998; 9:181A.
181. **Roy-Chaudhury P**, Miller MA, Reaves A, First MR, Munda R, Heffelfinger S. Venous neointimal hyperplasia in PTFE dialysis grafts. J Am Soc Nephrol, 1998; 9:182.
182. Zand MS, Li XC, Li YS, **Roy-Chaudhury P**, Strom TB. Initial characterization of IL-2 plus IFN-gamma double knockout mice: Lymphocyte subset distribution and delayed-type hypersensitivity. J Am Soc Nephrol 1997; 8:A2275-A2275.
183. **Roy-Chaudhury P**, Heffelfinger SC, Miller MA, Denman D, Munda R, First MR, Galla JH, Whiting J. An immunohistochemical analysis of venous stenosis in PTFE dialysis grafts. J Am Soc Nephrol 1997; 8:A0798-A0798.
184. **Roy-Chaudhury P**, Khong T, Williams JH, Haites NE, Wu B, Power DA. Expression of CD44 by mesangial cells in culture, in the THY 1.1 model and in human mesangial proliferative glomerulonephritis. Kidney Int 1996; 50(4):1415-1415.
185. Steiger J, Nickerson P, **Roy-Chaudhury P**, Steurer W, Thiel G, Strom TB. IL-2 for allograft rejection and IL-4 for allograft tolerance: Is it really that easy? Kidney Int 1996; 50(4):1432-1432.
186. **Roy-Chaudhury P**, Manfro RC, Steiger J, Nickerson PW, Zheng XX, Tian Y, Li YS, Strom TB.
187. Bushell A, **Roy-Chaudhury P**, Manfro RC, Zheng XX, Nickerson PW, Li YS, Wood K, Strom TB.
188. Zheng XX, Steele AW, Stevens AC, Nickerson PW, Li YS, **Roy-Chaudhury P**, Manfro RC, Tian Y, Strom TB. Cytolytic IL-2/Fc blocks diabetogenic autoimmunity in NOD mice by recruiting host ADCC and CDC effector mechanisms. J Am Soc Nephrol 1996; 7(9):A2401-A2401.
189. Hillis G, **Roy-Chaudhury P**, Duthie L, Brown P, Cruickshank C, Stewart K, Simpson J, MacLeod A. Changes in VLA integrin expression in mesangioproliferative glomerulonephritis. J Am Soc Nephrol, 1995; 6:896.

190. Nickerson P, Steiger J, Zheng XX, **Roy-Chaudhury P**, Steurer W, Steele A, Muller W, Strom TB. Islet cell engraftment in an IL-4 deficient model. J Am Soc Nephrol, 1995; 6:1061.
191. **Roy-Chaudhury P**, Nickerson PW, Steiger J, Zheng XX, Strom TB. CTLA4Ig blocks accelerated rejection in mouse islet allografts. J Am Soc Nephrol, 1995; 6:1064.
192. **Roy-Chaudhury P**, Simpson JG, Power DA. Endoglin (A TGF β binding protein) is upregulated in chronic progressive renal disease. J Am Soc Nephrol, 1995; 6:909.
193. **Roy-Chaudhury P**, Hillis G, McDonald S, Simpson JG, MacLeod AM, Power DA. Tubulointerstitial β 1 integrins are upregulated in chronic progressive renal disease. J Am Soc Nephrol, 1995; 6:909.
194. Khan IH, **Roy-Chaudhury P**, McKay NG, MacConnachie AA, Benjamin N, Haites NE, Edward N, Catto GRD, Macleod AM. Deletion Polymorphism of the gene encoding Angiotensin Converting Enzyme (ACE) in renal failure and hypertension. Presented at the Scottish Society of Experimental Medicine, Aberdeen, May 1995. Scott Med J, 1995.
195. **Roy-Chaudhury P**, Wu B, Haites NE, Macleod AM, Simpson JG, Power DA. Adhesion molecule interactions in the tubulointerstitium -- a role in tissue injury. J Am Soc Nephrol, 1994; 5:793.
196. Stewart KN, Hillis G, **Roy-Chaudhury P**, Brown PAJ, Simpson JG, Macleod AM. Integrin distribution in normal kidney and cultured human glomerular cells. Exp Nephrol Mar-Apr 1995; 3(2):140-141.
197. Hillis GS, Stewart KN, **Roy-Chaudhury P**, Brown PAJ, Simpson JG, Macleod AM, Power DA. The distribution of VLA integrins in normal renal biopsies and cell lines - evidence for the presence of VLA-2. Nephrol Dial Transplant, 1994; 9:1349.
198. **Roy-Chaudhury P**, Wu B, Macleod AM, Haites NE, Simpson JG, Power DA. Adhesion Molecule interactions in human glomerulonephritis. J Am Soc Nephrol, 1993; 4:629.
199. **Roy-Chaudhury P**, Williams J, Khong TF, Wu B, Macleod AM, Duthie LA, Simpson JG, Power DA. CD44 is expressed by cultured mesangial cells and in the proliferative phase of the Thy 1 model. J Am Soc Nephrol, 1993; 4:630.
200. **Roy-Chaudhury P**, Grabowski P, Haites NE, Macleod AM, Power DA. Epidermal Growth-Factor Receptors in IgA Nephropathy. Kidney Int Mar 1992; 41(3):699-700.
201. **Roy-Chaudhury P**, Wilson SJ, Brown PAJ, Stewart KN, Jones MC, MacLeod AM, Simpson JG, Power DA. Epidermal growth factor and insulin-like growth factor 1 in normal and diseased kidney tissue. Nephrology, Dialysis and Transplantation, 1991; 6:218.
202. Ballmer PE, Weber BK, **Roy-Chaudhury P**, McNurlan MA, Power DA and Garlick, PJ. Measurement of hepatic albumin synthesis in patients with nephrotic syndrome using stable isotopes. Nephrol Dial Transplant, 1991; 6:300.
203. McKay NG, Mukhtar A, **Roy-Chaudhury P**, Jones MC, Haites NE, Power DA. The effect of Interleukin 1 and Phorbol esters on fibronectin synthesis by cultured human mesangial cells. Nephrol Dial Transplant, 1990; 6:299.
204. Ballmer PE, Walshe D, Weber K, **Roy-Chaudhury P**, McNurlan MA, Power DA, Brunt PW, Garlick PJ. Modulation of albumin synthesis in diseases of the liver and kidney. Clin Nutr, 1990; 9:23S.
205. Stewart KN, Jones MC, Simpson JG, **Roy-Chaudhury P**, Macleod AM, Power DA. Production of monoclonal antibodies to human glomerular mesangial cells. Scott Med J, 1990; 35:155.
206. Stewart KN, **Roy-Chaudhury P**, Jones MC, Lumsden L, Macleod AM, Simpson JG, Power DA et al. Reactivity of monoclonal antibodies to cultured mesangial cells with normal kidney sections. Nephrol Dial Transplant, 1990; 5:684-685.

207. Webster J, Petrie JC, Jeffers TA, **Roy-Chaudhury P**, Crichton W, Witte K, Jamieson M Efficacy and tolerability of a sustained-release formulation of nicardipine in hypertension assessed by clinic and home blood-pressure recordings. Webster J, Petrie JC, Jeffers TA, **Roy-Chaudhury P**, Crichton W, Witte K, Jamieson M. Br J Clin Pharmacol, 1990, 29(5):587-588.
208. Webster J, Petrie JC, Jeffers TA, **Roy-Chaudhury P**, Crichton W, Witte K, Jamieson M. Efficacy of a sustained release formulation of Nicardipine in hypertension assessed by clinic and home blood pressure recordings. Eur J Clin Pharm, 1989; 36S:A339.
209. Scott AK, **Roy-Chaudhury P**, Webster J, Petrie JC. Selective 5 HT antagonist (ICI 169369): lack of effect on blood pressure in hypertensive patients. Br J Clin Pharm, 1988; 25:651P.
210. **Roy-Chaudhury P**, Gemmel H, Jamieson M, Mahaffey RG, Petrie JC, Smith FW, Webster J. Captopril inhaled scintigraphy in the diagnosis of renal artery stenosis. Scott Med J, 1988;33:317.

f. Products of Creative Activity

(Invention Disclosures and Patents)

University of Cincinnati Invention Disclosures

1. University of Cincinnati Invention Disclosure, Biodegradable Mg Spiral Laminar Flow Stent; Mark Schulz, John Yin, Vesselin Shanov, **Prabir Roy-Chaudhury**, Yang Wang, Begonia Campos, Tarek Helmy, Andy Chenhao Xu, Shaaban Abdallah, Tiasha Tarannum. October, 2017.
2. UC 114-073, Inflatable Breathable Stent to Prevent Restenosis in Veins, John Yin, Vesselin Shanov, Yonghai Zhang, Chenhao Xu, **Prabir Roy-Chaudhury**, Yang Wang, Begonia Campos, April 30, 2014
3. UC 113-054, Smart Biomedical Implants - Wiring-Up the Body to Live Longer, Mark J. Schulz, Begonia Campos-Naciff, David B Mast, **Prabir Roy-Chaudhury**, Vesselin N Shanov, Yang Wang, Zhangzhang Yin, Yonghai Zhang, Jan. 30, 2013.
4. UC 112-058, Elastic Biodegradable Metallic Stents, Zhangzhang Yin, Mark J. Schulz, Vesselin N. Shanov, **Prabir Roy-Chaudhury**, Campos-Naciff, Yang Wang, Jerome Jones, Gary Conroy, Dec 13, 2011
5. UC 111-087 - Magnetically Controlled Metal Stents and Implants, **Prabir Roy-Chaudhury**, Yang Wang, Vesselin Shanov, and Zhangzhang Yin, 4-4-2011.
6. UC 110-018 Self-Expanding Biodegradable Drug-Eluting Metallic Stent for Use in Coronary Arteries and Grafts, Mark J. Schulz, **Prabir Roy-Chaudhury**, Vesselin Shanov, Zhangzhang Yin, William Wagner, Frank Witte, 2010.
7. Biodegradable, Drug and Chemical Eluting Stents for Enhancing Arteriovenous Fistula Maturation, August 2009

Provisional Patents

1. Method of Making a Biodegradable Magnesium Staple for Surgical and Biomedical Applications, Vesselin Shanov, Tayyab Diwan and **Prabir Roy-Chaudhury**. 2013
2. Smart Biodegradable Implants, Mark Schulz, John Yin, Yonghai Zhang, Vesselin Shanov, **Prabir Roy-Chaudhury**, Yang Wang, Begonia Campos, Chenhao Xu, David Mast, Tarek Helmy. Provisional Patent, U.S. Serial No. 62/006,355; Title: Smart Biodegradable Implants; Inventors: Mark Schulz et al.; UC's Ref. 113-054, June 2, 2014.

Full Patents

1. Methods for making magnesium biodegradable stents for medical implant applications

Patent number: 10265205; Type: Grant; Filed: April 25, 2017; Date of Patent: April 23, 2019 Inventors: Vesselin N. Shanov, **Prabir Roy-Chaudhury**, Mark J. Schulz, Zhangzhang Yin, Begona Campos-Naciff, Yang Wang; University of Cincinnati

2. Arteriovenous fistula implant effective for inducing laminar blood flow

Patent number: 10849627; Type: Grant; Filed: August 29, 2016; Date of Patent: 12/1/2020; Inventors: Keith Louis Saum, **Prabir Roy-Chaudhury**, Begona Campos-Naciff, Diego Celdran-Bonafonte; University of Cincinnati

3. Catheters, Catheter Based Systems and Methods Thereof for Treating Hypervolemia;

Patent number: PCT/US20-19/057874 Type: Publication; Filed: 24 October 2019; Inventors: Murtaza Amin; Nathan Gooch; Ericka Prechtel; Andrew Sheffield; **Prabir Roy-Chaudhury**; BD

g. Refereed Unpublished Oral Presentations/Abstracts

1. Tubaldi E, Rosado J, He Y, Celdran-Bonafonte D, **Roy-Chaudhury P**. Functional Characterization of Arteriovenous Fistula on Swine Models using MRI. Summer Biomechanics, Bioengineering and Biotransport Conference. June 25-28, 2019. Seven Springs PA.
2. He Y, Pike D, Shiu Yan-Ting, **Roy-Chaudhury P**, Cheung A, Berceli S. Analyses of Hemodialysis Arteriovenous Fistula Geometry Obtained by Serial Magnetic Resonance Imaging. Summer Biomechanics, Bioengineering and Biotransport Conference. June 25-28, 2019. Seven Springs PA.
3. Campos B, Wang Y, Mistry MJ, Woodle BK, Cornea V, Lee TC, **Roy-Chaudhury P**. Early adventitial activation and proliferation in a mouse model of arteriovenous stenosis. American Society of Diagnostic and Interventional Nephrology Annual Scientific Meeting, New Orleans LA, 2012; *best presentation award* (oral presentation).
4. Lee TC, Safdar N, Mistry M, Wang Y, Chauhan V, Munda R, Campos B, Cornea V, **Roy-Chaudhury P**. Pre-existing venous calcification prior to dialysis vascular access surgery. American Society of Diagnostic and Interventional Nephrology Annual Scientific Meeting, New Orleans LA, 2012.
5. Trofe J, **Roy-Chaudhury P**, Gordon J, Wadih G, Alloway RR, Khalili K, Woodle ES. Viral Load Monitoring in Patients with Polyomavirus Nephropathy who have been Treated for Rejection Episodes. XX International Transplantation Society, Vienna, Austria, September 2004 (poster).
6. Trofe J, Gordon J, **Roy-Chaudhury P**, Wadih G, Alloway RR, Succop P, Jain A, Khalili K, Woodle ES. Outcomes of patients with polyomavirus nephropathy and rejection. XX International Congress of Transplantation Society, Vienna, Austria, September 2004 (poster).
7. Alexander JW, Metze T, Goodman H, Cardi M, Austin J, Goel S, Safdar S, Huang S, Munda R, Fidler J, Buell J, Hanaway M, Susskind B, **Roy-Chaudhury P**, Trofe J. Simultaneous avoidance of steroids and minimization of calcineurin inhibitors in renal transplantation. International Transplantation Society, Vienna, September 2004.
8. Boardman RE, Trofe T, **Alloway RR**, Rogers C, **Roy-Chaudhury P**, Cardi MA, Safdar S, Buell JF, Hanaway MJ, Thomas M, Alexander JW, Munda R, Woodle ES. Early steroid withdrawal does not increase risk for recurrent focal segmental glomerulosclerosis. International Transplantation Society, Vienna, September 2004.
9. Buell JF, Gross TG, Hanaway MJ, Trofe J, Beebe TM, Peddi VR, **Roy-Chaudhury P**, First MR, Woodle ES. Post-transplant lymphoproliferative disorder: The significance of central nervous system involvement. XX International Congress of Transplantation Society, Vienna, Austria, September 2004 (poster).
10. Hanaway MJ, Buell JF, **Roy-Chaudhury P**, Thomas M, Rudich S, Boardman R, Rogers C, Alloway R, Woodle ES. Corticosteroid elimination in renal transplantation: Experience in high immunologic risk recipients. XX International Transplantation Society, Vienna, Austria, September 2004 (poster).

11. Rogers C, Cardi M, Alloway R, Boardman R, Trofe J, Hanaway M, Alexander JW, **Roy Chaudhury P**, Buell J, Thomas M, Susskind B, Woodle ES. Global cardiovascular risk under early steroid cessation decreases progressively in the first year posttransplant. International Transplantation Society, Vienna, September 2004.
12. Rogers C, **Alloway R**, Alexander JW, Buell J, Boardman R, Cardi M, **Roy Chaudhury P**, First MR, Hanaway M, Succop P, Metze T, Munda R, Woodle ES. Body weight alterations under early corticosteroid withdrawal and chronic corticosteroid therapy with modern immunosuppression. International Transplantation Society, Vienna, September 2004.
13. Rogers C, Alexander J, Alloway RR, Boardman R, Trofe J, Gupta M, Merchen T, Buell J, Hanaway M, Cardi M, **Roy-Chaudhury P**, Woodle ES. Corticosteroid avoidance ameliorates lymphocele formation and wound healing complications associated with sirolimus therapy: 2 year follow up in 109 patients. XX International Transplantation Society, Vienna, Austria, September 2004 (oral presentation).
14. Succop P, Susskind B, Alloway RR, Hanaway M, Thomas M, Buell J, Boardman R, Rogers C, Merchen T, Gupta M, **Roy-Chaudhury P**, Woodle ES. Histocompatibility testing predicts acute renal allograft rejection risk in early corticosteroid cessation (ECS) regimens. XX International Transplantation Society, Vienna, Austria, September 2004 (oral presentation).
15. Sethu G, **Alloway RR**, Hanaway MJ, Buell JF, **Roy-Chaudhury P**, Cardi M, Trofe J, Woodle ES. Early corticosteroid withdrawal under modern immunosuppression in renal transplantation: Multivariate analysis of risk factors for acute rejection. XX International Transplantation Society, Vienna, Austria, September 2004 (oral presentation).
16. Zuckerman D, Misra S, **Roy-Chaudhury P**. Endovascular Radiation Therapy for Venous Stenosis in Dialysis Grafts: Initial Experience with the BRAVO Study. Radiological Society of North America 89th Scientific Assembly and Annual Meeting, Chicago IL, 2003. (poster)
17. Melhem M, **Roy-Chaudhury P**, Kasting J, Desai P. Local Polymeric Delivery of Paclitaxel for Neointimal Hyperplasia. Presented at the American Association of Pharmaceutical Sciences, Toronto, November 2002. (poster)
18. Kelly B, Heffelfinger S, Miller MA, Reaves A, Armstrong J, Narayana A, Whiting J, **Roy-Chaudhury P**. External beam irradiation for venous neointimal hyperplasia in PTFE dialysis grafts. Presented at the VIIth Vascular Access for Hemodialysis Symposium, San Antonio, May 2000. (poster)
19. Trofe J, Cavallo T, First MR, **Roy-Chaudhury P**, Peddi VR, Weiskittel P, Rilo H, Bryant M, Brown S, Khalili K, Gordon J, Alloway R, Hanaway MJ, Buell JF, Woodle ES. Polyomavirus in kidney and kidney pancreas transplantation: Minimizing renal allograft injury/loss by defined immunosuppression reduction and histologic monitoring. ATC, Washington DC, April 2002 (poster).
20. Trofe C, Cavallo T, First MR, **Roy-Chaudhury P**, Peddi VR, Weiskittel P, Bryant M, Brown S, Khalili K, Gordon J, Alloway RR, Hanaway MJ, Buell JF, Woodle ES. Polyomavirus interstitial nephritis in kidney pancreas transplantation: immunosuppression renal allograft loss by histologic monitoring and defined immunosuppression reduction. International Congress of Transplant Surgeon, Miami FL, August 2002 (poster).
21. Zuckerman DA, Alspaugh JP, Faiyaz R, Duncan HJ, Munda R, **Roy-Chaudhury P**. Increase in vascular access blood flow following venous angioplasty: A determinant of graft survival. Society of Cardiovascular and Interventional Radiology Annual Meeting, 2002. (oral presentation)
22. Trofe J, Cavallo T, First MR, Alloway R, **Roy-Chaudhury P**, Weiskittel P, Peddi VR, Woodle ES. Polyomavirus in kidney and kidney pancreas transplantation. 2nd International Congress on Immunosuppression, San Diego CA, December 2001 (oral presentation)
23. Peddi VR, **Roy-Chaudhury P**, Munda R, Woodle ES, First MR: Impact of Antiviral Prophylaxis on Cytomegalovirus Infection in Pancreas Transplant Recipients in the Current Immunosuppression Era. 8th World Congress of the International Pancreas and Islet Transplant Association, Innsbruck, Austria, June 2001. (poster)

24. Peddi VR, **Roy-Chaudhury P**, Buell J, Woodle ES, First MR: Cost-Analysis of Thymoglobulin Induction with Intermittent Dosing Based on CD3+ Lymphocyte Counts in Pancreas Transplant Recipients. 8th World Congress of the International Pancreas and Islet Transplant Association, Innsbruck, Austria, June 2001. (poster)
25. Peddi VR, **Roy-Chaudhury P**, Woodle ES, First MR: Efficacy of Thymoglobulin Induction with Intermittent Dosing Based on CD3+ Lymphocyte Counts in Pancreas Transplant Recipients - 8th World Congress of the International Pancreas and Islet Transplant Association, Innsbruck, Austria, June 2001. (poster)
26. Kelly B, Heffelfinger S, Miller MA, Reaves A, Armstrong J, Manzoor K, Narayana A, Whiting J, **Roy-Chaudhury P**. Differences between venous and arterial neointimal hyperplasia in PTFE dialysis grafts. Presented at the Annual Meeting of Black Academic Surgeons, Los Angeles, 1999. (poster)
27. Kelly BS, Heffelfinger SC, **Roy-Chaudhury P**. Characterization of venous neointimal hyperplasia in PTFE Grafts: A pig model. Cincinnati Surgical Society 1st Place Winner, May 2000. (poster)
28. **Roy-Chaudhury P**, Miller MA, Reaves A, First MR, Heffelfinger S. Venous neointimal hyperplasia and venous stenosis in PTFE dialysis grafts. Presented at the Veith Vascular Access for Hemodialysis Symposium, San Antonio, 1998.
29. Manfro RC, **Roy-Chaudhury P**, Steiger J, Zheng XX, Nickerson PW, Li YS, Maslinski W, Strom TB. Interleukin 15 gene transcripts are present in rejecting islet allografts. Accepted for the American Society of Transplantation Meeting, Dallas, May 1996.
30. Bushell A, **Roy-Chaudhury P**, Manfro RC, Zheng XX, Nickerson PW, Li YS, Wood K, Strom TB. IL-4 does not influence the rate of cardiac allograft engraftment: Studies in IL-4 knock out mice. Presented at the American Society of Transplantation Meeting, Dallas, May 1996.
31. Zheng XX, Li YS, **Roy-Chaudhury P**, Nickerson PW, Manfro RC, Sharpe A, Borriello F, Strom TB. Lack of B7-1 expression on donor grafts delays slightly but does not prevent acute allograft rejection. Presented at the American Society of Transplantation Meeting, Dallas, May 1996.
32. **Roy-Chaudhury P**, Manfro RC, Steiger J, Nickerson JW, Zheng XX, Li YS, Strom TB. IL-2 and IL-4 double knock out mice reject islet allografts. Presented at the American Society of Transplantation Meeting, Dallas, May 1996.
33. **Roy-Chaudhury P**, Jones MC, MacLeod AM, Haites NE, Simpson JG, Power DA. An immunohistological study of epidermal growth factor and neu receptor expression in proliferative glomerulonephritis. Presented at the International Congress of Nephrology, Jerusalem, June 1993.
34. **Roy-Chaudhury P**, Wu B, McDonald S, MacLeod AM, Haites NE, Simpson JG, Power DA. Adhesion molecules and cellular infiltrates in the pathogenesis of Thy 1 glomerulonephritis. Presented at the International Congress of Nephrology, Jerusalem, June 1993.

h. Non-Refereed Papers

1. Vandana Niyar, Prabir Roy-Chaudhury, Shane Perry. Transforming Dialysis Access Together. Kidney News 2022, Volume 14, Issue 10/11
2. **Roy-Chaudhury P**. Leveraging Vascular Access Clinical Trial End Points to Enhance Innovation. Endovascular Today, June 2019
3. **Roy-Chaudhury P**. The Kidney Health Initiative: Reflections and Future Perspectives, Kidney News, American Society of Nephrology 2018
4. Trerotola S, Steiner K, Holden A, **Roy-Chaudhury P**. Ask the Experts: What Outcomes will Foster or Stymie Adoption of Drug Coated Balloons in AV Fistula Intervention. Endovascular Today, June 2017.
5. **Roy-Chaudhury P**. Economics and the next Decade of Dialysis Access Intervention. Endovascular Today, June 2017.

6. Epstein M, **Roy-Chaudhury P**. Arrhythmias and sudden cardiac death in hemodialysis patients. Temporal profile, electrolyte abnormalities, and potential targeted therapies. *Nephrology News & Issues* 2016;30:suppl 23-6.
7. **Roy-Chaudhury P**, Ramani K, Dawoud D, Arterial and Venous Maturation in Hemodialysis Vascular Access in the Interventional Nephrology Self Assessment Program (web based), Invited Review, 2014.
8. **Roy-Chaudhury P**. Research Opportunities in Interventional Nephrology, *Kidney News*, American Society of Nephrology, 2012
9. **Roy-Chaudhury P**. Hemodialysis Vascular Access Dysfunction: Touch Briefings; US Kidney, 2009
10. **Roy-Chaudhury, P**. Hemodialysis Vascular Access Dysfunction: Opportunities for targeting an Unmet Clinical Need. Touch Briefings, US Kidney 2006.

i. *Digital and Other Novel Forms of Scholarship (with electronic links displayed, if relevant)*

1. Genius Podcast, April 2021
2. HIMSS video/podcast, April 2021
3. Quoted in Nashville Medical News article, March 2020
4. Quoted in Kidney News Article on AVF, March 2020
5. CNBC interview on Kidney Disease, Feb. 2020
6. Plenary Session Video, American Society of Nephrology 2018, San Diego, CA
7. International Society of Nephrology TV interview on Vascular Access.
https://www.youtube.com/watch?v=7OgcXkb_I0U; 200+ views, April 2019
8. ASN TV interview on the Kidney Health Initiative, ASN Kidney Week
<https://www.youtube.com/watch?v=8evm9OAmTF4>; 2.3K views, October 2018
9. ASN podcast on the Kidney Health Initiative with Ray Harris and Tod Ibrahim.
<https://www.kidneynews.org/kidney-news/kidney-news-podcast>, 2018
10. Quoted in Kidney News, Innovative RRT Roadmap, 2018
11. Twitter Chat Lead on Cardiorenal Syndrome #AskASN, 2018
12. Twitter Chat Lead on Kidney Health Initiative #AskASN, 2015
13. ASN Podcast on Day 2 of the ASN annual meeting.
<https://www.kidneynews.org/kidney-news/kidney-news-podcast?page=5>, 2013
14. Northern Kentucky Radio piece on the Kidney Foundation of Greater Cincinnati, 2004
15. Cincinnati Business Courier story on Endovascular Radiation, 2002

VI. TEACHING ACTIVITIES

a. *Lectures to Students*

- 2017 1st year Medical Students, University of Arizona College of Medicine
- Ethics
- 2017 Internal Medicine Residents, University of Arizona College of Medicine
- Transplantation

b. Lectures to Graduate Students

2015 – 2017 Renal Fellows, University of Arizona College of Medicine

- Vascular Access
- Immunology of Transplantation
- Poisonings

2015 Renal Fellows, University of Arizona College of Medicine

- Acute Kidney Injury
- Continuous Renal Replacement Therapy
- Post-Transplant Course

c. Grand Rounds and Continuing Education Lectures (at UNC)

1. Moving AV Fistula Maturation Assessment to the Dialysis Unit; Renal Grand Rounds, UNC Kidney Center, September 2021
2. Aligning Incentives with Value: CMS and Kidney Disease, UNC Medical Grand Rounds, October 2020
3. Dialysis Vascular Access Dysfunction: Challenging the Status Quo. Renal Grand Rounds, UNC Kidney Center, March 2019
4. Patient Centered Innovation in Kidney Diseases: the Time is Now, Medical Grand Rounds, Dept. of Medicine, UNC, October 2019
5. A Kidney Pot-Pourri, Renal Grand Rounds, UNC Kidney Center, October 2019
6. Real World Evidence Generation in Kidney Diseases, Journals Club, UNC Kidney Center, February 2020

d. Grand Rounds and Continuing Education Lectures (outside UNC)

1. Global Kidney Care, Annual AFMC Alumni Association Meeting, August 2023 (to be delivered)
2. Finerenone in ESKD and Transplantation, Bayer Cardiorenal Initiative, Barcelona, May 2023
3. Innovating for Global Kidney Care: from patients to Policy to Precision Medicine, Plenary Oration, 75th Jubilee Celebrations, Armed Forces Medical College, Pune, India, May 2023
4. Developing a Clinical Trial Program in Vascular Access, Vascular Access Society, Porto, Portugal, April 2023
5. Mechanisms of AVF Maturation Failure, Vascular Access Society, Porto, Portugal, April 2023
6. Transplantation and Precision Medicine in Kidney Care, Alexion Advisory Board, Dublin, April 2023
7. Dialysis Vascular Access, University of Florida Renal Grand Rounds, April 2023
8. Dialysis Vascular Access: of Patients, Precision Medicine and Policy, Beth Israel Deaconess Medical Center Renal Grand Rounds, March 2023
9. Enrichment and Precision Medicine Strategies for Vascular Access and Dialysis, Kidney Disease Kidney Trialists Workshop, Washington DC, March 2023
10. Sirolimus Eluting Collagen Based Drug Delivery for Vascular Access, ASDIN Meeting, Orlando, February 2023
11. Patient Centered Innovation in Kidney Diseases, Special Invited Presentation, Command Hospital, Southern Command, Pune, India, January 2023
12. Patient Centered Innovation in Kidney Diseases: the Time is Now. Alison Norris Symposium at the New York Academy of Medicine, November 2022.
13. Dialysis Vascular Access: of Patients, Policy and Precision Medicine, Salisbury VA Medical Grand Rounds, April 2022

14. Innovations in Vascular Access: A Model for Translational Medicine. NC A&T presentation, August 2022.
15. Dialysis Vascular Access: Time for a Change. Plenary presentation, IDEAS Meeting, August 2022
16. Dialysis Vascular Access, Holderness Presentation, March 2022
17. GEMAV Barcelona, AVF and Bioengineering (Virtual), September 2022
18. GEMAV Barcelona, Strategies for AVF Maturation (Virtual), August 2022
19. DASY Singapore, Patients Helping Patients: from Patient Preferences to Patient Centered Innovation (Virtual), October 2022.
20. DASY Singapore, New ASN Initiatives for Patient Centered Vascular Access Care (Virtual), October 2022.
21. Disease Management-Lab Values Explained, AAKP Annual Meeting, September 2022
22. Introduction presentations x 2: ASN Highlights, India, January 2022
23. Accelerating Technology Development During A Pandemic To Bring More People With Kidney Failure Home, VEITH Symposium, November 2021
24. Drug Coated Balloons: the Chinese Trial. Controversies in Dialysis Access (CiDA) meeting, December 2021
25. Cardio-Kidney end points for Safety, Cardiovascular Clinical Trials (CVCT) meeting, December 2021
26. Patient Centered Innovation in Kidney Disease: the Time is Now, Renal Grand Rounds at Emory University, November 2021
27. Coordinated Registry Networks and Pragmatic Trials for Vascular Access, Kidney Disease Clinical Trials Meeting, October 2021
28. Vascular Access Innovation: of Devices and Dollars, Society of Dialysis Access Professionals, October 2021, Singapore (Virtual)
29. Patient Centered Innovation, Medical Grand Rounds, Mt. Sinai West and Morningside, September 2021
30. Dialysis Vascular Access: from Patients to Policy, Renal Grand Rounds, George Washington University, August 2021
31. Patient Centered Innovation in Medicine; the Time is Now. Invited Lecture, Gleneagles Global Hospital, Mumbai, August 2021
32. Outcomes for Vascular Access: from Patients to Policy, Vascular Access Society of the America's meeting, May 2021
33. Outcomes and Quality Indicators for Vascular Access: from Patients to Policy, Vascular Access Society meeting, April 2021
34. Dialysis Vascular Access: of Patients, Policy and Precision Medicine, BD Seminar, March 17, 2021
35. The Innovation Substrate for Kidney Disease, Kidney Capital Markets Day (hosted by ASN) at the New York Stock Exchange, February 2021
36. Kidney Disease Innovation: from Patients to Policy, Medical Grand Rounds, University of Texas, San Antonio, February 2021
37. Davidson Interview and Panel Discussion on AVG Complications, Controversies in Dialysis Access (CiDA) meeting, November 2020
38. Chair for Panel Discussion on "Patient Centered Care for Vascular Access". Global Dialysis Access Forum, Vascular Access Society of the America's meeting
39. Kidney Disease Innovation, Eshelman School of Pharmacy, November 2020
40. Global Kidney Disease Innovation (webinar), UNC Modern Indian Studies Initiative, November 2020

41. Biology to Personalize Vascular Access Selection and Treatment: Myth or Reality, Invited presentation, ASN, October 2020
42. Patient Centered Innovation in Kidney Diseases, University of Virginia, Renal Grand Rounds, October 2020
43. Disparities in Kidney Disease; Introductory Chair Presentation at Kidney Disease Clinical Trials Conference (virtual), September 2020
44. Patients Centered Innovation in Kidney Disease: the Time is Now, Africa Health Network Fireside Chat, September 2020
45. Clinical Trials: Opportunities for All, AAKP Annual Meeting (virtual), September 2020
46. Introductory Chair Presentation, ASN Highlights (virtual) in India, August 2020
47. Soft Skills for Hard Conversations with Cardiovascular Patients, Webinar May 6, 2020
48. Vascular Access in the Age of Covid; Webinar organized through the DeBakey Webinar Series, March 30, 2020
49. Innovation in Kidney Diseases: Keeping the Patient Front and Center. Salisbury VA Medical Center Grand Rounds, March 2020
50. Patient Centered Innovation in Kidney Diseases, Invited Special Lecture at the Armed Forces Medical College, Pune, India, March 2020
51. Innovations in Dialysis Vascular Access, Invited Presentation, Transplant and Kidney Institute, Global Hospital, Lower Parel, Mumbai, March 2020.
52. Preventing, Treating and Curing Kidney Disease Together, ASN team visit at Verily, San Francisco, February 2020
53. Dialysis Vascular Access: Changing the Status Quo. Renal Conference, Buddhist Tzu Chi Hospital, Taipei City, Taiwan, November 2019
54. Patient Centered Innovation in Kidney Diseases; the Time is Now. Meedical Grand Rounds, Tri-Services General Hospital, Taipei City, Taiwan, November 2019
55. Vascular Access Calcification; from Bench to Bedside. Renal Conference, Tri-Services General Hospital, Taipei City, Taiwan, November 2019
56. Uremic Vascular Biology: from Cardiovascular Disease to Vascular Access. Taiwan Society of Nephrology Annual Meeting, November 2019
57. Is Comprehensive ESRD Care the Responsibility of a Society? VEITH Symposium, New York, November 2019
58. Can our Understanding of AV Fistula Stenosis be Translated into Better Patient Care? VEITH Symposium, New York, November 2019
59. Innovations in Vascular Access. ASN Kidney Week Annual Meeting, Washington DC, November 2019
60. Parachute vs Placebo. The Need to go Beyond Randomized Controlled Device Trials. Controversies in Dialysis Access, San Diego, October 2019
61. When no Kidney and PD isn't an Option: When should an AVF be Created so that the Patient can Avoid a Catheter? Controversies in Dialysis Access, San Diego, October 2019
62. It's Access Academic. Roy-Chaudhury P, Saad T, Wasse M. Controversies in Dialysis Access, San Diego, October 2019
63. Panel Member, Med Tech Innovator Panel for Kidney X Prize Winners, ASN 2019, San Diego
64. Adopting New Effective Therapies: What Matters to the Patient. Controversies in Dialysis Access, San Diego, October 2019

65. Development and Validation of a Uremic Pig Model for CKD and ESKD, IDEAS Conference, Seattle, August 2019
66. Dialysis Vascular Access: Challenging the Status Quo. Next Generation Kidney Research Meeting, Tokyo, Japan, August 2019
67. How Close are we to a Tailored Therapy for the Hemodialysis Patient? Endovascular Access (EVA) Meeting, Patras, Greece, June 2019 (through audio/video)
68. What is New and Interesting in Dialysis Access? The Nephrologists Viewpoint. Endovascular Access (EVA) Meeting, Patras, Greece, June 2019 (through audio/video)
69. When do we Need Sham Controls? Kidney Disease Clinical Trialists Meeting, Washington DC, May 2019
70. DCB/DES – What’s the Role in Access? Vascular Access Society of America Practicum, Houston, May 2019
71. Patient Panel Discussion, Moderator, Vascular Access Society of America Practicum, Houston, May 2019
72. Creating an Innovation Substrate for Dialysis Vascular Access: of Biology, Technology, Regulation and Reimbursement, Renal Grand Rounds, Weil Cornell Medical School, New York, NY, May 2019
73. Patient-Centered Innovation in Kidney Disease: the Time is Now. Medicine Grand Rounds, Weil Cornell Medical School, New York, NY, May 2019
74. Novel Devices and Therapies for Dialysis Vascular Access. World Congress of Nephrology, Melbourne, Australia, April 2019
75. Patient-Centered Innovation in Vascular Access. Dialysis Access Synergy, Singapore, March 2019
76. Of Fistulae, Flow and Finance. Dialysis Access Synergy, Singapore, March 2019
77. KHI, the Innovative RRT Roadmap and Kidney X: Lessons in developing PRO’s as a regulatory tool, Washington DC, March 2019 (part of a KHI project meeting)
78. Key Messages from the MiD Study. Annual Dialysis Conference, Dallas, March 2019
79. Angioplasty should no longer be the standard of care for access stenosis. CACVS meeting, Paris, France, February 2019
80. Antibody Mediated Rejection: from Bedside to Bench to Bedside. Indian Society of Nephrology Annual Meeting, Bhubaneshwar, India, December 2018
81. Patient-Centered Innovation. Indian Society of Nephrology Annual meeting, Bhubaneshwar, India, December 2018
82. Kidney Health Initiative: Past, Present and Future. KHI Board of Advisors Meeting, Washington DC, December 2018
83. Real World Evidence. Cardiovascular Clinical Trials. Washington DC, November 2018
84. Developing Efficient and Effective Regulatory Pathways for Patient-Centered Device Innovation. VEITH Symposium, New York City, November 2018
85. Local Drug Delivery for AV Access Dysfunction. VEITH Symposium, New York City, November 2018
86. Innovating for Kidney Disease, Renal Care Solutions, Medtronic, Minneapolis, November 2018
87. Patient-Centered Innovation in Kidney Disease. American College of Physicians Chapter Meeting, Phoenix, AZ, November 2018
88. It’s Access Academic. 2018 Winners, Controversies in Dialysis meeting, Washington DC, November 2018
89. Payment for Procedure or Payment for Performance. Controversies in Dialysis meeting, Washington DC, November 2018

90. Can our Understanding of AVF Stenosis be Translated into Better Clinical Care? Controversies in Dialysis meeting, Washington DC, November 2018
91. Kidney Health Initiative Roadmap, Late Breaking Public Policy Session. American Society of Nephrology Annual meeting, San Diego, October 2018
92. Dialysis Vascular Access: from Biology to Business. American Society of Nephrology Annual meeting, San Diego, October 2018
93. Kidney Health Initiative. US Kidney Organizations meeting, American Society of Nephrology Annual meeting, San Diego, October 2018
94. Global Burden of CKD and ESRD. Cardiorenal Society of America Annual Meeting, October 2018
95. Cardiorenal Prevention and Innovation. Cardiorenal Society of America Annual Meeting, Phoenix, October 2018
96. Kidney Health Initiative and Kidney X. Medicine Grand Rounds, Methodist Health system, Dallas, September 2018
97. Mentorship. University of Arizona, Department of Medicine, Fellows Retreat, September 2018
98. From Biology to Process of Care. Tianjin Nephrology Congress, Tianjin, September 2018
99. Patient-Centered Innovation. Tianjin Nephrology Congress, Tianjin, September 2018
100. Kidney Health Initiative Roadmap. Kidney X Listening Session, Seattle, August 2018
101. Biodegradable Stents. IDEAS Conference, Seattle, August 2018
102. Innovation in Kidney Disease. Georgetown University Hospital, August 2018
103. Biology of Vascular Stenosis. Albany Vascular Access Meeting, July 2018
104. Improving Patient Safety in Vascular Access. Albany Vascular Access Symposium, July 2018
105. From the Kidney Health Initiative to Kidney X: A Call to Action for Kidney Disease. Opening Plenary at the American Society for Artificial Internal Organs meeting, Washington DC, June 2018
106. Kidney Care in the Veterans Health Care System. American Association of Kidney Patients Annual meeting, St. Petersburg, June, 2018
107. The Kidney Health Initiative. Vascular Access Society of the Americas, New Orleans, May 11, 2018
108. Do Fistula's Mature: If, When and How Often? The Henry lecture. Vascular Access Society of the Americas, New Orleans, May 12, 2018
109. Dialysis Vascular Access: Of Biology, Technology and Process of Care 2018. Muljibhai Patel Urological Hospital, Nadiad, India, March 2018
110. Findings from the MiD study on Sudden Cardiac Death. Muljibhai Patel Urological Hospital, Nadiad, India, March 2018
111. Patient-Centered Innovation in Kidney Disease. 40-year Celebration Session of the Muljibhai Patel Urological Hospital, Nadiad, India, March 2018
112. A Kidney and Vascular Pot Pourri. Muljibhai Patel Urological Hospital, Nadiad, India, March 2018
113. Dialysis Vascular Access. Hinduja Hospital, Mumbai, India, March 2018
114. Sudden Cardiac Death in ESRD Patients: Lessons from the MiD Study. Max Saket Hospital, New Delhi, March 2018
115. Dialysis Vascular Access: Biology, Technology and Process of Care/Policy. Ganga Ram Hospital, New Delhi, India, March 2018

116. Health Economics and the Use of Early Cannulation Grafts. American Society of Diagnostic and Interventional Nephrology Annual Meeting, Industry Breakfast presentation, February 2018
117. Tripartite Collaborations for Vascular Access Care: An alphabet Soup of LDO's, VAC's and HPO's. American Society of Diagnostic and interventional Nephrology Annual Meeting February 2018
118. Dialysis Vascular Access: from Pig to Patient to Policy. Controversies and Updates on Vascular Surgery, Paris, France, January 2018
119. The Patient Perspective. Cardiovascular Clinical Trials Forum, Washington DC, 2017
120. Cardio Renal End Points. Cardiovascular Clinical Trials Workshop, Washington December 2017
121. What are the Most Important Factors Affecting AVF Maturation? VEITH Symposium, New York City, NY
122. Kidney Health Initiative: Advancing the Science of Vascular Access. VEITH Symposium, New York City, NY
123. Biology of Dialysis Access Dysfunction. Medtronic Advisory Board Meeting, Boston, 2017
124. Hemodialysis Fistula Maturation Consortium. Controversies in Dialysis, San Diego, November 2017
125. ESRD in India, Controversies in Dialysis. San Diego, November 2017
126. Kidney Failure Risk Equation, Controversies in Dialysis. San Diego, November 2017
127. Novel Cardiac Monitoring. American Society of Nephrology, New Orleans, November 2017
128. The Kidney Health Initiative. Advances in Research Conference, American Society of Nephrology, New Orleans, November 2017
129. Endovascular AVF, Transcatheter Therapeutics. Harmonization by Design Session. Denver October 2017
130. 35 years of the MSc in Clinical Pharmacology: of Mentorship, Science and Friendship. Aberdeen, October 2017
131. Innovation in Renal Medicine: from Pig to Patient to Policy. Armed Forces Medical College alumnus Meeting, Chicago, July 2017
132. Neutrolin Catheter Lock Solution: An Unmet Clinical Need. Cormedix Advisory Board meeting, July 2017, New York City, NY
133. Biology of Vascular Access Dysfunction. American Society for Artificial Internal Organs Annual meeting, Chicago, June 2017
134. Primary and Post Angioplasty AVF Stenosis: from Bench to Balloon. Bard-Lutonix Advisory Meeting, Phoenix, June 2017
135. Bioengineered Solutions for Dialysis Vascular Access: Challenging the Status Quo. International Society of Tissue and Vascular Engineering, Columbus, OH, June 2017
136. Dialysis Vascular Access: from Flow to Finance. Renal Grand Rounds, Boston University Medical Center, Boston, MA, June 2017
137. Arteriovenous Fistula Maturation: from Biology to Technology. Arizona Research Institute for Biomedical Imaging, Tucson AZ
138. Translational Research Panel Presentation. University of Arizona, April 2017
139. Patient Centric Innovation in Vascular Access and ESRD. Max Hospital and Research Center, New Delhi, India
140. Mechanisms of AVF Stenosis. Vascular Access Society Meeting, Ljubljana, April 2017
141. Patient-centric Innovation in Vascular Access. Leiden University Medical Center, March 2017
142. Innovative Renal Replacement Therapy. Kidney Health Initiative Workshop, Washington DC, March 2017

143. Bench to Bedside: Future of AV Access. American Society of Diagnostic and Interventional Nephrology, February 2017
144. Kidney Health Initiative. Invited Lecture, University of Tokyo, February 2017
145. Dialysis Vascular Access: of Biology, Technology and Process of Care. Indian Society of Nephrology, North Zone Meeting, Lucknow, February 2017
146. Process of Care in Vascular Access. Indian Society of Nephrology, North Zone Meeting, Lucknow, February 2017
147. Can the Changing Healthcare Environment Incentivize Innovation and Quality in Vascular Access Care? Physician Operators Forum, Davita Vascular Care, Las Vegas, January 2017
148. The New Dialysis Unit: A Factory for Innovation and Clinical Research. American Society of Nephrology Annual Meeting, Chicago, November 2016
149. Patient-Centric Innovation. Department of Medicine Grand Rounds, University of Arizona, Tucson, November 2016
150. AV Access Venous Outflow Stenosis at the Tissue Level: Are Most Stenosis Similar or Quite Variable? Controversies in Dialysis Conference, October 2016, Austin, Texas
151. The Kidney Health Initiative: What it is; Why does it Matter. Controversies in Dialysis Conference, October 2016, Austin, Texas
152. Renal Replacement Therapy: Challenges in India. Controversies in Dialysis Conference, October 2016, Austin, Texas
153. Dialysis Vascular Access: of Flow, Fistulae and Finance. Department of Medicine Research Conference, October 2016
154. Precision Medicine and Population Health: Opportunities and Challenges for Academic-Community Partnerships. Las Vegas, October 2016
155. Biology of Vascular Access Creation and Maintenance. North Texas Vascular Access Symposium, September 2016
156. Leveraging Large Dialysis Organizations. Vascular Access Centers and Healthcare Provider Organizations to improve Dialysis Vascular Access Care. NIDDK Roundtable, July 2016
157. Biodegradable Stents for AVF Maturation. Revolutionizing Metallic Biomaterials, NSF Engineering Research Center meeting, Greenville, June 2016.
158. Kidney Health Initiative. Vascular Access Society of the Americas Annual Conference, Chicago, May 2016
159. Vascular Access Innovation in a Changing Health Care Environment: Opportunities and Challenges. American Society of Diagnostic and Interventional Nephrology, Breakfast Symposium, February 2016
160. Dialysis Vascular Access: A Tale of Technology, Biology and Process of Care. Chugh Oration, Indian Society of Nephrology, Bangalore, December 2016
161. Sudden Cardiac Death in the ESRD Population: Opportunities for Diagnosis and Therapy. Cardiovascular Clinical Trials, Washington DC, December 2016.
162. Beyond the Balloon. American Society of Nephrology Annual Meeting, November 2015
163. The Kidney Health Initiative. American Society of Nephrology Annual Meeting, November 2015
164. Minimizing Catheters. American Society of Nephrology Annual Meeting, November 2015
165. Academic Community Partnerships. Renal Care Organization, Phoenix, October 2015
166. Cardiac Arrhythmias in Dialysis Patients. Hemodialysis University, Chicago, October 2015
167. Overview of the Failing AVF and AVG; NIH Vascular Access Conference, Bethesda, September 2015

168. Hemodialysis Vascular Access: Challenging the Status Quo. Japanese Society of Dialysis Access, September 2015
169. Innovating for Novel Therapies. Australia and New Zealand, Interventional Nephrology Conference, September 2015
170. Translational Innovation. Australian and New Zealand Nephrology Conference, Canberra, September 2015
171. Dialysis Vascular Access; Challenges and Opportunities. Australia and New Zealand, Interventional Nephrology Conference, September 2015
172. AV Fistula Maturation: The Good, the Bad and the Ugly. Australian and New Zealand Nephrology Conference, Canberra, September 2015
173. Dialysis Vascular Access: A Tale of Biology, Technology and Process of Care. (Plenary Presentation) at the Australian and New Zealand Nephrology Conference, Canberra, September 2015
174. Renal Pot Pourri. APEX Nephrology Board Review Course, Mumbai, May 2015
175. Donor-recipient Incompatibilities: Maneuvering through this Challenge. APEX Nephrology Board Review Course, Mumbai, May 2015
176. Miss Rita has an Antibody Mediated Rejection: What Should I be Doing Next? APEX Nephrology Board Review Course, Mumbai, May 2015
177. Translational Innovation: Beyond Vascular Access. APEX Nephrology Board Review Course, Mumbai, May 2015
178. Hemodynamics in AV Fistula Maturation. Vascular Access Society, Barcelona, Spain, April 2015
179. Arteriovenous Fistula Maturation. Plenary Session, Vascular Access Society, Barcelona, Spain, April 2015
180. Kidney Health Initiative. California Dialysis Council, April 2015
181. Medicine Grand Rounds. Louisiana State University, Shreveport, April 2015
182. Malcom Feist Lecture. Louisiana State University, Shreveport, April, 2015
183. Process of Care Issues in Dialysis Vascular Access. Indovasc Meeting, Bangalore, India, March 21, 2015
184. Biology of AVF Maturation Failure. Indovasc Meeting, Bangalore, India, March 21, 2015
185. Novel Therapies for Dialysis Vascular Access Dysfunction. Indovasc Meeting, Bangalore, India, March 21, 2015
186. Dialysis Vascular Access: from Bench to Bedside. Indovasc Meeting, Bangalore, India, March 21, 2015
187. Dialysis Vascular Access. World Congress of Nephrology, Cape Town, South Africa, March 16, 2015
188. Innovation in Medicine. Renal Grand Rounds, Indiana University, January 15th, 2015
189. Biology of Dialysis Vascular Access and Uremic Vascular Disease. Renal Research Conference, Indiana University, January 14th, 2015
190. Involving Patients, Regulators and Payers: Closing the Loop. American Society of Nephrology, Philadelphia, November 2014.
191. Translational Innovation. University of Arkansas, Renal Conference, October 30th, 2014.
192. Translational Innovation. Beyond Vascular Access, University of Michigan Combined Conference, October 2014
193. RT Jain Oration, Beyond AMR. West Zone Meeting, Indian Society of Nephrology, Mumbai, October 11, 2014
194. Workshop Presentation on Dialysis Vascular Access. West Zone Meeting, Indian Society of Nephrology, Mumbai, October 10, 2014

195. Beyond AVF and PTFE. West Zone Meeting, Indian Society of Nephrology, Mumbai, October 9, 2014
196. Vascular Biology of Dialysis Access Dysfunction. West Zone Meeting, Indian Society of Nephrology, Mumbai, October 9, 2014
197. Dialysis Vascular Access. National Kidney Foundation, Lafayette, LA, 2014
198. Hemodialysis Access, National Kidney Foundation, Lafayette LA, 2014
199. Dialysis Vascular Access. Renal Grand Rounds, University of Maryland, Baltimore MD, 2014
200. Hemodynamics and Dialysis Vascular Access. American Society for Artificial Internal Organs Annual meeting, Washington DC, June 19, 2014
201. Drug Eluting and Hybrid Grafts. European Vascular Course, Maastricht, Netherlands, May 14, 2014
202. Pharmacological Enhancement of AVF Maturation. European Vascular Course, Maastricht, Netherlands, May 13, 2014
203. Hemodialysis Vascular Access: Challenging the Status Quo. Renal Grand Rounds, University of Michigan, Ann Arbor MI, May 7, 2014
204. Hemodialysis Vascular Access; Changing the Paradigm. Renal Grand Rounds, Cleveland Clinic Foundation, Cleveland, OH, May 5, 2014
205. The Kidney Health Initiative. ISN Nexus Conference, Bergamo, Italy, April 4, 2014
206. Neointimal Hyperplasia: from Bench to Bedside. Vascular Flow Therapies Advisory Board, Frankfurt, Germany, March 28th, 2014
207. Hemodialysis Vascular Access. University of Arizona at Tucson, March, 2014
208. The Hemodialysis Fistula Maturation Study. American Society of Diagnostic and Interventional Nephrology, February 2014, Phoenix, AZ
209. Medicine. Sycamore High School Biology Club, Cincinnati, OH, February 2014
210. Case Presentations in Vascular Access. Silver Jubilee Celebrations, Sanjay Gandhi Post Graduate Institute, Lucknow, India, February 2014
211. Cephalic Arch Stenosis. Silver Jubilee Celebrations, Sanjay Gandhi Post Graduate Institute, Lucknow, India, February 2014
212. Early Fistula Failure and its Management. Silver Jubilee Celebrations, Sanjay Gandhi Post Graduate Institute, Lucknow, India, February 2014
213. Biology of Vascular Access Dysfunction. Silver Jubilee Celebrations, Sanjay Gandhi Post Graduate Institute, Lucknow, India, February 2014
214. Research Opportunities in Dialysis Access. Silver Jubilee Celebrations, Sanjay Gandhi Post Graduate Institute, Lucknow, India, February 2014
215. Animal Models of Uremia and Dialysis Vascular Access. Medtronic Inc. Minneapolis, MN, January 2014
216. A New Look at Dialysis Vascular Access. Renal Conference, University of San Antonio, January 8, 2014
217. New Paradigms for Dialysis Vascular Access. Renal Conference, Ohio State University, Columbus, Ohio, November 22, 2013
218. Recombinant Human Elastase to Promote Hemodialysis Access Patency. VEITH Symposium, New York, November 2013
219. Individualizing Vascular Access Therapy; Myth or Reality. VEITH Symposium, New York, November 2013
220. New Technologies for Dialysis Vascular Access. American Society of Nephrology Annual Meeting, Atlanta, November 2013

221. Preparing CKD Patients for Hemodialysis in the Context of a High Rate of AVF Maturation Failure. American Society of Nephrology Annual Meeting, Atlanta, November 2013
222. Kidney Health Initiative: Process and Projects Ahead. American Society of Nephrology Annual Meeting, Atlanta, November 2013
223. Dialysis Vascular Access. Renal Research Conference, University of Cincinnati, October 2013
224. Novel Paradigms for Dialysis Vascular Access: A Tale of Biology, Technology and Process of Care. Renal Grand Rounds, University of North Carolina, Chapel Hill, NC, October 2013
225. Case Presentations in Vascular Access. AIIMS/Brigham Course, New Delhi, India, October 4, 2013
226. Overview of CKD/Dialysis. AIIMS/Brigham Course, New Delhi, India, October 4, 2013
227. Case Presentations in Nephrology. Armed Forces Medical College, Pune India, September 2013
228. The Kidney Health Initiative. Nephrology Grand Rounds, University of Cincinnati, September 13, 2013
229. The Kidney Health Initiative. Kidney Health initiative Annual Meeting, Washington DC, September 11, 2013
230. Emerging Therapies in CKD: Are We There Yet? Armed Forces Medical College, Pune India, September 2013
231. Early Cannulation Grafts. WL Gore Global Meeting, Phoenix, July 31, 2013
232. Individualizing Dialysis Vascular Access: Myth or Reality? Western New York, Dialysis Vascular Access Forum, Buffalo, New York, July 18, 2013
233. Clinical Research in Dialysis Vascular Access. Renal Research Conference, University of Cincinnati, September 2013
234. Practical Research Portfolios for Dialysis Vascular Access (Interactive Table Sessions x 3). World Congress of Nephrology, Hong Kong, June 2-4, 2013.
235. Research Opportunities in Interventional Nephrology. World Congress of Nephrology, Hong Kong, June 2, 2013.
236. Perivascular Therapy for Vascular Regeneration. International Symposium on Vascular Tissue Engineering, Leiden, Netherlands, May 2013
237. Novel Stents for AVF Maturation. Engineering Research Center on Revolutionizing Metallic Biomaterials, North Carolina Agricultural and Technical University, May 2013
238. Systemic Therapies for Dialysis Access Dysfunction. Vascular Access Society Meeting, Prague, Czech Republic, April 2013
239. Neointimal Hyperplasia in Grafts. Vascular Access Society Meeting, Prague, Czech Republic, April 2013
240. Flow and Cannulation: Nursing Priorities for Dialysis Vascular Access. 34th Charing Cross Symposium, London, England, April 7th, 2013.
241. Improved Hemodynamics to Reduce Intimal Hyperplasia. 34th Charing Cross Symposium, London, England, April 7th, 2013.
242. Early Cannulation Grafts to reduce CVC Dependency. 34th Charing Cross Symposium, London, England, April 7th, 2013.
243. Novel Research Trials. 34th Charing Cross Symposium, London, England, April 7th, 2013.
244. Individualizing Dialysis Vascular Access Care. Medical Grand Rounds, Scott and White Health Care System, Temple, TX, March 29, 2013
245. Leveraging Technology to Individualize Vascular Access Care, Morning Symposium. American Society of Diagnostic and Interventional Nephrology Annual Meeting, February 17, 2013.

246. Vascular Access Selection in the Failed Transplant Patient. American Society of Diagnostic and Interventional Nephrology Annual Meeting, Washington DC, February 16, 2013.
247. Logistics, Communication, Competency and Training in AV Fistula Maturation. VEITH Symposium, New York, November 14, 2012
248. Optiflow Anastomotic Device Update. VEITH Symposium, New York, November 14, 2012
249. Cardiorenal Syndromes. National Kidney Foundation of Ohio Grand Rounds, November 2012
250. Worldwide ESRD and CKD. Renal Research Conference, University of Cincinnati, OH, 2012
251. Dialysis Case Reviews, Postgraduate Nephrology. AIIMS-Brigham Postgraduate Course, All India Institute of Medical Sciences, New-Delhi, India, October 2012
252. Dialysis Update, Postgraduate Nephrology. AIIMS-Brigham Postgraduate Course, All India Institute of Medical Sciences, New-Delhi, India, October 2012
253. Fistula Device. Engineering Research Center, Clinical Advisory Board, Chicago, September 2012
254. Dialysis Vascular Access: Challenges and Opportunities. Nephrology Grand Rounds, Medical College of Milwaukee, WI, September 11, 2012
255. Hemodynamics and Vascular Access Dysfunction. Taipei Veterans General Hospital, Taipei, Taiwan, June 25, 2012
256. Hemodialysis Vascular Access Dysfunction: from Biology to Therapy. Chinese Medical Society Annual Meeting, Taipei, Taiwan, June 24, 2012
257. From Biology to Therapy: Innovative and Translational Approaches to Dialysis Vascular Access. Medical Center Fund Board Meeting, Cincinnati, OH, June 12, 2012
258. AVF Devices, Engineering Research Center Site Visit on Revolutionizing Metallic Biomaterials. North Carolina Agricultural and Technical University, Greensboro, North Carolina, May 22, 2012
259. Optimizing Hemodynamics to Reduce PTFE Graft Stenosis. W.L. Gore Global Meeting, Orlando, May 15th, 2012
260. Avoiding Catheters through the use of Immediate Stick Grafts. W.L. Gore Global Meeting, Orlando, May 15, 2012
261. Vascular Access Maturation Success is more a Problem of Training and Competency. St Georges Vascular Access Course, Charing Cross Symposium, London, April 16th, 2012
262. Hybrid Device Reduces Venous Stenoses in a Pig Arteriovenous Graft Model. St Georges Vascular Access Course, Charing Cross Symposium, London, April 16th, 2012
263. Optiflow, Sirolimus Wrap and Other Novelties. St Georges Vascular Access Course, Charing Cross Symposium, London, April 16th, 2012
264. Novel Anastomotic Connectors. American Society of Diagnostic and Interventional Nephrology, New Orleans, Feb 26, 2012
265. Neointimal Hyperplasia. American Society of Diagnostic and Interventional Nephrology, New Orleans, Feb 25, 2012
266. Hybrid Vascular Graft. W.L. Gore Symposium, American Society of Diagnostic and Interventional Nephrology, New Orleans, Feb 25, 2012
267. New Paradigms for Dialysis Vascular Access. Medtronic World Headquarters, Minneapolis, MN, Feb 17, 2012
268. Novel Therapies for Dialysis Vascular Access Dysfunction. Advances in Nephrology Conference, San Diego, Feb 4, 2012

269. Arteriovenous Fistula Maturation. Advances in Nephrology Conference, San Diego, Feb 4, 2012
270. Global Trends in Dialysis. WL Gore Advisory Panel Meeting, Phoenix, December 2011
271. Novel Drug Delivery Technologies. WL Gore Advisory Panel Meeting, Phoenix, December 2011
272. Treatment of Antibody Mediated Rejection. American Society of Nephrology, Philadelphia, November 2011
273. Pathogenesis of Dialysis Access Dysfunction. Spanish Society of Nephrology, Seville, Spain, October 16, 2011
274. Use of cell therapy and biomedical engineering in vascular access. KDIGO conference on Novel techniques and innovation in blood purification: How can we improve clinical outcomes in hemodialysis? Paris, France, October 14, 2011
275. Bortezomib. Indian Society of Organ Transplantation, New Delhi, October 8, 2011
276. Treating Antibody Mediated Rejection. Indian Society of Organ Transplantation, New Delhi, October 7, 2011
277. Novel Technologies for Antibody Mediated Rejection. Indian Society of Organ Transplantation, New Delhi, October 7, 2011
278. Catheters. Acuseal Investigator Meeting, Society of Vascular Surgeons, Chicago, June 15th, 2011
279. Hemodynamic Stress Causes Vascular Access Failure. American Society of Artificial Internal Organs Meeting, Washington DC, June 11, 2011
280. Novel Therapies for Dialysis Vascular Access Dysfunction. Vascular Access Society Annual Meeting, Istanbul, May, 2011
281. Vascular Biology of Dialysis Access Failure. Vascular Access Society Annual Meeting, Istanbul, May, 2011
282. A Novel Device to Enhance AV Fistula Maturation. Engineering Research Center Meeting on Revolutionizing Metallic Biomaterials, NCAT, Greensboro, North Carolina, April 2011
283. Hybrid Sutureless anastomotic devices. 33rd Charing Cross Vascular Symposium, London, England, April 10, 2011
284. There are drugs that could improve patency: Myth or consensus? 33rd Charing Cross Vascular Symposium, London, England, April 10, 2011
285. Research Opportunities in Interventional Nephrology. World Congress of Nephrology, Vancouver, April 8, 2011
286. Optiflow anastomotic device. European Vascular Course, Maastricht, March 4, 2011
287. Anatomical configurations in arteriovenous fistulae. European Vascular Course, Maastricht, March 3, 2011
288. Research in Interventional Nephrology. Interventional Nephrology Course, International Society of Hemodialysis, New Delhi, India, March 2nd, 2011
289. Interventional Nephrology: What, Why and How? Interventional Nephrology Course, International Society of Hemodialysis, New Delhi, India, March 2nd, 2011.
290. Novel Technologies for Antibody Mediated Rejection. The Transplantation Society, New Key Opinion Leaders meeting, Goa, India, Feb 26, 2011.
291. Antibody Mediated Rejection: Diagnosis and Treatment. The Transplantation Society, New Key Opinion Leaders meeting, Goa, India, Feb 24, 2011.
292. Animal Models in Dialysis Vascular Access. American Society of Diagnostic and Interventional Nephrology, Las Vegas, February, 2011
293. Gerald Beathard State-of-the-Art lecture. American Society of Diagnostic and Interventional Nephrology, Las Vegas, February, 2011

294. Optiflow for Connecting Vessels. VEITH Symposium, New York, November 18th, 2010
295. Biology of AVF Maturation. American Society of Nephrology, PGE Symposium, Denver, November 16th, 2010
296. Antibody Mediated Rejection: Novel Concepts and Therapies. Harvard-Mayo Course on Nephrology and Nephropathology, Manipal Medical College, Manipal, Karnataka, India, October 31st, 2010
297. Transplant Immunology. Harvard-Mayo Course on Nephrology and Nephropathology, Manipal Medical College, Manipal, Karnataka, India, October 31st, 2010
298. The Achilles Heal, Toe and Floor of AVGs: What causes AVG Venous Anastomotic Stenoses? Controversies in Dialysis Access, San Francisco, October 28, 2010
299. Some AVF Veins Dilate and some Don't: Why? Controversies in Dialysis Access, San Francisco, October 28, 2010
300. Optiflow Connecting Device. Cincinnati Hemodialysis Vascular Access Symposium, Cincinnati, October 2, 2010
301. Sutureless Anastomosis Grafts. Cincinnati Hemodialysis Vascular Access Symposium, Cincinnati, October 2, 2010
302. Dialysis Access Dysfunction. Physician Scientist Training Program Lunch Meeting, Cincinnati, September 2010
303. Pathophysiology and Therapeutic Aspects in Vascular Access Patients. European Society of Vascular Surgery Annual Meeting, Amsterdam, September 18th, 2010.
304. New Horizons in Local Drug Delivery. WL Gore Experts Advisory meeting, Phoenix, September 11, 2010.
305. Interventional Nephrology and the UC Health Vascular Access Center (with Dr Wadehra). Nephrology Research Conference, August 2010.
306. Dialysis Access Dysfunction: from Hemodynamics to Vascular Biology. Nephrology Grand Rounds, Weill Cornell Medical College, New York City, June 2010
307. Dialysis Access Dysfunction (Mini Course for Fellows). Division of Nephrology, Weill Cornell Medical School, New York, June 2010
308. To Stent or not to Stent? Neointimal Hyperplasia is a Major Predicament. National Kidney Foundation Spring Clinical Meetings, Orlando, FL, April 14, 2010
309. Endovascular versus Surgery: Is there a pharmacological and molecular basis? Charing Cross Vascular meeting, London, April 12, 2010
310. Update in Dialysis Vascular Access. Postgraduate Nephrology Courses in Shimla and Cochin, India, April 8th and 10th, 2010
311. Vascular Access: Newer Concepts. Nephrology CME, Cochin, India April 10, 2010
312. Antibody-Mediated Rejection 2010. Nephrology CME, Cochin, India April 10, 2010
313. Vascular Access Case Presentations. Nephrology CME, New-Delhi, April 9, 2010.
314. Vascular Access: from bench to bedside. Nephrology CME, New-Delhi, April 9, 2010.
315. Case Presentations in Transplantation. Nephrology CME, New-Delhi, April 9, 2010.
316. Antibody Mediated Rejection: Diagnosis. Pathogenesis and Treatment. Nephrology CME, New-Delhi, April 9, 2010.
317. Transplant Immunology and Mechanism of Action of Immunosuppressive Drugs. Nephrology CME, New-Delhi, April 9, 2010.

318. AV Fistula Maturation. American Society of Diagnostic and Interventional Nephrology, Annual Meeting, Orlando, FL, February 19, 2010
319. Hemodialysis Vascular Access Update. Renal Research Conference, Cincinnati Children's Hospital Medical center, January 28, 2010.
320. Biology of AV Fistula Failure. 1st Israeli Vascular Access Meeting, January 12, 2010
321. Venous Angioplasty. Controversies in Dialysis Access Meeting, San Francisco, November 2009
322. Biology of AV Fistula Maturation. Invited Lecture, ASN Annual Meeting, San Diego, October 2009
323. AV Fistula Maturation. PGE Symposium on Interventional Nephrology, ASN Annual Meeting, San Diego, October 2009
324. New Paradigms for Dialysis Access Dysfunction; from hemodynamic stress to endothelial dysfunction. Nephrology Grand Rounds, Weill Cornell Medical College, New York City, April 2009
325. Dialysis Access Dysfunction (Mini Course for Fellows). Division of Nephrology, Weill Cornell Medical School, New York, April 2009
326. Hemodynamics and Endothelial Dysfunction. Vascular Access Society Meeting, Rome, April 2009
327. Novel Therapies for Dialysis Access Dysfunction. Nephrology Grand Rounds, University of Utah, Salt Lake City, March 2009
328. Biology of Vascular Access Dysfunction. European Vascular Society, Maastricht, Netherlands, February 2009
329. Arteriovenous Fistula: How, Where and Why? Indian Society of Nephrology Annual Meeting, Pune, December 2008
330. Surveillance of the Dialysis Access. VEITH Symposium, New York, November 2008
331. AV Fistula Maturation. PGE Symposium on Interventional Nephrology, ASN Annual Meeting, Philadelphia, November 2008
332. Hemodialysis Vascular Access. PGE Symposium on Dialysis: Practice and Principles, ASN Annual Meeting, Philadelphia, November 2008
333. Hemodialysis Vascular Access Dysfunction: from Pathogenesis to Therapy. Flagstaff, AZ, October 2008.
334. Hemodialysis Vascular Access Dysfunction: A Global Overview. Flagstaff, AZ, October 2008
335. Angioplasty versus Surgery for AV Fistula Maturation. Controversies in Dialysis Access Meeting, Boston, MA, October 2008
336. Cephalic Arch Stenosis. Controversies in Dialysis Access Meeting, Boston, MA, October 2008
337. Animal Models of Vascular Stenosis: from Bedside to Bench to Bedside. Cincinnati Animal Technicians Rounds, October 2008.
338. Angioplasty: Is Three Enough? Vascular Access Society of the Americas, Annual Meeting, Orlando, May 2008
339. Animal Models for Dialysis Access. Stenosis Workshop, 3rd St Michaels Access to Science Course, Toronto, Canada, May 2008
340. Novel Paradigms for Access Stenosis. 3rd St Michaels Access to Science Course, Toronto, Canada, May 2008
341. Antibody Mediated Rejection. All India Nephrology Training Course, Shimla, India, April, 2008
342. Hemodialysis Vascular Access. MPUH CME Course, Nadiad, Gujarat, India, April 2008
343. Novel Therapies for Dialysis Access Stenosis. American Society of Diagnostic and Interventional Nephrology, Salt Lake City, UT, February 2008

344. Cells, Genes and Drugs: Novel Therapies for Dialysis Access Dysfunction. National Kidney Foundation Annual Meeting, Dallas, TX, April 2008
345. New Paradigms for Hemodialysis Vascular Access Dysfunction. Division of Nephrology, Ohio State University, Columbus, Ohio, January 2008.
346. Hemodynamics and Stenosis in Hemodialysis Vascular Access Dysfunction. Nephrology Grand Rounds, Weill Cornell Medical School, New York, November 2007.
347. Hemodialysis Vascular Access: Basic Science. PGE Symposium on Dialysis: Practice and Principles, ASN Annual Meeting, San Francisco, November 1st, 2007
348. Mechanisms of AV Fistula Failure. PGE Symposium on Interventional Nephrology, ASN Annual Meeting, San Francisco, October 31st, 2007
349. From Cells to Stenosis. Cincinnati Hemodialysis Vascular Access Symposium 2007
350. Vascular Biology. St. Georges Vascular Access Symposium, Royal College of Surgeons of London, September 18, 2007
351. Novel Therapeutic Paradigms for Vascular Stenosis. Apollo Indraprastha Hospital, New Delhi, June 29th, 2007
352. How to Manage and Prevent Dialysis Graft Stenosis. Luncheon Session, American Society of Artificial Internal Organs Meeting, Chicago, June 8th, 2007
353. From Dialysis Access to Transplant: A Multidisciplinary Approach to CKD. Kidney Foundation of Greater Cincinnati Symposium on “A Clinical Approach to Chronic Kidney Disease”, Cincinnati, June 2nd, 2007.
354. Hemodynamics, Cells and Stenosis. Molecule to the Bedside Series, University of Cincinnati, May 24th, 2007
355. Dialysis Access and Endothelial Dysfunction: New Paradigms for an Old Problem. Invited Presentation at the American Society of Pediatric Nephrology, Toronto, May 5th 2007.
356. Non-Invasive Strategies to Limit Access Stenosis. Invited Presentation, 3rd Annual Meeting of the American Society of Diagnostic and Interventional Nephrology, Puerto Rico, April 29th, 2007
357. Biology of Early AV Fistula Failure. Invited Presentation, 3rd Annual Meeting of the American Society of Diagnostic and Interventional Nephrology, Puerto Rico, April 27th, 2007
358. DOQI Guidelines. Pre-Congress Interventional Nephrology Course, World Congress of Nephrology, Rio de Janeiro, Brazil, April 20th, 2007
359. Dialysis Access Dysfunction: from Cell to Stenosis. Pre-Congress Interventional Nephrology Course, World Congress of Nephrology, Rio de Janeiro, Brazil, April 20th, 2007
360. Pathobiology of Vascular Stenosis. Vascular Access Practicum, Duke University, Durham, NC, March 10, 2007
361. Vascular Access Failure: Basic Science. Post Graduate Education Course on “Maintenance Dialysis: Principles, Practical Aspects and Case Based Workshops”, American Society of Nephrology, Annual Meeting, San Diego, November 15th, 2006.
362. Hemodialysis Vascular Access Dysfunction: New Paradigms for a Difficult Clinical Problem. Brazilian Congress of Nephrology, Gramado, Brazil, October 10, 2006.
363. Polyoma Virus Nephropathy: from Bench to Clinical Practice. Invited Presentation, Brazilian Congress of Nephrology, Gramado, Brazil, October 9, 2006.
364. Immunosuppression without Steroids. Invited Presentation, Brazilian Congress of Nephrology, Gramado, Brazil, October 9, 2006.

365. Novel Local Therapies for Dialysis Access Dysfunction: Guest Lecture at the Interventional Nephrology Course, Brazilian Congress of Nephrology, Gramado, Brazil, October 7, 2006
366. Vascular Biology of Dialysis Access Dysfunction. Invited Presentation, University of Louisville, Vascular Access Symposium, September 15th, 2006.
367. Advances in Hemodialysis Vascular Access. Invited Presentation, University of Louisville, Sept 14th, 2006.
368. Hemodialysis Vascular Access: Injury, Cells and Drugs. Invited Presentation at “Nephrology in the 21st Century” National Kidney Foundation of Illinois, Chicago, Sept 10th, 2006.
369. Transplant Immunosuppression Update: Corticosteroid Withdrawal. Invited Presentation, St Georges Hospital NHS Trust, London, United Kingdom, August 2nd, 2006.
370. Pathobiology of Neointimal Hyperplasia. Invited Presentation, St Georges Hospital NHS Trust, London, United Kingdom, August 1st, 2006.
371. Hemodialysis Vascular Access Dysfunction: from Hemodynamics to Stenosis. Invited Presentation, St Georges Hospital NHS Trust, London, United Kingdom, August 1st, 2006.
372. Avian Flu: Virology, Epidemiology, Pharmacology and Politics. Medical Grand Rounds, University of Cincinnati, July 12, 2006.
373. Vascular Stenosis: Lessons from the Graft-Vein and Artery-Vein Anastomosis. Vascular Access: A Call to Arms. 2nd St Michaels Hemodialysis Vascular Access Conference, Toronto, June 2nd, 2006
374. Pathogenesis and Pathology of Hemodialysis Vascular Access Dysfunction. Nephrology Research Conference, Division of Nephrology, University of Miami, May 26th, 2006.
375. Hemodialysis Vascular Access Dysfunction: from Bedside to Bench to Bedside. John Cunio Memorial Lecture and Medical Grand Rounds, University of Miami, Miller School of Medicine, National Kidney Foundation of Florida, May 25th 2006.
376. From Hemodynamics to Cell Biology: A New Look at Hemodialysis Vascular Access Dysfunction. Nephrology Research Conference, University of Birmingham, Alabama, April 17th, 2006.
377. Vascular Stenosis in Medicine and Nephrology: Novel Therapies for a Recalcitrant Clinical Problem. Guest Speaker, Peritoneal Dialysis Society of India Annual Meeting, Chandigarh, India, Feb 5th, 2006
378. Hemodialysis Vascular Access Dysfunction: from Vascular Biology to Clinical Stenosis. Nephrology Grand Rounds, Loyola University Medical Center, Chicago, December 15th, 2005.
379. Biology of Intimal Hyperplasia. Clinical Symposium, American Society of Nephrology Meeting, Philadelphia, November 13th, 2005
380. Vascular Pathobiology. Invited Presentation at the “Essential Concepts of Diagnostic and Interventional Nephrology, PGE Course”, American Society of Nephrology Meeting, Philadelphia, November 8th, 2005
381. Hemodialysis Vascular Access Dysfunction. Nephrology Research Conference, St Michaels Hospital, Toronto, June 21st, 2005
382. Biology of Venous Arterialization in Uremic Patients. Workshop at the St Michaels Dialysis Access Symposium, Toronto, June 20th, 2005
383. Plenary Session Presentation, Uremic Vasculopathy and Dialysis Access: from Bedside to Bench to Bedside. St. Michael’s Hospital, Toronto, Ontario, June 20th, 2005.
384. Science in Medicine- “Spare Parts: Dialysis and Transplantation.” UC College of Medicine, Cincinnati, OH, April 13th, 2005.
385. Biology of Intimal Hyperplasia. American Society of Diagnostic and Interventional Nephrology, Scottsdale, Feb 11-13, 2005.

386. Novel Therapies for Hemodialysis Vascular Access Dysfunction: Fact or Fiction". 7th International Conference on Dialysis - Advances in ESRD, New Orleans, January 2005.
387. Invited Presentation, Development of a Clinically Relevant Histological Grading System for Polyomavirus Nephropathy. Fujisawa Investigator Meeting on Polyomavirus, Chicago, June 9th, 2004
388. Radiation Therapy for Dialysis Access Grafts and Panel Discussion. Cardiovascular Radiation Therapy 2004, Washington DC, May 6th, 2004 PM
389. Issues in Access: Bench to Bedside. Vascular Access for Hemodialysis IX, Orlando, Florida, May 6th, 2004 AM
390. Neointimal Hyperplasia: Changing Paradigms for a Complex Clinical Problem. Molecule to Bedside Series, University of Cincinnati, April 22, 2004.
391. Hemodialysis Vascular Access: From Molecular Biology to Interventional Radiology. Radiology Teaching Rounds, University of Cincinnati, April 8, 2004.
392. Endovascular Radiation Therapy for Dialysis Access. Cincinnati Hemodialysis Vascular Access Symposium 2004, Cincinnati, OH, March 20th
393. Essential Drugs in the Developing World. Medical Grand Rounds, University of Cincinnati, March 3rd, 2004.
394. Venous Neointimal Hyperplasia and the Interventional Nephrologist. Invited Speaker, RMS Lifeline Annual Meeting, Baltimore, Feb 21st, 2004
395. Neointimal Hyperplasia; from Biology to Intervention. Invited Presentation, Hinduja Hospital, Mumbai, India, December 2003.
396. Polyoma Virus Nephropathy. Invited Presentation at the Indian Society of Nephrology Meeting, Vishakhapatnam, India, December 5th, 2003
397. Alternatives to Avoid Neointimal Hyperplasia. Invited Presentation, 3rd Vascular Access Society Meeting, Lisbon, May 21st, 2003
398. Hemodialysis Vascular Access. Medical Grand Rounds, St Luke's Roosevelt Hospital, New York, May 8th, 2003
399. Endovascular Radiation. Novoste Investigator Meeting, Las Vegas, April 2003
400. Hemodialysis Vascular Access Dysfunction: Opportunities and Pitfalls. Nephrology Grand Rounds, University of Louisville, Louisville, KY, March 21, 2003
401. Hemodialysis Vascular Access Dysfunction. Renal Research Conference, Children's Hospital Medical Center, Cincinnati, Feb 3, 2003
402. Pathophysiology of Hemodialysis Vascular Access Dysfunction. Renal Research Institute, Advances in ESRD Meeting, Miami, Feb 1, 2003
403. Hemodialysis Vascular Access Dysfunction: from Bench to Bedside. Invited presentation at the Council on Renal Nutrition, Fall Meeting, Cincinnati, November 15th, 2002
404. Opportunities in Hemodialysis Vascular Access Dysfunction. Nephrology Grand Rounds, Cleveland Clinic Foundation, Sept 27, 2002
405. Hemodialysis Vascular Access. Invited Presentation, Amylin Pharmaceuticals, San Diego, July 25th, 2002
406. Endovascular Radiation for Dialysis Vascular Access. Novoste Investigator Meeting, Palm Beach, Florida, June 2002
407. Hemodialysis Vascular Access Dysfunction: from Bench to Bedside to Bench. Invited Speaker, Vascular Access for Hemodialysis VIII, Rancho Mirage, CA, May 9, 2002

408. Arresting Neointimal Hyperplasia: Pharmacologic and Non-Pharmacologic Approaches. ESRD Network 9-10 Meeting, Chicago, May 3, 2002
409. Pathobiology of the Failing Access. Hemodialysis Course, National Kidney Foundation, Spring Clinical Meeting, Chicago, April 2002
410. Hemodialysis Vascular Access Dysfunction. Pathology Research Seminar, University of Cincinnati, January 2002
411. Arresting Neointimal Hyperplasia, Pharmacologic and Non-Pharmacologic Approaches. Invited Speaker, Clinical Symposium on "Vascular Access: Improving Outcomes", World Congress of Nephrology (joint American Society of Nephrology and International Society of Nephrology meeting), San Francisco, Oct 2001.
412. Hemodialysis Vascular Access Dysfunction: from Basic Biology to Clinical Intervention. Red River Vascular Symposium. Shreveport, Louisiana, September 2001
413. Pathogenesis of Hemodialysis Vascular Access Dysfunction. Hemodialysis Access 2001 Symposium, Cincinnati, September 2001
414. Venous Neointimal Hyperplasia: from Basic Biology to Clinical Intervention. Hemodialysis Access 2001, ESRD Network 9-10 meeting, Indianapolis, May 2001
415. Invited lecture on "Hemodialysis Vascular Access Dysfunction: from Polymer to Patient." Department of Engineering, University of Cincinnati, 2001
416. Pathogenesis of Venous Neointimal Hyperplasia. Invited Mini Lecture, American Society of Nephrology, Toronto, October 2000
417. Venous Neointimal Hyperplasia. Invited Presentation. Medical College of Wisconsin, Milwaukee, Wisconsin, May 2000.
418. Venous Neointimal Hyperplasia. Millennium Nephrology Conference, New Delhi, India, Feb, 2000
419. Pathophysiology and Prevention of Venous Stenosis. DCI Annual Meeting, St Petersburg, Florida, October 1999
420. Venous Stenosis in PTFE Dialysis Grafts. Maine Medical Center, Portland, Maine, March 1999.
421. Venous Stenosis in PTFE Dialysis Grafts: A Role for Angiogenesis, Macrophages and Specific Cytokines. Division of Nephrology, Mount Sinai Medical Center, New York, January 1999.
422. Pathophysiology of Graft Fistula Failure. Symposium on Angio-Access for Dialysis. Cincinnati Museum Center, September 1997
423. Tolerance and Rejection: Studies in Knockout Animals. Multidisciplinary Transplant Conference, University of Cincinnati, June 1997.
424. Essential Drugs. Department of Pharmacy, University of Sussex, Brighton, March 1987

e. Meeting Chair/Session Chair/Panel/Moderator

- | | |
|------|--|
| 2023 | Panelist/Moderator for Bayer Cardiorenal Initiative, Barcelona, May 2023 |
| 2023 | Panelist for Astra Zeneca Rare Diseases session on Transplantation, Dublin, April 2023 |
| 2023 | Moderator for Kidney Disease Clinical Trialists Meeting; PRO's in Hemodialysis Trials |
| 2023 | Moderator for Kidney Disease Clinical Trialists Meeting; Targeting Kidney end Points in Trials for Patients with Sickle Cell Disease |
| 2023 | Moderator for ASN Highlights India, Feb 2023 |
| 2022 | Panelist for Bayer Cardiorenal Initiative, New York City |

2022	KDIGO meeting on Long Term Allograft Survival, Vienna, March 2022
2022	Panelist for Milken Institute Workshop II on Chronic Kidney Disease, Feb 2022
2022	Moderator for ASN Highlights India, January 2022
2022	Panelist for Astra Zeneca session on SGLT-2 inhibition
2022	Panelist for Astra Zeneca session on Difelekefalin
2021	Moderator for Fluid Management Session at Kidney Disease Clinical Trials 2021
2021	Moderator for Vascular Access Session at Kidney Disease Clinical Trials 2021
2021	Moderator for Southeast Regional Board Discussion on Difelekefalin
2021	Panelist for Milken Institute Workshop I on Chronic Kidney Disease
2021	Panelist for CardioKidney III at CVCT 2021
2021	Panelist for CardioKidney II at CVCT 2021
2021	Panelist for CardioKidney I at CVCT 2021
2021	Co-Chair (Research Track) for the Vascular Access Society of the Americas Meeting
2020	Moderator for Vascular Access Society of the Americas session on “the Patient Perspective”
2020	Moderator of BD Symposium on Dialysis Vascular Access: of Patients, Policy and Precision Medicine
2019	Convener for Innovation and Research Session, Dialysis Access Synergy, Singapore
2019	Moderator, ASN Highlights, Mumbai, India
2015 – 19	VEITH Symposium
2014 – 19	Controversies in Dialysis Access (CiDA)
2017 – 18	Kidney Disease Clinical Trials
2016 – 18	Cardiovascular Clinical Trials (CVCT)
2013 – 18	Session Chair, Kidney Health Initiative Annual Meeting
2017	VA Innovation Summit, Washington DC
2017	Vice Chair, Renal Program, American Society for Artificial Internal Organs (ASAIO)
2016 – 17	American Society of Diagnostic and Interventional Nephrology
2009 – 11, 2017	Session Chair, American Society of Diagnostic and Interventional Nephrology
2003 – 2017	Symposium/Session Chair, American Society of Nephrology Kidney Week or Pre-Course (2003, 2007-08, 2010 – 17)
2015	Chair, “Curing Kidney Disease: at the Crossroads of Biology, Infrastructure, Patients and Government,” American Society of Nephrology Kidney Week
2014	Session Chair, European Vascular Course, Maastricht, Netherlands
2011 – 13	Session Chair, Charing Cross Vascular Symposium
2009 – 13	Session Chair, Vascular Access Society Biennial Meeting (Rome, Italy ’09; Istanbul, Turkey ’11; Prague, Czech Republic ’13)
2009 – 10, 2013	Session Chair, Postgraduate Nephrology, New-Delhi, India: Session Chairman

- 2001 – 2013 Organizer and Co-Chair, Cincinnati Hemodialysis Vascular Access Network, Cincinnati OH (in collaboration with The Renal Network) (2001, 2004, 2007, 2010, 2013)
- 2008, 2012 Session Chair, Vascular Access Society of Americas
- 2011 Organizer and Chair, Interventional Nephrology Course, International Society of Hemodialysis, New Delhi, India
- 2004, 2006 Session Chair, American Society for Artificial Internal Organs (ASAO)

f. Lab or Research Teaching/Mentorships

1. Nephrology and Transplant Surgery Faculty at the University of Cincinnati

- Timmy Lee
NIH/NIDDK K23 DK083528 (Lee TC, PI) 07/01/2013 – 06/30/2014
 Novel biological markers of impaired AV fistula maturation
Role: Mentor
- NKF Franklin McDonald Research Grant** 2009 – 2012
 Processes of Care in Dialysis Vascular Access
Role: Mentor
- Amit Govil, 1999-2001
- Karthik Ramani, 2013-2015
- Dalia Dawoud, 2014-2015
- Bharvi Oza-Gajera, 2015
- Amit Tevar, 200-2001
- Tayyab Diwan, 2008-2009
- Madison Cuffy, 2008-2009

2. International Scholars

- Jasleen Sidhu 2019
- Elly Varma (now a renal fellow at Cornell), 2015
- James Chan (Nephrologist, Armed Forces Hospital, Taipei, Taiwan), 2012
- Sukit Rakasuk (Nephrologist, Mahidol University, Thailand), 2013
- Chun Wong (Nephrologist, Leiden University, Netherlands), 2011
- Lihua Wang, Tianjin University, China, 2014-2015
- Ashish Varma (now a renal fellow at Brigham and Womens Hospital), 2010

3. Renal Fellows/Residents

- Amit Govil, 199-2001
- Debby DeSalvo, 2002-2003
- Arsh Tindni, 2010-2012
- Ahsan Ullah, 2010-2012
- Neetu Sharma, 2010-2012
- Reema Kang, 2011-2013
- Joe DeJonckheere, 2000-2002

4. College and High School Students

- Nida Safdar (now a medical student at Vanderbilt University), 2005
- Arjun Hura (now a medical student at the University of Cincinnati), 2006
- Arjan Minhas (now a student at the University of Michigan), 2007
- Nikhil Grandhi (now a student at Ohio State University), 2008
- Matthew Kurian (now a medical student at North Eastern Ohio College of Medicine), 2012
- Michelle Kurian (now a medical student at Wright State University), 2007
- Ben Woodle (now a medical student at the Medical College of the Caribbean), 2010
- Rueshil Fadia (now a student at University of California-San Diego), 2015
- Brenda Valencia (now in the combined Masters to MD program at the University of Arizona), 2015
- Tommie Valencia, 2015

5. Masters Students

- Taylor Gabrielle Lewis (now a medical student at Rosalind Franklin Medical School, Chicago), 2017

g. Clinical Teaching

- 2015 – 19 Attending on the Internal Medicine Service, Southern Arizona VA Health Care System; 6 weeks per year
- 2015 – 19 Transplant/General Nephrology Attending Physician, University of Arizona College of Medicine; 4 weeks per year

h. Graduate Committees and External Examiner for PhD students

- 2021 Amanda Graboski (UNC Chemistry)
- 2021 Stephanie Hwang (UNC, Biomedical Engineering)
- 2020 Zhanhe Lui (Clemson University)
- 2019 Rosa Marticorena (University of Toronto, Canada)
- 2019 Prashanthinie Mohan (with Public Health, University of Arizona)
- 2017 Keith Saum (with Biomedical Engineering, University of Cincinnati)
- 2016 James Wodicka (with Biomedical Engineering, Purdue University)
- 2013 Chun Yu (University of Leiden, Netherlands)
- 2010 Manesh Krishnamoorthy (with the College of Engineering, University of Cincinnati)
- 2006 Murad Melhelm (with the College of Pharmacy, University of Cincinnati)

VII. GRANTS/FUNDED RESEARCH

a. Active Grants

- R01DK132328** **Roy-Chaudhury/Xi (MPI; 2.7m)** 05/01/22 – 03/31/27
Modulation of VSMC phenotype through the Insulin Receptor Substrate-1/Kruppel-like factor-4 signal transduction pathway: a Novel Target for AVF Dysfunction
The goal of this proposal is to modulate Insulin Receptor Substrate-1/Kruppel-like factor-4 signal transduction
- R01 HL119371** **Roy-Chaudhury (Site PI; 1.5m)** 09/01/19 - 08/31/24
Synthetic Mesenchymal Stem Cell Niches for Vascular Therapy
The goal of this proposal is to engineer precision niches for stem cells to enhance dialysis vascular access

1I01BX006169-01 (VA Merit) **Roy-Chaudhury (PI; 700k)-selected for funding** 01/01/23 – 12/31/26
Hemodynamics, Uremia, Vascular Biology and Bioengineering: Creating the Ideal HD Vascular Access
The goal of this study is to create the ideal vascular access

R41 HL151235 **Roy-Chaudhury (MPI; 225k)** 07/17/20 - 08/16/23
Photodynamic Therapy to Prevent Arteriovenous Fistula Maturation Failure
The goal of this proposal is to use photodynamic therapy to prevent arteriovenous fistula maturation failure

R43 DK129107 **Roy-Chaudhury (MPI; 275k)** 10/01/20 – 12/31/23
Dialysis access monitoring using a digital stethoscope-based deep learning system
The goal of this proposal is to use artificial intelligence to risk stratify maturing AVFs

TL1TR002491 **Roy-Chaudhury (PI; 500k)** 03/01/18-02/28/23
North Carolina Translational and Clinical Science Institute (NC TraCS) TL1
This postdoctoral training program offers trainees 1-2 years of funding in translational science

R25DK131344 **Roy-Chaudhury (MPI; 500k)** 10/01/22 – 09/30/27
Transforming Kidney Care through Skill and Workforce Development: the North Carolina Kidney Technology Incubator (NC-KTI)
The goal is to train senior undergraduate students in kidney technology innovation

Bayer Investigator Initiated Grant **Mottl/Roy-Chaudhury (MPI; 1.9m)** 10/01/22 – 03/31/24
EFFECTOR, a randomized study of Finerenone in Kidney Transplant Recipients
The goal is to do an RCT of Finerenone in transplant patients

U01DK133095 **Mottl/Brosius (MPI; 1.5m)-Roy-Chaudhury Co-I** 10/01/22 – 09/30/27
Kidney Precision Medicine Project Biopsy Site
The goal is to provide biopsies for precision medicine interrogation

R43DK133005 **PI: Brunner-Roy-Chaudhury Consultant** 09/12/22 – 08/31/23
Ceragenin-based antimicrobial coating to tackle hemodialysis catheter-related infections
The goal is to develop new technologies to target catheter infections

b. Completed Grants

VA Merit Review (Roy-Chaudhury, PI) 10/01/2013 - 09/30/2020
Veterans Administration
Hemodynamics, Uremia and Vascular Biology: Interactive Pathways for AVF Maturation
The goal of this study is to examine the impact of hemodynamics and uremia on the vascular biology of a pig model of AVF maturation.
Role: Principal Investigator

NIH R43 DK111332 (STTR) Roy-Chaudhury (PI) 09/15/2016 - 06/30/2021 1.8 calendar months
Inovasc LLC \$80,000 (subcontract)
HELical Biodegradable Photochemical Stents (HELPS) for AVF Maturation
The goal of this proposal is to create and test out HELical Biodegradable Photochemical Stents (HELPS) for AVF Maturation
Role: Principal Investigator

R44DK100156-02 (Stuart K, PI) 2015-2018
NIH/NIDDK \$1,466,956
A Luminal Vascular Coating to Reduce Time to Maturation and Failures of AV Fistulas for Hemodialysis Access
The purpose of this study was to develop a novel treatment for use in vascular access aimed at addressing the injury that occurs in the creation of an arteriovenous fistula.

Role: Co-Investigator

5R01 DK08877-04 (Cheung A, PI)	01/07/2011 – 01/05/2017	
NIH/NIDDK	\$638,855	20%
“Hemodynamics and vascular wall biology determine arteriovenous fistula maturation”		
The purpose of this study was to identify predictors of arteriovenous fistula maturation failure and collect indirect evidence about mechanistic hypothesis. The study also examined the interplay among hemodynamic wall shear stress, vascular wall properties and arteriovenous fistula maturation over time.		

Role: MPI

NIH R21 EB16737(Roy-Chaudhury P, Meyerhoff ME, Co-PI)	09/30/2013 – 08/31/2016	20%
NIH/NIBIB	\$76,702	
Reducing Tunneled Dialysis Catheter Dysfunction through Nitric Oxide Release		
The goal of this study as to investigate the ability of nitric oxide releasing catheters to reduce the complications infection, thrombosis and central vein stenosis.		

Role: MPI

NIH 5UL1TR000005 (Roy-Chaudhury as Arizona PI)	2016 – 2018	10%
University of Pittsburgh PinCh Award	\$100,000	
The Phoenix Graft		
The goal of this study is to develop a bioengineered graft for dialysis vascular access.		

Role: Site Principal Investigator

R41DK111332 (Roy-Chaudhury, PI)	09/15/2016 – 08/31/2017	20%
NIH/NIDDK	\$275,529	
HELical biodegradable photochemical (HELP) stents for AVF maturation		
The purpose of this grant was to demonstrate in vivo degradation of toxicity profiles, biocompatibility and toxicity and in vivo proof of principle experiments to document therapeutic efficacy (flow and diameter) of HELP stents.		

Role: Principal Investigator

WL Gore Medical (Roy-Chaudhury, PI)	2011 – 2015	10%
A Novel Graft-Device for Dialysis Access	\$50,000	
The purpose of this study was to investigate the possibility of using an early cannulation graft for dialysis, with the goal of reducing infections and improving mortality and morbidity, and possibly reducing the incidence of central vein stenosis.		

Role: Principal Investigator

Univ. of Cincinnati Accelerator Grant (Roy-Chaudhury P, PI)	2013 – 2014	10%
	\$40,000	

“A Novel Device for Dialysis Vascular Access”

To introduce into clinical practice a biodegradable maturation-enhancing stent in AVF which targets sequential pathways (venous segment diameter, hemodynamic profiles and local vascular wall biology) involved in AVF maturation failure could completely change current clinical paradigms for vascular access placement and maintenance. **This was one of only four fast-tracked commercialization initiatives within the University of Cincinnati.**

Role: Principal Investigator

Lutonix Inc. (Roy-Chaudhury P, PI)	2013 – 2014 \$70,000	10%
<p>A Novel Device for Dialysis Access</p> <p>The purpose of this study was to investigate a drug-coated balloon for dialysis access for treatment of dysfunctional arteriovenous fistulas.</p> <p><i>Role: Principal Investigator</i></p>		
R21 EB016150 (Roy-Chaudhury P, PI) NIH/NIBIB	09/30/2012 – 08/31/2014 \$234,158	20%
<p>Biodegradable Magnesium Stents to Enhance AV Fistula Maturation</p> <p>To investigate the placement of a malleable, coated (drug/cell/gene/chemical), biodegradable maturation enhancing stent at the time of AV fistula creation to determine whether it will dilate small veins, optimize anatomical configuration to improve hemodynamics, and improve local vascular biology as a result of the coated agents.</p> <p><i>Role: Principal Investigator</i></p>		
UL1RR026314 (Roy-Chaudhury P, PI) NIH/NCCR	2013 – 2014 \$100,000	10%
<p>Electrochemical Generation of Nitric Oxide</p> <p><i>Role: Principal Investigator</i></p>		
R01DK088777 (Cheung AK, PI) NIH/NIDDK	2011 – 2015 \$721,587	20%
<p>Hemodynamics and Vascular Wall Biology Determine Arteriovenous Fistula Maturation</p> <p>This study was to identify predictors of AVF maturation failure and examine the role of aberrant hemodynamics in the pathogenesis of AVF maturation failure.</p> <p><i>Role: MPI</i></p>		
R21 DK089280 (Roy-Chaudhury P, PI) NIH/NIDDK	08/15/2011 – 01/13/2014 \$232,272	20%
<p>Real-Time Nitric Oxide Measurements as a Determinant of AV Fistula Maturation</p> <p>The purpose of this study was to measure and quantify associations between S-nitrosothiols [RSNO] and S-nitrosohemoglobin [HbSNO] levels and physiological a flow-mediated dilation study and at the time of mandated ultrasound examinations for AVF blood flow and diameter.</p> <p><i>Role: Principal Investigator</i></p>		
U01DK082218-01 (Roy-Chaudhury P, PI) NIH/NIDDK	2008 – 2013 \$345,400	20%
<p>Clinical, Hemodynamic and Biological Markers of AV Fistula</p> <p>The central objective of this study was to identify predictive markers for AV fistula success or failure with the long-term aim to allow the development of novel therapies to enhance AV fistula maturation.</p> <p><i>Role: Principal Investigator</i></p>		
UL1RR026314 (Roy-Chaudhury P, PI) NIH/NCCR CTSA Grant (University of Cincinnati)	2011 – 2012 \$100,000	10%
<p>Stents for AV Fistula Maturation</p>		

Role: Principal Investigator

NIH R01	2007 – 2012	15%
Biomimetic Generation of Nitric Oxide	\$500,000	
(Roy-Chaudhury, Cincinnati PI)		

Bioconnect Systems (Roy-Chaudhury P, PI)	2007 – 2012	10%
Prevention of AV Fistula Stenosis	\$100,000	

Role: Principal Investigator

U01 ARRA Supplement, NIH	2009 – 2011	10%
Identification of Factors Associated with Failure of Arteriovenous Fistulas to Mature	\$200,000	

The purpose of this grant was to investigate clinical factors which may be predictive and/or are associated with the failure of newly placed arteriovenous fistulas to mature in patients with end-stage kidney disease.

Role: Principal Investigator

Genzyme (Roy-Chaudhury P, PI)	2007 – 2011	5%
Thymoglobulin for Ischemia-Reperfusion in a Mouse Model	\$50,000	

Role: Principal Investigator

UL1RR026314, (Roy-Chaudhury P, PI)	2009 – 2010	10%
NIH/NCCR CTSA Grant (University of Cincinnati)	\$100,000	
Nitric Oxide Sensor for Predicting AV Fistula Maturation		

Role: Principal Investigator

NIH SBIR (Roy-Chaudhury P, PI)	2009 – 2010	20%
Perivascular Delivery of Paclitaxel	\$280,000	

Role: Site Principal Investigator

Orthologic (Roy-Chaudhury P, PI)	2007 – 2009	5%
Prevention of AV Graft Stenosis	\$50,000	

Role: Principal Investigator

Satellite Dialysis Units Research Grant (Roy-Chaudhury P, PI)	2004 – 2007	5%
Local Nitric Oxide Delivery Systems for PTFE Dialysis Grafts	\$50,000	

Role: Principal Investigator

Ys Therapeutics (Roy-Chaudhury P, PI)	2005 – 2006	5%
Use of a PSGL Blocker in Dialysis Access Grafts	\$30,000	

Role: Principal Investigator

Kidney Foundation of Greater Cincinnati (Roy-Chaudhury P, PI)	2004 – 2005	5%
Evaluation of Novel Biomarkers of Ischemic Injury in Kidney Transplant Recipients	\$5,000	

Curriculum Vitae

64 | Page

Roy-Chaudhury, Prabir

Role: Co-Principal Investigator

Paul Teschan Research Foundation	2003 – 2004	5%
Monitoring for Polyomavirus Infection and Nephropathy in Kidney Transplant Recipients		\$50,000

Role: Co-Investigator

University of Cincinnati, NCI funded Core Grants	2003 – 2004	5%
BK Virus and Post-Transplant Lymphoproliferative Disorder	\$10,000	

Role: Co-Investigator

R01DK061689 (Roy-Chaudhury P, PI)	2002 – 2006	20%
NIH/NIDDK	\$356,218	

Antiproliferative Rx for Venous Neointimal Hyperplasia

To test novel, locally delivered anti-proliferative therapies in a validated pig model of venous neointimal hyperplasia, including external radiation therapy and local polymeric delivery of paclitaxel and TNP-470.

Role: Principal Investigator

Cordis (a Johnson & Johnson company) (Roy-Chaudhury P, PI)	2001 – 2005	5%
Placement of Sirolimus-Coated Stents in a Pig Model of Venous Stenosis		\$50,000

Role: Principal Investigator

Gore Grant Research Program (Roy-Chaudhury P, PI)	1999 – 2000	5%
	\$20,000	

Blocking Venous Neointimal Hyperplasia in PTFE Dialysis Grafts: An Anti-Angiogenic Gene Therapy Approach

To investigate the pathophysiologic pathways that underlie the formation of neointimal hyperplasia in PTFE dialysis grafts and explore targeted gene therapy to prevent the causes of neointimal hyperplasia with the long-term aim of improving clinical outcomes.

Role: Principal Investigator

Paul Teschan Research Fund	2000 – 2001	10%
	\$50,000	

Combination Radiation and Anti-Angiogenic Therapy for the Treatment of Venous Neointimal Hyperplasia in PTFE Dialysis Grafts

To investigate the pathophysiologic pathways that underlie the formation of neointimal hyperplasia in PTFE dialysis grafts and explore directed radiation and targeted gene therapy to prevent the causes of neointimal hyperplasia with the long-term aim of improving clinical outcomes.

Role: Principal Investigator

Kidney Foundation of Greater Cincinnati	2000 – 2001	5%
	\$30,000	

Anti-Proliferative Therapies for Venous Neointimal Hyperplasia

To explore interventions aimed at the specific mediators and processes that contribute to the pathogenesis of venous neointimal hyperplasia, including the role of macrophages, specific cytokines and angiogenesis within the neointima and adventitia.

Role: Co-Investigator

Paul Teschan Research Fund (Roy-Chaudhury P, PI)	1999 – 2000 \$50,000	5%
Neointimal Hyperplasia in PTFE Dialysis Grafts: Correlations Between Hemodynamic Stress, Cytokine Profiles and the Magnitude of Neointimal Hyperplasia		
<i>Role: Principal investigator</i>		
Paul Teschan Research Fund (Roy-Chaudhury P, PI)	1998 – 1999 \$50,000	5%
Blocking Venous Neointimal Hyperplasia in PTFE Hemodialysis Grafts: A Combined Gene Therapy and Radiation Therapy Approach		
<i>Role: Principal Investigator</i>		
Paul Teschan Research Fund (Roy-Chaudhury P, PI)	1997 – 1998 \$50,000	5%
Venous Stenosis in PTFE hemodialysis grafts: Molecular Analysis of Human Samples and Interventional Studies in a Porcine Model of AV Graft Stenosis		
<i>Role: Principal Investigator</i>		
Kidney Foundation of Greater Cincinnati	1997 – 1998 \$5,000	2%
Cytokines and Adhesion Molecules in Chronic Allograft Nephropathy: Identification of Specific Molecules Responsible for Disease Progress		
<i>Role: Principal Investigator</i>		
Radiology Research Challenge Program University of Cincinnati	1997 – 1998 \$10,000	2%
Evaluation of Radiation Inhibition of PTFE Graft Stenosis		
<i>Role: Co-Investigator</i>		
Research Fellowship Grant (Strom TB, Sponsor) National Kidney Foundation	1994 – 1996 \$50,000	75%
Costimulation in Transplantation		
<i>Role: Principal Investigator</i>		
Aberdeen Hospitals Trust (Roy-Chaurdhury P, PI) Aberdeen, Scotland	1993 – 1994 GBP 20,000	50%
The Role of Angiotensin as a Modulator of Cellular Proliferation and Matrix Accumulation		
<i>Role: Principal Investigator</i>		
National Kidney Research Foundation (Roy-Chaudhury P, PI) United Kingdom	1992 – 1994 GBP 10,000	50%
The Role of Cytokines in the Pathogenesis of Mesangial Proliferative Glomerulonephritis		
<i>Role: Principal Investigator</i>		
Grampian Health Board (Roy-Chaudhury P, PI)	1992 – 1993	50%

Scotland GBP 10,000
The Role of Epidermal Growth Factor Receptor in the Pathogenesis of Mesangial Proliferative Glomerulonephritis
Role: Principal Investigator

Scottish Home and Health Department 1992 – 1994 50%
GBP 10,000
Dynamic Expression of Cytokines and Their Receptors in Mesangial Proliferative Glomerulonephritis
Role: Co-Investigator

d. Previous Clinical Trial Funding

FIDELIO-DKD (16244) 09/2015 – 07/2019
Sponsor: Bayer
Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
<https://clinicaltrials.gov/ct2/show/NCT02540993>
Role: Principal Investigator

FDA uFIGARO-DKD (17530) 09/2015 – 07/2019
Sponsor: Bayer
Efficacy and Safety of Finerenone in Subjects with Type 2 Diabetes Mellitus and Diabetic Kidney Disease
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care
<https://clinicaltrials.gov/ct2/show/NCT02545049>
Role: Principal Investigator

PRO2TECT-CONVERSION (AKB-6548-CI-0015) 02/2016 – 06/2019
Sponsor: Akebia Therapeutics
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease
Phase III, randomized, open-label, active-controlled study.
<https://clinicaltrials.gov/ct2/show/NCT02680574>
Role: Sub-Investigator

PROTECT-CORRECTION (AKB-6548-CI-0014) 01/2016 – 06/2019
Sponsor: Akebia Therapeutics
Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease
Multicenter, randomized, open-label, active-controlled Phase III study.
<https://clinicaltrials.gov/ct2/show/NCT02648347>
Role: Sub Investigator

- The Access Trial (VT-304)** 07/2015 – 05/2019
Sponsor: Vascular Therapies, Inc.
 Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
 A phase 3, randomized, multicenter, single-blind controlled study evaluating arteriovenous fistula outcomes with and without a perivascular sirolimus-eluting collagen implant in subjects on hemodialysis.
<https://clinicaltrials.gov/ct2/show/NCT02513303>
Role: Principal Investigator
- IM103-076** 09/2012 – 04/2019
Sponsor: Bristol Myers Squibb
 Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant (ENLIST)
 A Phase 4 observational study.
<https://clinicaltrials.gov/ct2/show/NCT01386359>
Role: Co-Investigator
- HUMANITY (CLN-PRO-V006)** 05/2016 – 03/2019
Sponsor: Humacyte, Inc.
 Comparison of the Human Acellular Vessel (HAV) with ePTFE Grafts as Conduits for Hemodialysis.
 A Phase III, prospective, multicenter, multinational, open-label, randomized, two-arm comparative study.
<https://clinicaltrials.gov/ct2/show/NCT02644941>
Role: Principal Investigator
- BPV-14-005** 06/2016 – 08/2018
Sponsor: C. R. Bard
 Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft (AVeNEW)
 A prospective, multi-center, randomized, concurrently-controlled clinical study of the BARD COVERA arteriovenous (AV) stent graft in the treatment of stenosis in the venous outflow of AV fistula access circuits.
<https://clinicaltrials.gov/ct2/show/NCT02649946>
Role: Principal Investigator
- 1407-004** 09/2016 – 05/2018
Sponsor: Baxter Healthcare Corporation
 Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
 Randomized, open-label, parallel assignment Phase III study.
<https://clinicaltrials.gov/ct2/show/NCT02860130>
Role: Sub-Investigator
- M11-352** 05/2013 – 03/2018
Sponsor: AbbVie
 Study of Diabetic Nephropathy with Atrasentan (SONAR)
 A Phase III, prospective, randomized, double-blind, enriched-population, placebo-controlled, multicenter study in adult participant with type 2 diabetes and nephropathy.
<https://clinicaltrials.gov/ct2/show/NCT01858532>
Role: Principal Investigator

PRT-201-320

08/2015 – 02/2018

Sponsor: Proteon Therapeutics

A study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula (AVF) Creation in Patients with Chronic Kidney Disease (PATENCY-2)

Multicenter, double-blind, placebo-controlled study.

<https://clinicaltrials.gov/ct2/show/NCT02414841>

Role: Principal Investigator

US OI 124

03/2015 – 09/2017

Sponsor: Oxford Immunotec

T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays (PROTECT)

A prospective observational trial to evaluate the correlation of T-SPOT response to CMV infection and T cell-mediated acute graft rejection.

<https://clinicaltrials.gov/ct2/show/NCT02382211>

Role: Sub-Investigator

LOCK-IT-100

12/2015 – 06/2017

Sponsor: CortMedix

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection

A phase III, prospective, multicenter, double-blind, randomized, active control study to demonstrate the safety and effectiveness of Neutrolin in preventing catheter-related bloodstream infections in subjects receiving hemodialysis therapy as treatment for end stage renal disease.

<https://clinicaltrials.gov/ct2/show/NCT02651428>

Role: Sub-Investigator

PRT-201-310

07/2014 – 12/2016

Sponsor: Proteon Therapeutics

A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients with Chronic Kidney Disease (PATENCY-1).

A multicenter, double-blind, placebo-controlled study of an experimental drug in patients receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis.

<https://clinicaltrials.gov/ct2/show/study/NCT02110901>

Role: Principal Investigator

CL0023-01

06/2015 – 09/2016

Sponsor: C. R. Bard

Study Comparing Lutonix AV Drug Coated Balloon vs. Standard Balloon for Treatment of Dysfunctional AV Fistula.

A prospective, global, multicenter, randomized, controlled study to evaluate the safety and effectiveness of the Lutonix 035 AV Drug Coated Balloon PTA Catheter compared to a standard PTA Catheter in treating patients presenting with clinical and hemodynamic abnormalities in native arteriovenous fistulae located in the upper extremity.

<https://clinicaltrials.gov/ct2/show/study/NCT02440022>

Role: Sub-Investigator

FD004573

06/2013 – 01/2016

Curriculum Vitae

69 | Page

Sponsor: University of Cincinnati

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

An open-label, prospective, multicenter, randomized, replicate, six-period, six-sequence crossover study to compare the steady state pharmacokinetics of Prograf to Generic Hi to Generic Lo in stable renal and liver transplant subjects.

<http://grantome.com/grant/NIH/U01-FD004573-01>

Role: Principal Investigator

BCS_TP1070

02/2014 – 10/2015

Sponsor: Bioconnect Systems, Inc.

Optiflow Maturation and Patency Clinical Trial (OPEN Study).

A multicenter, prospective, single-arm clinical study of Optiflor performance and safety.

<https://clinicaltrials.gov/ct2/show/NCT01921933>

Role: Principal Investigator

G120171

01/2013 – 09/2015

Sponsor: Medtronic Corporate Technologies and New Ventures

Study the Characteristics of Cardiac Related Events in Hemodialysis Patients (MiD)

Monitoring in Dialysis (MiD study) to estimate the proportion of hemodialysis patients who experience clinically significant cardiac arrhythmias using continuous cardiac monitoring over a 6-month period with an implanted Medtronic Reveal ICM device.

<https://clinicaltrials.gov/ct2/show/NCT01779856>

Role: Nephrology Investigator

FDA Solicitation 13-223-SOL-00102

03/2013 – 08/2015

Sponsor: University of Cincinnati/US FDA

Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

A randomized, prospective study.

<https://clinicaltrials.gov/ct2/show/NCT02014103>

Role: Co-Investigator

AVG01-SRM003

03/2013 – 10/2014

Sponsor: Shire

An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access

A Phase 2, single-blind, randomized, controlled, multicentre study.

<https://clinicaltrials.gov/ct2/show/study/NCT01806584>

Role: Principal Investigator; Chair, Writing Committee

GV28418

12/2012 – 10/2014

Sponsor: Genentech, Inc.

A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients

A Phase II Randomized, Double-blind, Placebo Controlled Trial

<https://clinicaltrials.gov/ct2/show/study/NCT01753167>

Role: Co-Investigator

- LCRM101** 01/2014 – 06/2014
Sponsor: Elcelyx Therapeutics, Inc.
 Assessing the Behavior of Met DR in Subjects with Kidney Dysfunction
 A Phase 2 randomized, crossover study evaluating a single dose of delayed-release metformin in patients with normal kidney function, or mild to severe kidney dysfunction.
<https://clinicaltrials.gov/ct2/show/study/NCT01658514>
Role: Principal Investigator
- C10-001** 11/2011 – 05/2014
Alexion Pharmaceuticals
 Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients During Desensitization
 A randomized, open-label, multicenter trial of eculizumab in prevention of antibody-mediated rejection.
<https://clinicaltrials.gov/ct2/show/study/NCT01399593>
Role: Co-Investigator
- 0624-201** 11/2010 – 06/2013
Sponsor: Viropharma
 A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients with Acute Antibody-Mediated Rejection
 A randomized, double-blind, placebo-controlled pilot study.
<https://clinicaltrials.gov/ct2/show/study/NCT01147302>
Role: Co-Investigator
- PRT-201-102** 09/2009 – 11/2012
Sponsor: Proteon Therapeutics
 A Study of PRT-201 Administered After Afteriovenous Graft (AVG) Creation in Patients with Chronic Kidney Disease
 A multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.
<https://clinicaltrials.gov/ct2/show/study/NCT01001351>
Role: Principal Investigator
- AVG 08-06** 06/2010 – 09/2012
Sponsor: W.L. Gore & Associates
 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access (ACUSEAL)
 A prospective, non-randomized, multicenter evaluation of the performance of the GORE® ACUSEAL vascular graft.
<https://clinicaltrials.gov/ct2/show/study/NCT01173718>
Role: Study Director
- IM103-047** 03/2008 – 09/2012
Sponsor: Bristol-Myers Squibb
 Belatacept Pharmacokinetic Trial in Renal Transplantation
 An open-label pharmacokinetic study in *de novo* renal transplant subjects receiving a belatacept-based immunosuppression regimen.
<https://clinicaltrials.gov/ct2/show/study/NCT00578448>

Role: Co-Investigator

7163-CL-0103

11/2010 – 01/2012

Sponsor: Astellas Pharma, Inc.

A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in *de novo* Kidney Transplantation

A Phase 1b, randomized, double-blind, parallel group, placebo-controlled, single-dose, pharmacokinetic, pharmacodynamics, safety and tolerability study in kidney transplant recipients.

<https://clinicaltrials.gov/ct2/show/NCT01279538>

Role: Co-Investigator

Ark 103

04/2009 – 09/2011

Ark Therapeutics, 2006-2009:

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access: Novel Trinam Against Control Evidence (AdV-VANTAGE)

A Phase II, randomized, controlled, open-label, multicenter study of EG004 in hemodialysis patients with end-stage kidney disease

<https://clinicaltrials.gov/ct2/show/study/NCT00895479>

Role: Co-Investigator

LTC-499-301107

09/2008 – 05/2011

Sponsor: W.L. Gore & Associates

GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis (REVISE)

Interventional Phase 3 study to establish efficacy and safety of the GORE VIABAHN endoprosthesis when used to revise AV prosthetic grafts.

<https://clinicaltrials.gov/ct2/show/study/NCT00737672>

Role: Principal Investigator

012-VWAV06

03/2007 – 04/2009

Sponsor: Angiotech Pharmaceuticals

Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access

A multi-center clinical study in subjects requiring arteriovenous grafts in the upper extremity for hemodialysis access.

<https://clinicaltrials.gov/ct2/show/study/NCT00448708>

Role: Lead National Principal Investigator

Sponsor: Mercator MedSystems, Inc.

2006 – 2008

HAPPI Trial for Perivascular Dexamethasone Delivery in Dialysis Access Graft Stenosis

Role: Lead National Principal Investigator

Sponsor: American Bioscience

2004 – 2007

Pilot study of Abraxane (paclitaxel) in PTFE Dialysis Access Grafts

Role: Lead National Principal Investigator

Sponsor: Novoste Corporation

2002 – 2006

Beta Radiation for Treatment of Arterial-Venous Graft Outflow (BRAVO-1)

Pilot study of vascular brachytherapy in hemodialysis patients with patent but dysfunctional grafts. (BRAVO-1)

<https://www.ncbi.nlm.nih.gov/pubmed/?term=BRAVO%20%20Investigators%5BCorporate%20Author%5D>

Role: National Nephrology Principal Investigator

(Between 1998 – 2002, I was Co-Investigator on over 40 clinical trials in clinical transplantation.)

VIII. PROFESSIONAL SERVICE

a. To discipline

U.S. Food and Drug Administration

12/2016 Invited Member, **National Evidence Generation Committee, December 2016** (chaired by FDA Commissioner, Robert Califf)

08/2016 Invited Member, **FDA Listening Session** (chaired by FDA Commissioner, Robert Califf)

National Institutes of Health

NIH/VA Review Panels

- NIH Review Panel, June, 2023
- NIH Review Panel, April 2023
- NIH Review Panel March 2023
- VA Review Panel, December 2022
- NIH Review Panel December 2022
- NIH Review Panel, November 2022
- NIH Review Panel, December 2019
- NIH SBIR/STTR Fast Track Review Panel, July 2019 (Chair)
- NIH R-21 Review Panel, February 2019 (Chair)
- NIH Review Panel, November 2018
- NIH Review Panel, November 2018
- NIH Review Panel, October 2018 (Chair)
- NIH Review Panel, July 2018 (Chair)
- NIH R-21 Review Panel, June 2018 (Chair)
- NIH SBIR Review Panel, April 4, 2018 (Co-Chair)
- NIH U-01 Review Panel, March 27, 2018
- NIH Review Panel, Feb 27, 2018
- NIH Review Panel, Feb 21, 2018
- NIH Review Panel, October 2, 2017
- NIH SBIR Review Panel, June 22, 2017
- NIH R-21 Review Panel, June 27, 2017
- NIH R-21 Review Panel, March 2017 (Chair)
- NIH SBIR Review Panel, November 2016 (Chair)
- NIH R-21 Review Panel, Feb 2016
- NIH R-21 Review Panel, October 2015 (Chair)

NIH Special Emphasis Panels

- NIH, Special Emphasis Panel, Cardiology Small Business, November 2021
- NIH, Special Emphasis Panel, Nephrology Small Business, March 2021 (Chair)
- NIH, Special Emphasis Panel, Nephrology Small Business, 2021 (Chair)

- NIH, Special Emphasis Panel, Urology Nephrology Small Business, November 2020 (Chair)
- NIH U01, Special Emphasis Panel on Opioids in Hemodialysis, August 2019 (Chair)
- NIH SBIR/STTR Special Emphasis Panel February 2015 (Chair)
- NIH Special Emphasis Panel October 2014 (Chair)
- NIH Special Emphasis Panel, July 2014 (Chair)
- NIH Special Emphasis Panel, June 2014
- NIH Special Emphasis Panel, March 2014
- NIH Special Emphasis Panel, November 2013
- NIH Special Emphasis Panel, July 2013
- NIH Special Emphasis Panel, March 2013 (Chair)
- NIH R-21 Special Emphasis Panel, November 2012 (Chair)
- NIH Special Emphasis Panel, June 25/26, 2012
- NIH Special Emphasis Panel, June 6, 2012
- NIH Special Emphasis Panel, March 19, 2012
- NIH Special Emphasis Panel, February 2012
- NIH Special Emphasis Panel, ZRG1 DKUS-C, March 2011
- NIH Special Emphasis Panel (GDD), December 2008
- NIH Special Emphasis Panel (GDD), June, 2008
- NIH Special Emphasis Panel (GDD), February, 2008
- NIH Special Emphasis Panel, August, 2007
- NIH Special Emphasis Panel, June 2005
- NIH Special Emphasis Panel ZRG1 RUS-B 05, March 2005
- NIH Special Emphasis Panel ZRG1 RUS-B 05, March 2005
- NIH Special Emphasis Panel, June 2005
- NIH Special Emphasis Panel ZRG1 RUS-B 02, August 2004

Study Sections

- NIH PBKD Study Section, Temporary Member, February 2010
- NIH CKD U01 RFA Study Section, July 2009
- NIH GDD Study Section, Temporary Member, Feb 2009
- NIH GDD Study Section, Temporary Member, Feb 2009

American Society of Nephrology

2023	Selection Committee for JASN EIC
2023	Chair, Transforming Dialysis Access Together
2023	Member, Nephrologists Transforming Dialysis Safety
2020 – 2022	Council Liaison for Research, Discovery and Innovation
2019 – 2021	Council Liaison to the Media and Communications Committee
2019	Selection Committee for Kidney 360 EIC
2019	Selection Committee for Kidney News EIC
2019 – present	Council Liaison to the Public Communications Committee
2017 – present	Member, Steering Committee, Renal Replacement Therapy Roadmap Project
2012 – 2019	Member, Postgraduate Education Committee
2018-2022	Kidney x Innovation Accelerator, Steering Committee
2018	Member, RPA Leadership Meeting
2017 – 2018	Member, Innovation and Discovery Task Force
2017 – 2018	Member, Steering Committee, FDA BAA on PRO's for Renal Devices
2014 – 2018	Member, Nominations Committee, Kidney Health Initiative

2013 – 2018	Co-Chair, Kidney Health Initiative
2013 – 2018	Member, Kidney Health Initiative Lupus Nephritis Project Work Group
2013 – 2018	Review Committee, Project Proposal, Kidney Health Initiative
2013 – 2016	Member, Board of Advisors
2013 – 2016	Member, Capitol Hill Team
2013 – 2016	Member, Core Committee, Kidney Health Initiative Vascular Access Endpoints project
2015	Member, Industry Innovation Group
2013 – 2015	Member, Kidney Health Initiative CRRT Project Work Group
2013 – 2015	Member, Kidney Health Initiative Barriers to Innovation Project Work Group
2009 – 2015	Member, Interventional Nephrology Advisory Group
2014	Member, X Prize Advisory Team
2012	Member, Program Committee

American Society of Diagnostic and Interventional Nephrology

2013 – 2022	Member, International Committee
2016 – 2018	Member, Nominations Committee
2008 – 2018	Chair, Research Committee
2014 – 2016	Member, General Nephrology Training Sub-Committee
2013 – 2015	Member, ASDIN/ASN/ABIM Subcommittee on Procedures for Nephrologists
2007 – 2014	Councilor
2004 – 2007	Clinical Research Liaison

Hemodialysis Fistula Maturation Consortium

2013 – present	Member, multiple Writing Committees
2011 – present	Chairman, RNA Task Force
2008 – present	Member, Steering Committee

Renal Networks 9 and 10

2011 – 2015	Member, Transplant Advisory Panel
2005 – 2015	Member, Medical Review Board
2004 – 2015	Member, Vascular Access Advisory Panel

International Society of Nephrology

2013 – present	Member, South Asia Committee
2009 – present	Member, Interventional Nephrology Committee
2010 – 2018	Co-Chair, Transplant Committee

American Nephrologists of Indian Origin

2015 – 2018	President
2009 – 2015	Secretary

Vascular Access Society of the Americas

2008 – 2013, 2018 – present	Board of Directors
-----------------------------	--------------------

Cardio-Renal Society of America

2018 – present	Member, Board of Directors
----------------	----------------------------

Southwest Nephrology Conference

2015 -2018	Member, Planning Committee
------------	----------------------------

International Professorships

NTR University, Hyderabad, Andhra Pradesh, India

b1. Consultant to Industry (Active)

- Astra Zeneca
- Bard-BD
- Bayer
- Cormedix
- Humacyte
- Medtronic
- W. L. Gore

b2. Consultant to Industry (Inactive)

- Abbott Vascular
- Akebia
- American BioScience
- Amylin Pharmaceuticals Novoste Corporation
- Angiotech
- Benjamins Combat Gear
- BioConnect Systems
- Cook
- Far Infra Red
- Fujisawa
- Light Sciences Corporation
- Minimus Surgical
- Novartis
- Protein Therapeutics
- Reata
- Shire
- Tissue Regenix Limited
- Vascular Therapeutics

c. Advisory Boards

- Bayer CardioRenal Initiative, May 2023
- Astra Zeneca Rare Diseases Advisory Board, April 2023
- Bayer CardioRenal Initiative and Clinical Research Council, November 2022
- Astra Zeneca Clinical Advisory Board, August 2022
- Bayer Clinical Research Council, December 2021
- Vifor Regional Advisory Board, December 2021
- Bayer Cardiorenal Initiative-Transplant, 2021
- Bayer Cardiorenal Initiative-Patient Perspective, 2021
- Bayer Cardiorenal Initiative-Full Board, 2021
- Bayer Cardiorenal Initiative-Early Detection, 2021 NIH, Special Emphasis Panel, Nephrology Small Business, March 2021
- Humacyte, Clinical Advisory Board, 2021
- Vifor-Relypsa, Global Hyperkalemia Council, November 2019
- InRegen Advisory Board, November 2019
- Medtronic MITG Advisory Board Meeting, October 2019

- WL Gore Advisory Board Meeting, August 2019
- Reata Regional Advisory Board, May 2019
- Bayer, Cardioresenal Initiative, Madrid, January 2019
- Vifor-Relypsa, Global Hyperkalemia Council, November 2018
- Medtronic R and D Advisory Meeting, November 2018
- Medtronic Advisory Board Meeting, October 2018
- WL Gore Advisory Board Meeting, October 2018
- Bard-BD R and D Advisory Meeting, September 2018
- Bard-BD R and D Meeting, July 2018
- Vifor-Relypsa, Global Hyperkalemia Council, June 2017
- Medtronic Advisory Board, Boston, February 2018
- Akebia Advisory Meeting, Boston, January 2017
- Bard/Lutonix Advisory Meeting, Philadelphia, December 2014
- Abbott Vascular Advisory Meeting/Talk, Santa Clara, September 2014
- Bard/Lutonix Advisory Meeting, Minneapolis, August 2014
- WL Gore Advisory Meeting, Chicago, June 2014
- Medtronic Advisory Meeting, Minneapolis, MN, January 13th, 2014
- WL Gore, Dialysis Access Clinical Advisory Board meeting, Phoenix, December 2013
- Lutonix Advisory Board Meeting, New Orleans, April 2013
- Ariste Medical Advisory Board Meeting, Memphis, Tennessee, December 2012
- WL Gore Dialysis Access Clinical Advisory Board Meeting, Phoenix, December 2012
- WL Gore, Acuseal DSMB Meeting, Chicago, October 2012
- Engineering Research Council Clinical Advisory Board Meeting, Chicago, September 2012
- Shire Protocol Meeting, Cincinnati, March 19, 2012
- Medtronic Advisory Meeting, Feb 17, 2012
- FDA meeting with CDRH (for Bioconnect Systems), January 19, 2012
- WL Gore Dialysis Access Clinical Advisory Board Meeting, Phoenix, December, 2011
- WL Gore Acuseal Clinical Advisory Board Meeting, New York, November, 2011
- Bioconnect Advisory Panel Meeting, Washington DC, October 2011
- WL Gore Acuseal Clinical Advisory Board Meeting, Charlotte, March 2011
- Medtronic Advisory Meeting, August, 2011
- WL Gore Dialysis Access Clinical Advisory Board Meeting, Phoenix, September 10-11, 2010
- Shire Clinical Advisory Board Meeting, Miami, March 2010
- Proteon Advisory Board Meeting, Boston, May 2009
- Gore Expert Advisory Panel Meeting, Charlotte, March 2009
- Pervasis Expert Advisory Panel Meeting, Boston, February 2009
- FDA Conference Call for Angiotech, 2008
- BioConnect Clinical Advisory Board Meeting, Philadelphia, November 2008
- Pervasis Expert Advisory Panel Meeting, Boston, June, 2008
- Angiotech Expert Advisory Panel Meeting, Chicago, March 2007
- Proteon Therapeutics Advisory Panel Meeting, Boston, January 2007
- Pervasis Therapeutics/Flagship Ventures, Advisory Panel Meeting, Boston, Jan 6th, 2006
- Pervasis Therapeutics/Flagship Ventures, Advisory Panel Meeting, Chicago, May 16th, 2005
- FDA meeting with the Center for Cardio-Renal Health, Amylin Pharmaceuticals Inc., Washington DC, Sept 10, 2002
- FDA CDRH Meeting, Novoste Endovascular Radiation Study, April 2002
- Novoste Endovascular Radiation Study Advisory meeting, Atlanta, April 2002

- Novoste Endovascular Radiation Study, Analyst meeting, Atlanta, March 2002
- Novoste Endovascular Radiation Study Advisory meeting, Atlanta, February 2002
- Cordis Sirolimus Stent Study, Advisory Meeting, Newark, March 2001

d. Editorial Boards

2008 – present	Overseas Editorial Board, Medical Journal of the Armed Forces of India
2011 – present	International Editorial Board, Acta Nephrologica (Taiwan)
2019 – present	Editorial Board, Seminars in Nephrology
2012 – present	Editorial Board, Journal of Vascular Access
2008 – present	Faculty of 1000, Reviewer for Nephrology
2017 – 2019	Chair, Interventional Nephrology Section, Clinical Nephrology
2008 – 2018	Assistant Editor, Seminars in Dialysis (ASDIN Section)
2011 – 2014	Editorial Board, American Journal of Kidney Diseases
2008 – 2009	Section Web Editor, Tissue Engineering and Dialysis Access, American Society of Artificial Organs

e. Company Founder

Founder and Chief Scientific Officer: Inovasc LLC

f. Institutional (outside of UNC)

University of Arizona

2018 – 2019	Member, Academic Management Council, Research and Innovation Committee, Banner University Medical Center, Tucson and Phoenix
2018 -2019	Member, High Level Research Negotiation Team, University of Arizona and Banner Health
2015 – 2019	Member, Reappointments and Tenure Committee
2015 – 2019	Member, Mentorship Committee
2015 – 2019	Member, Graduate Program in Physiology
2015 – 2019	Member, Graduate Program in Cardiovascular Medicine
2015 – 2019	Member, MD/PhD Committee
2015 – 2019	Dean’s Research Council

University of Cincinnati

2014 – 2015	Member, Technology Commercialization Advisory Committee
2014 – 2015	Member, Accelerator Governance Committee
2008 – 2015	Faculty, Medical Scientist Training Program
2012 – 2015	Member, Scientific Advisory Committee, Clinical Trials Research Center, University of Cincinnati and Children’s Hospital Medical Center
2008 – 2015	Faculty Member, Graduate Program in Pathobiology, Department of Medicine
2013	Member, Rhodes/Marshall Scholars Mentorship Group
2011 – 2013	Member, Research Governance Committee, Department of Medicine
2009 – 2013	Member, Faculty Mentoring Committee, Department of Medicine
2008 – 2009	Member, Medical School Admission Committee
2008 – 2011	Member, Quality Assurance Committee, Department of Medicine
2004 – 2005	Member, Israel Penn Tumor Transplant Registry
2004 – 2005	Member, Scientific Advisory Board

University Hospital, Cincinnati

2004 – 2005	Member, Medicines Safety Committee
-------------	------------------------------------

Cincinnati Children's Hospital and Medical Center

2003 – 2005 Chairman, Data Safety Monitoring Board: The Use of Sirolimus in Tuberous Sclerosis

g. Local**National Kidney Foundation**

2010 – 2015 Trustee, National Kidney Foundation, Greater Cincinnati and Northern Kentucky Chapter

2010 – 2015 Member, Medical Advisory Board, National Kidney Foundation, Greater Cincinnati and North Kentucky Chapter

Kidney Foundation of Greater Cincinnati

2006 – 2010 Member, Board of Trustees

2004 – 2010 Member, Medical Advisory Board

2004 – 2006 Chair, Medical Advisory Board

Life Center Organ Procurement Organization, Cincinnati

2009 – 2015 Member, Scientific Advisory Board

Association of Indian Physicians, Cincinnati

- Executive Committee, Association of Indian Physicians (Cincinnati Chapter) 2003-2005
- President, Association of Indian Physicians (Cincinnati Chapter) 2004

IX. RESEARCH STATEMENT

My research charge is to build up a Kidney and Vascular Innovation Program within the UNC Kidney Center as described below. This vision includes research, teaching and service aspects.

Kidney and Vascular Program, UNC Kidney Center

VISION


- A comprehensive, unique program and one of its kind that cares for the cardiovascular health of patients with CKD and ESKD

MISSION

- To create an integrated bedside to bench to bedside program that targets cardiovascular health (cardiovascular disease and vascular access dysfunction) in CKD and ESKD patients through basic and translational science, technology development, clinical research and education/public policy inputs
- To develop novel and innovative biomarkers, drugs, devices, process of care and awareness/education pathways, that will improve cardiovascular health in CKD and ESKD patients
- To organize an integrated, Patient-Centered clinical care pathway that is focused on cardiovascular health in CKD and ESKD patients and which could serve as test bed for the previously described innovations

OVERVIEW (see figure)

Cardiovascular disease and Vascular Access Dysfunction (both likely due to the negative impact of uremia on blood vessels and the heart) are responsible for the bulk of the morbidity, mortality, cost and quality of life issues for CKD and ESRD patients. Specifically, we spend 114 billion dollars per year on kidney care, of which 34 billion dollars is for the care of ESKD patients who have a dismal three year survival of 50%, mainly due to cardiovascular disease



and vascular access complications. The Kidney and Vascular Innovation program will therefore be focused on overall cardiovascular health in these patients and will be comprised of two parallel but interlinked initiatives.

The **translational** initiative will focus on the impact of uremia on blood vessels and the heart. It will do so through an innovative, integrated, multi-disciplinary, transformative and Patient-Centered approach, with four major and interconnected domains: (a) Translational Science (b) Technology Development (c) Clinical Research, Outcomes and Epidemiology and (d) Awareness, Education and Public Policy.

The **clinical** program will develop a process of care pathway for the vascular access and cardiovascular problems faced by CKD and ESKD patients. Key components will be the identification of subspecialists (cardiologists [heart failure, electrophysiology and interventional], pulmonologists, transplant and vascular surgeons, endocrinologists, podiatrists, radiologists and interventional nephrologists) who will collaborate with nephrologists and primary care physicians, to deliver high quality cardiovascular care to CKD and ESRD patients.

Most importantly, these two programs will interact in the following ways:

- (a) The innovations from the translational program (biomarkers, drugs, devices, process of care and education/awareness pathways) will improve the cardiovascular health of patients in the clinical program
- (b) The clinical program will serve as a test bed for the above innovations
- (c) The clinical program will identify unmet clinical needs that will then be addressed by the translational program
- (d) The co-localization of the two programs will result in an unprecedented opportunity for the teaching, training, professional growth and mentorship of a multidisciplinary cadre of healthcare professionals focused on cardiovascular health in CKD and ESKD patients

X. TEACHING STATEMENT

I see my teaching impact occurring mainly in three settings:

a. Clinical teaching: during renal and perhaps internal medicine rounds at UNC and at the Salisbury VA. I enjoy teaching and have been very lucky to be generally considered as one of the best clinical teachers in nephrology. An important aspect of this teaching is to enthuse and excite younger physicians about Nephrology.

b. Didactic lectures: at UNC to medical students, residents and fellow. An important focus would be vascular access and I have a set of 10 short lectures in this area

c. National and International Talks: I have been extremely lucky to be invited to lecture all over the world. I generally deliver between 20-25 invited lectures per year. This year for example my travel has already (till mid May) included India x 2, Ireland, Portugal, and Spain. My hope is that I will be able to spread the word about the wonderful work that is being done here at UNC, across the world.

XI. SERVICE AND ENGAGEMENT STATEMENT

In 2023, I was elected to be a Council Member for the American Society of Nephrology (ASN) on the Executive track for a 4-year term (Secretary-2023; President Elect 2024; President 2025; Past President 2026). ASN is the largest professional nephrology organization in the world with over 20,000 members and its apex leadership body is the 8-member council of which I am a part. In my role as ASN Secretary and through involvement in multiple ASN initiatives, I am lucky to be able to play an impactful service role on behalf of the Nephrology community in this country and overseas. I have also been closely associated with multiple federal agencies, HHS, NIH, FDA, CMS in my previous role as the ASN co-chair of the Kidney Health Initiative which is a public-private partnership between ASN and FDA. I was also previously a member of the steering committee of the KidneyX Innovation Accelerator which is a public-private partnership between the American Society of Nephrology and Health and Human Services.